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Abstract 
Type 2 diabetes mellitus is a chronic disease that is associated with substantial 
morbidity, mortality, and health care cost. All patients with diabetes require a high 
level of clinical care to prevent the development of diabetic complications. The aim of 
this study was to compare the impact of a pharmaceutical care diabetic clinic within a 
primary care setting to standard care on clinical, humanistic and process outcomes in 
Type 2 diabetes patients. A randomised controlled trial was conducted in 9 general 
practices in Greater Glasgow Health Board. All patients with Type 2 diabetes, aged 
18 years or over, taking an oral antidiabetic drug were recruited and stratified by 
practice, age, and gender, and then randomised into an active or control group. The 
patients in both groups were invited to a pharmaceutical care diabetic clinic within 
their general practice for three visits at three-monthly intervals. Active patients 
received review and allocated intervention by the pharmacist while control patients 
received review only without intervention by the pharmacist. Allocation remained blind 
until after the first evaluation. The pharmacist evaluated the appropriateness of the 
medication for the individual and their overall diabetic care. The pharmacist prepared 
a list of drug-related problems and a referral where appropriate. GP referrals were 
actioned in the active group but held back until after the conclusion of the study in the 
control group. Patient outcome measures include changes in HbA 1 c value, systolic 
blood pressure, health related quality of life (HRQOL), and drug related problems 
(DRPs) from baseline to the end of the study for both groups. 
Three hundred and eighty seven patients were targeted for recruitment to the study, 
of which 198 signed informed consent and attended for interview with 160 (81%) 
patients attending two or more clinic visits, and 82 (51%) patients attending all three 
clinic visits. The results demonstrated a significant change in systolic blood pressure 
iv 
in the active group from clinic visit 1 to 2 (9 mmHg, P = 0.007) and clinic visit 1 to 3 
(15 mmHg, P = 0.001) but no change in HbA1c and HRQOL. There were 177 DRPs 
in the active group at baseline which decreased to 67 at clinic visit 2. Equivalent 
numbers of DRPs for the control group were 179 and 114 respectively. The risk 
reduction in the active group was therefore 0.59 with a number needed to treat (NNT) 
of 4 (19 weeks). Results also demonstrated a high GP acceptance rate as evidenced 
by 80% of recommendations being completely agreed and only 2% rejected. 
The hypothesis of this study was 'pharmaceutical care delivered by community 
pharmacists does improve patient outcomes of Type 2 diabetics in a primary care 
setting'. We conclude that two of the patient outcome measures (systolic blood 
pressure and DRPs) showed a significant improvement, with no reduction in HRQOL 
and no change in HbA 1 c. 
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Chapter 1: Review of Literature 1 
Chapter 1 
Review of Literature 
1.1 Introduction 
Diabetes mellitus is a group of metabolic disorders characterised by chronic 
hyperglycaemia resulting from defects in insulin secretion, insulin action, or both 
(Expert Committee, 1997). The effects of diabetes include microvascular and 
macrovascular complications that contribute to an increase in morbidity and mortality 
and a reduction in the quality of life. There are two main types of diabetes mellitus: 
Type 1 diabetes and Type 2 diabetes. 
Type 1 diabetes mellitus (previously known as insulin-dependent diabetes mellitus) 
develops most frequently in children and young adults, but also may occur in adults. 
In patients with Type 1 diabetes, the pancreatic beta cells have been destroyed by an 
autoimmune response causing insulin deficiency. If the balance between diet, 
physical activity levels and insulin dosage is not maintained, this can lead to 
hypoglycaemia. Patients with Type 1 diabetes need insulin treatment to survive. 
Failure to take insulin can result in diabetic ketoacidosis. 
Type 2 diabetes mellitus, previously known as adult-onset diabetes or non-insulin-
dependent diabetes, is the most prevalent form of diabetes. It is a complex metabolic 
disorder which may originate from insulin resistance and relative insulin secretory 
deficiency, either of which may be predominant (Alberti and Zimmet, 1998). Patients 
with this form of diabetes are not absolutely dependent on exogenous insulin for 
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survival and are not prone to the development of ketoacidosis except during 
conditions of severe stress such as those caused by infections, trauma or surgery. 
The risk of developing Type 2 diabetes increases with age, obesity, and lack of 
physical activity. It is more common in individuals with a family history of diabetes and 
in members of certain ethnic groups. Most patients with Type 2 diabetes are obese, 
and obesity itself causes or aggravates some degree of insulin resistance (Campbell 
and Carlson, 1993; Kissebah et aI., 1982). Type 2 diabetes is often asymptomatic in 
its early stages and can remain undiagnosed for many years. Such patients are at 
significantly higher risk for developing macrovascular and microvascular 
complications than the non-diabetic population (Walters et aI., 1994). 
In 1989 the St. Vincent Declaration set out specified targets for diabetes care and the 
reduction of diabetic-related complications for all countries throughout Europe 
(Anonymous, 1990). Results from the United Kingdom Prospective Diabetes Study 
(UKPDS) (UKPDS Group, 1998a; UKPDS Group, 1998d), the largest and longest 
clinical trial in Type 2 diabetes, have shown that intensive management of blood 
glucose and blood pressure can dramatically reduce the risk of developing 
complications. 
Chapter 1: Review of Literature 3 
1.2 Overview of Type 2 diabetes mellitus 
1.2.1 Diagnostic criteria 
The most widely used diagnostic criteria for diabetes mellitus were developed by the 
World Health Organisation (WHO) in 1980 (WHO, 1980) and updated in1985 (WHO, 
1985). According to the 1985 WHO criteria, diabetes was diagnosed by either fasting 
plasma glucose (FPG) ~ 7.8 mmolll or 2-hour glucose concentration ~ 11.1 mmolll 
during a 75-g oral glucose tolerance test (OGTI). In 1997 the American Diabetes 
Association (ADA) introduced new diagnostic criteria for diabetes (Expert committee, 
1997). The ADA criteria are based mainly on FPG and use a cut-off value of at least 
7.0 mmolll for diagnosis, which is lower than the WHO criteria. This lower cut-off point 
was chosen because the microvascular complications begin to become more 
prevalent at this concentration. The ADA also introduced a new intermediate category 
called impaired fasting glucose (fasting glucose 6.1-6.9 mmolll), which differs from 
the WHO category of impaired glucose tolerance (FPG < 7.8 mmolll and 2-h plasma 
glucose (2-h PG) ~ 7.8 mmolll and < 11.1 mmolll). In 1999, the WHO changed the 
diagnostic criteria, lowering the FPG criterion to ~ 7.0 mmolll for the diagnosis of 
diabetes but retained the recommendation for the OGTI for the diagnosis of diabetes 
and staging of impaired glucose regulation (WHO, 1999). 
Both the 1997 ADA and 1999 WHO criteria agreed to lower the diagnostic value of 
the FPG to facilitate identification of undiagnosed diabetes and thereby identify more 
people at risk of complications of diabetes at an earlier stage in their disease. Use of 
FPG was advocated by the ADA because it is a much simpler test than an OGTT, 
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can be widely applied in clinical practice and because its predictive value for 
microvascular complications is nearly the same as that of 2-h PG. 
1.2.2 Incidence and prevalence of Type 2 diabetes 
The prevalence of Type 2 diabetes is increasing not only in the United Kingdom but 
also around the world. The WHO Collaborating Centre for diabetes in Melbourne has 
estimated that the number of Type 2 diabetes patients worldwide will increase from 
99 million in 1994 to 216 million in 2010 (Zimmer and McCarty, 1995). In the UK 
alone, according to the report by the Audit Commission (2000), it was predicted that 
the number of diabetic patients might double from 1.4 million (estimated as 3% of the 
population) to 3 million by the year 2010. This is thought to be due to a number of 
factors, namely an ageing population, the increasing prevalence of obesity and 
changes in lifestyle (Clark and Perry, 1999). 
In Scotland, approximately 108,000 Scottish residents have diabetes (Cromie and 
Teo, 1999), equivalent to 2.1 % of the estimated Scottish population of 5,119,200 
(General Scotland Register Office, 2000). It is likely to increase to 6.5% by the year 
2006 due to the increase in the elderly population. Each year, it is estimated that 
3,850 new adult cases of diabetes are diagnosed, equal to the UK incidence of new 
cases, which are 100 per 100,000 each year. In addition 2,700 people are recorded 
annually as dying of a diabetic related complication (Cromie and Teo, 1999). 
In the UK and many other countries Type 2 diabetes is a particular problem in certain 
ethnic minority groups, such as Asians, and African-Caribbeans where prevalence of 
known Type 2 diabetes rates are three to four times higher than in comparable white 
Caucasian populations (Audit Commission, 2000). In Scotland this group comprises 
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1.25% of the population, but is higher in some big cities including Edinburgh and 
Glasgow where ethnic communities comprise 3% of the population (Cromie and Teo, 
1999). 
1.2.3 Complications of Type 2 diabetes: mortality, morbidity and effects of 
near-normoglycaemia 
Diabetic complications can be classified into two main categories, acute metabolic 
complications, and chronic complications. Acute complications of Type 2 diabetes 
include severe hyperglycaemia, leading to polyuria, increased thirst, dehydration, weight 
loss, blurred vision, fatigue and occasionally hyperosmotic non-ketotic coma. Patients 
with diabetes are also at risk of suffering from chronic complications, including 
microvascular complications of retinopathy, nephropathy, neuropathy, and 
macrovascular complications of cardiovascular, cerebrovascular, and peripheral 
vascular disease. Long-term complications can have serious consequence on the 
health and quality of life of the patient. The following review will focus mainly on chronic 
complications, which are major causes of mortality and morbidity amongst patients with 
Type 2 diabetes. 
1.2.3.1 Microvascular complications: diabetic neuropathy 
Diabetic neuropathy is an important cause of morbidity in patients with diabetes often 
leading to foot ulceration and amputation and the cost to the health service is 
considerable. Data from a study in Newcastle upon Tyne hospitals during 1989-1991 
showed an incidence of diabetes amputation of 5.7 per 1,000 diabetic patients per year 
and identified that 42% of all operations were performed on diabetic patients 
(Deerochanawong and Alberti, 1992). 
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One British study of patients attending a hospital diabetes clinic (Young et aL, 1993) 
found that diabetic peripheral neuropathy was present in more than 50 percent of Type 
2 diabetic patients aged over 60 years. Studies in the UK reported that prevalence of 
neuropathy in Type 2 diabetes varied widely from 17.2% (Walters et aL, 1992),32.1% 
(Young et aL, 1993) to 41.6% (Kumar et aL, 1994) mainly due to differences in 
diagnostic criteria and selection criteria used in the studies. In addition, the prevalence 
rate of diabetic foot ulceration reported has ranged from 5.3% to 7.4% (Kumar et aI., 
1994; Reiber, 1996). 
In the US foot ulcers affect up to 15% of patients with diabetes during their lifetime 
(Reiber, 1996). Half of all nontraumatic lower-extremity amputations occur in patients 
with diabetes (Leese, 1991). The prevalence of amputation in the US in 1989 was 2.8% 
for patients with diabetes (Mayfield et aI., 1998). The direct costs for care of foot ulcers 
were estimated to be $145 million in 1986 (Mayfield et aI., 1998). 
Poor glycaemic control and long duration of diabetes increases the risk of neuropathy 
and amputation. A high HbA1c (>10.7%) and high fasting plasma glucose (>13.4 
mmol/L) was associated with a twofold increase in risk of amputation in a Finnish 
population with Type 2 diabetes (Lehto et aI., 1996). A study of Young et al. (1993) 
showed significant increasing prevalence of diabetic peripheral neuropathy with duration 
of diabetes, from 20.8% in 2,199 patients with diabetes duration of less than 5 years 
from diagnosis to 36.8% in 2,532 patients with diabetes for more than 10 years. 
However, the study did not specify the type of diabetes. In addition, it should be noted 
that the duration of Type 2 diabetes can never be accurately recorded because of the 
variable asymptomatic period prior to the diagnosis of the disease. 
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Of all possible interventions, tight glycaemic control is probably the only one that may 
slow the progression of the neuropathic state. As shown in the Diabetes Control and 
Complications Trial (DCCT), patients with Type 1 diabetes who achieved near-normal 
glycaemic control experienced a 69% reduction in the incidence of appearance of 
neuropathy and a 57% reduction in subclinical neuropathy, as compared with control 
subjects who received the usual treatment and subsequently had higher levels of 
glycaemia (DCCT Research Group, 1993). The epidemiological literature suggests a 
similar association in Type 2 diabetes (Klein et aI., 1996; Ohkubo et aI., 1995). 
1.2.3.2 Microvascular complications: diabetic retinopathy 
Diabetic retinopathy remains the leading cause of blindness in adults of working age in 
the developed world (ADA, 1998b; Evans, 1995; Leese, 1991) despite the fact that if it 
is detected and treated early, over 50% of blindness caused by diabetes is prevented 
(Rohan et aI., 1989). 
It is estimated that retinopathy begins to appear approximately 5 years after the onset of 
fasting hyperglycaemia (Jarret, 1986). Dolben et al. (1988) showed that retinopathy is 
related to the duration of disease and degree of hyperglycaemia and was found in up to 
29% of Type 2 diabetes patients at the time of clinical diagnosis. In the UK 37% of 
patients with Type 2 diabetes had retinopathy at the time of diagnosis, according to the 
UKPDS (Aldington et aI., 1994). In Type 2 diabetes (diagnosed after 30 years of age) of 
15 or more years' duration, the risk of any retinopathy is approximately 78% (Neely et 
aI., 1998). 
In Type 1 diabetes, the DCCT Research Group (1993) demonstrated that tight 
glycaemic control was associated with a reduction in the onset and progression of 
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diabetes retinopathy. Studies in patients with Type 2 diabetes suggest a similar relation 
between level of glycaemic control and rate of retinopathy. An intervention study of 
Japanese Type 2 diabetic patients (Ohkubo et aI., 1995) reported a 6-year cumulative 
development and progression of retinopathy of 7.7% in the intensively treated group 
(mean HbA1c 7.1%) compared with 32% in the conventionally treated group (mean 
HbA 1 c 9.4%), confirming the benefit of tight glycaemic control in Type 2 diabetes. The 
UKPDS also showed that intensive blood glucose control by either sulphonylureas or 
insulin substantially decreases the risk of microvascular complication (UKPDS Group, 
1998d). 
1.2.3.3 Microvascular complications: Diabetic nephropathy 
Diabetes has become the leading cause of end-stage renal disease (ESRD), accounting 
for about one-third of all cases of ESRD in the United States (ADA, 1998a). In the UK, 
it is estimated that about 600 new diabetic patients start on the renal replacement 
therapy programme every year (Viberti et aI., 1996). 
Nephropathy is a potential problem for all diabetics. Patients with diabetes have a 17 
fold increased risk of ESRD compared with those without diabetes (Leese, 1991). 
Although a smaller proportion of those with Type 2 diabetes develop ESRD, the much 
greater prevalence of Type 2 accounts for the fact that half of the diabetics with end-
stage renal disease have Type 2 diabetes (ADA, 1998a; Viberti et aI., 1996). 
In patients with Type 2 diabetes, nephropathy can be present at the time of diagnosis 
and this may be due to delayed diagnosis and the presence of macrovascular 
disease and hypertension (BDA, 1995). In addition, ethnic origin is an important 
factor in determining the risk of nephropathy. Viberti et al. (1996) reported that 
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diabetic nephropathy is two-fold more commonly seen in Afro-Caribbean, Asian 
Indians, and Japanese patients with Type 2 diabetes than those of European origin. 
Onset of diabetic nephropathy may be delayed with good glycaemic control, such as 
that used in the DCCT which achieved an average HbA1c level of 7.1% (DCCT 
Research Group, 1993). The DCCT documented that intensive control of glucose in 
Type 1 diabetes decreased the frequency of albuminuria by 60%. In Type 2 diabetes, a 
study of Ohkubo et al. (1995) showed a decrease in the frequency of development of 
both microalbuminuria (57%) and macroalbuminuria (70%) with intensive insulin 
therapy. In a long term follow-up study of a mixed Type 1 and Type 2 diabetic cohort, 
Hellman et al. (1997) showed that a comprehensive diabetes treatment programme 
resulted in reduction of total mortality, renal failure rate, and cardiac mortality. As with 
other microvascular complications in Type 2 diabetes, the results of the UKPDS 
(UKPDS Group, 1998d) indicated that intensive glycaemic control with sulphonylureas 
or insulin reduced the risk of diabetic nephropathy. However, UKPDS only evaluated the 
progression of complications in newly diagnosed patients with Type 2 diabetes. Levin et 
al. (2000) also showed that intensive glycaemic control (goal HbA1c 7.1%) retarded 
microalbuminuria in patients who had a confirmed diagnosis of Type 2 diabetes for 
several years (mean duration of known diabetes was 8 years). 
1.2.3.4 Macrovascular complications 
Coronary heart disease (CHD) mortality and morbidity rates are increased two- to 
four-fold among diabetic patients compared with non-diabetic persons (Laakso and 
Lehto, 1998), and the risk of myocardial infarction (MI) is as high as in non-diabetic 
people who have already had an MI (Haffner et aI., 1998). As shown in a 16-year 
follow-up study in Framingham, the prevalence of coronary heart disease, 
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cerebrovascular accidents, and intermittent claudication were 1.8, 2.4, and 4.5 times 
greater, respectively, in patients with diabetes than in age- and sex- matched non-
diabetics (Gracia et aL, 1974). In the Whitehall Study all causes mortality was 42% in 
the diabetic patients compared with 16% in the non-diabetic patients. Moreover, the 
cardiovascular mortality was 26% in the diabetic group in comparison with less than 
9% in non-diabetic subjects (p < 0.0001) (Jarrett et aL, 1984). 
In DCCT (1993), the risk of macrovascular disease was reduced by 41% in patients 
with Type 1 diabetes achieving intensive blood glucose control, although this 
difference was not statistically significant because of the low incidence of such 
complications. Macrovascular disease is a major cause of death in patients with Type 
2 diabetes (Donnelly, 2001; Groeneveld et aL, 1999; Roper et aI., 2001; Wei, 1998). 
In patients with Type 2 diabetes, the Kumamoto study (Okhubo, 1995) and the VA 
Cooperative study (Abraira et aI., 1997), did not support the finding that intensive 
blood glucose control in Type 2 diabetes significantly lowers the rate of 
macrovascular complications. However, there were small samples in both studies 
(110 patients in Kumamoto study and 153 patients in VA Cooperative study) which 
limits its generalisability. In the UKPDS, blood glucose lowering was found to have 
less effect on cardiovascular complications than on microvascular complications 
(UKPDS Group, 1998d). There was evidence of a 16% risk reduction (p = 0.052) for 
fatal and non-fatal MI with a difference in median HbA 1 c of 0.9% between intensively 
and conventionally treated groups (7.0% versus 7.9%, respectively) (Stratton et aI., 
2000). 
It is particularly notable that in the UKPDS sub-population of patients with 
hypertension, it was found that blood pressure control was more effective than blood 
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glucose control in reducing the risk of macrovascular complications (UKPDS Group, 
1998a). 
Several prospective studies have indicated that poor glycaemic control could 
increase the risk of cardiovascular disease. Uusitupa et al. (1993) observed a 
significant effect of severity of hyperglycaemia on mortality in Type 2 diabetic 
patients. They found that fasting plasma glucose concentration and HbA 1 c values at 
5 years after diagnosis were higher in diabetic patients who died during the follow-up 
than in those who survived. Increased levels of glycosylated haemoglobin were also 
shown to be associated with CHD in a Finnish study of Type 2 diabetic patients 
(Laakso, 1996). 
In addition to hyperglycaemia, other risk factors for cardiovascular mortality and 
morbidity in Type 2 diabetes include hypertension, obesity, and dyslipidaemia, 
especially hypertriglyceridaemia and low levels of high density lipoprotein cholesterol 
(Laakso and Lehto, 1998). As a result of the UKPDS (1998a), it was confirmed that 
the major causes of the increased risks of CHD in patients with diabetes are due to 
hyperglycaemia together with other risk factors and that glucose control alone may 
not improve CHD in diabetes. Therefore, all risk factors for Type 2 diabetes should 
be addressed. This is also supported by studies that have demonstrated that 
treatment of high cholesterol, blood pressure and weight loss in addition to control of 
blood glucose reduces the risk for macrovascular complications (Marshall, 1999; 
Passa, 1998; Steiner, 2000). 
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1.3 Studies focusing on the benefits of improved glycaemic 
control and primary prevention 
The DCCT, which was completed in 1993, studied 1,441 patients with Type 1 
diabetes mellitus (mean age 27 years) and showed that intensive therapy, which 
resulted in a mean HbA1c level of 7.1%, compared with conventional therapy, which 
resulted in a level of 9.0%, reduced progression of diabetic microvascular 
complications (DCCT Research Group, 1993). Although all DCCT subjects had Type 
1 diabetes, there is a theoretical reason to believe that similar benefits of intensive 
glucose control could be found in Type 2 diabetes because hyperglycaemia has been 
established as the cause of the microvascular pathology in both types of diabetes 
(Cerveny et aI., 1998). 
A limited number of studies have demonstrated reduced macrovascular 
complications with tight glycaemic control in patients with Type 2 diabetes. The 
University Group Diabetes Programme (UGDP, 1982) studied 1,021 patients with 
Type 2 diabetes (mean age 53 years) and concluded that there was no benefit from 
improved glucose control induced by insulin, biguanide, or sulphonylurea therapy in 
preventing macrovascular diabetic complications. However, this study has been 
criticised due to the unnecessary discontinuation of the oral hypoglycaemic therapy 
after 7 years leaving only the diet and insulin groups to complete the study for an 
average 12.5 years. 
In the Kumamoto trial (Ohkubo et aI., 1995), 110 Japanese Type 2 diabetic patients 
were randomised to intensive or conventional insulin therapy and were followed up 
for 6 years. The HbA 1 c level at the end of the study was 7.1 % in the intensively 
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treated group and 9.4% in the conventionally treated group. The results of the study 
demonstrated that tight control with multiple daily insulin injections resulted in a 
decrease in the onset and progression of diabetic retinopathy, nephropathy and 
neuropathy in comparison with conventional insulin therapy. However, the study has 
several limitations. It was performed in nonobese Japanese Type 2 diabetic patients. 
This may not be representative of Type 2 diabetes patients, especially those in 
Western countries. The study excluded patient with hypertension, therefore the 
reduction in the risk of nephropathy might be overestimated because of the significant 
relationship between hypertension and nephropathy. In addition, the number of 
participants was limited to 110 patients, and did not include patients receiving oral 
hypoglycaemic agents. 
The UKPDS was a large, long-term, multicentre clinical trial involving 23 centres in 
the UK between 1977 and 1991. A total of 5,102 patients with newly diagnosed Type 
2 diabetes were monitored for an average of 10 years. The study aimed to determine 
firstly whether intensive therapy of Type 2 diabetes (fasting plasma glucose <6 
mmol/l) using oral antidiabetic drugs or insulin reduced the risk of macrovascular and 
microvascular complications of diabetes compared to conventional management 
(fasting plasma glucose <15 mmol/l) which is diet therapy and secondly whether the 
use of sulphonylurea, metformin, or insulin had specific advantages or disadvantages 
(UKPDS Group, 1998d; UKPDS Group, 1998e). 
After 10 years, the results of the study showed that the mean HbA 1 c was 7.0% in the 
intensively treated group and 7.9% in the diet group (P<0.0001). This 0.9% reduction 
was associated with 12% fewer diabetes-related end-points in the intensively treated 
group (P=0.029). Diabetes-related end points were defined as sudden death, death 
from hyperglycaemia or hypoglycaemia, myocardial infarction, angina, heart failure, 
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stroke, renal failure, amputation, and eye complications. Most of this benefit was 
found with a 25% risk reduction in microvascular end-points (P=0.0099). The 
incidence of myocardial infarction was reduced by 16% in the intenSively treated 
group, but this did not reach statistical significance (P=0.052) (UKPDS Group, 
1998d). However, hypoglycaemia was more common (P<0.001) in the intensively 
treated group (0.7%lyear for conventional treatment, 1.0%/year for chlorpropamide, 
1.4%lyear for glibenclamide, and 1.8%lyear for insulin). Weight gain was significantly 
higher in the intensively treated group than in the conventional group (P<0.001). 
This evidence has demonstrated that intensive lowering of blood glucose levels 
reduces the risk of diabetic complications, the greatest effect being on microvascular 
complications. However, this effect was associated with weight gain and 
hypoglycaemia, and therefore the risks and benefits of therapy should be carefully 
considered in each individual (Krentz, 1999). 
In addition, patients with Type 2 diabetes (n = 1,148) who were also hypertensive 
were randomised to 'less tight' blood pressure control (target blood pressure < 
180/105) or 'tight' control (target blood pressure <150/85). The UKPDS study also 
investigated any benefits of lowering blood pressure in hypertenSive Type 2 diabetics 
and to ascertain whether the use of ACE inhibitors (captopril) or beta-blockers 
(atenolol) had particular therapeutic advantages or disadvantages (UKPDS Group, 
1998a; UKPDS Group, 1998b). The results of the study showed a reduction in risk of 
developing a diabetes-related end-point (P=0.005), diabetes-related death (P=0.019), 
stroke (P=0.013), and microvascular disease (P=0.009) when average blood 
pressure of 144/82 mmHg was achieved with tight control compared with an average 
blood pressure of 154/87 mmHg with less tight control. Captopril and atenolol were 
Chapter 1: Review of Literature 15 
found to be equally effective in reducing the risk of macrovascular end points, 
suggesting that BP reduction in itself may be more important than the treatment used. 
Based on these findings, there is clearly evidence to support diabetic patients to try to 
achieve and maintain long term near-normal blood glucose and blood pressure levels 
(Krentz, 1999). To achieve this, all patients with diabetes require a high level of 
health care to prevent the development of diabetic complications. This includes the 
need for regular monitoring of blood pressure, urine and blood glucose and foot and 
eye examination. The health care team has a duty to ensure that patients receive a 
high standard of care and also education about the disease to facilitate self-
management. 
1.4 Outcome measures in diabetes care 
1.4.1 HbA1c monitoring 
Haemoglobin A 1 c (HbA 1 c) is a reliable marker of chronic hyperglycaemia, and an 
appropriate predictor of diabetic complications (DCCT Research Group, 1993; 
UKPDS Group, 1998d). Since it is often difficult to perform an oral glucose tolerance 
test or obtain fasting blood samples, especially in a large-scale longitudinal study, the 
HbA 1 c test is a good alternative for assessment of glucose control. Another 
advantage of HbA 1 c is that it gives an objective assessment of glucose control over 
the past 2-3 months (Bunn, 1981). 
Several assays to measure glycosylated haemoglobin are currently available, with 
high performance liquid chromatography (HPLC) still considered the reference 
method (DCCT Research Group, 1993; UKPDS Group, 1998d). However, most of 
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these methods are time-consuming and technically demanding, and the results of the 
assay are not available at the time of the clinic visit. It should be noted that HbA 1 c 
has different normal ranges, and that various laboratories use different measures; 
each laboratory should therefore report the actual range to clinicians. 
1.4.2 Monitoring diabetic complications 
Overt diabetic nephropathy is classified as a protein positive (1 + or greater) urine 
dipstick test, which represents macroalbuminuria, or an albumin concentration of 
greater than 300 mg/g creatinine. Dipstick tests that are negative or show positive 
traces of protein should be followed with screening for early diabetic nephropathy, 
commonly referred to as microalbuminuria which is a good predictor of mortality 
(especially in Type 2) and morbidity in diabetes (Vijan et aI., 1997). 
Microalbuminuria is usually defined as an excretion rate of albumin between 30-300 
mg/day or 20-200 Jlg/min or a urinary albumin-to-creatinine ratio of 3-30 Jlg/mg. Due 
to the significance of microalbuminuria in the development of subsequent renal 
disease and because treatment may be effective at this stage, it is important to 
screen for this biochemical abnormality. Detection of microalbuminuria is critical in 
the diagnosis of early renal disease, particularly in patients with both diabetes and 
hypertension. An excretion rate below 30 mg/day is designated normoalbuminuria. 
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1.4.3 Quality of life measurement 
It is being increasingly recognised that the impact of chronic illness and its treatment 
should be considered in terms of their influence on quality of life in addition to 
traditional clinical variables (Muldoon et aI., 1998). Quality of life is a patient outcome 
measure, and its improvement is supported as one of the ultimate goals of 
pharmaceutical care (Hepler and Strand, 1990). While there is a growing interest in 
the measurement of patient's quality of life and in the number of instruments being 
developed (Sanders et aI., 1998), there is an absence of clear agreement on a 
definition of quality of life (Leplege and Hunt, 1997; Muldoon et aI., 1998). QOL has 
been defined by the WHOQOL Group (1993) as the "individuals' perceptions of their 
position in life in the context of the culture and value systems in which they live, and 
in relation to their goals, expectations, and concerns". 
To distinguish between quality of life, which refers to an assessment of all aspects of 
a person's life, the term 'health related quality of life (HRQOL) is frequently used in 
order to be more specific on those aspects that are significantly influenced by the 
personal health status (Guyatt et aI., 1993). An assessment of HRQOL typically 
measures a number of domains (also known as mUlti-dimensional construct), 
including physical, emotional and social functioning (Leplege and Hunt, 1997). 
In the case of diabetes and its treatment, health related quality of life considerations 
are of special importance. Diabetes can have considerable impact on the quality of 
life, with possible limitations of work, social life, family relations, sexual relationships 
and leisure activities. As shown in the study of Wandell and Tovi (2000), the HRQOL 
assessed by the Swedish Health-Related Quality of Life Survey (SWED-QUAL) was 
found to be poorer in elderly diabetic subjects (n = 177 respondents) than in age-
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matched controls from the general population, especially regarding different aspects 
of physical functioning. Poor metabolic control, with HbA 1 c levels more than 2% over 
reference, was also associated with reduced cognitive function. 
Glycaemic control can enhance the health related quality of life in diabetic patients by 
minimising the effects of hyperglycaemia and morbidity. However, Jacobson et al. 
(1994) reported that patients taking oral medications had more diabetes-related 
worries than those controlling their diabetes with diet and exercise only, and that 
those taking insulin reported less satisfaction with treatment and more burden of 
illness than those taking oral medications. Others have suggested that experiencing 
hypoglycaemia and the difficulty associated with intensive therapeutic regimens could 
have adverse effects on patient's health related quality of life (OCCT Research 
Group, 1993). 
HRQOL was assessed in Finnish Type 2 diabetic patients aged under 65 years using 
the Medical Outcomes Study Short Form (SF-20) (Hanninen et aI., 1998). In this 
study 260 diabetic subjects were compared with 177 non-diabetic age- and gender-
matched controls. The results indicated that patients with Type 2 diabetes had 11-
27% lower mean scores than the controls in all six dimensions. The study also 
showed that obesity, longer duration of diabetes, insulin treatment and impaired 
visual acuity were associated with poor HRQOL. Similar results were also found in 
the study of Keinanen-Kiukaanniemi et al. (1996) in the district of Oulu, Northern 
Finland. The HROOL of 1,804 adult diabetic patients was studied by using the 
Nottingham Health Profile (NHP) in order to describe differences in the HRQOL 
between the different treatment groups and between diabetic patients and the 
general population. The results demonstrated that the HROOL was poorer in diabetic 
subjects with tablet treatment than in the general population in all NHP dimensions. 
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Among the different treatment groups, they found that the diet group had a 
significantly better HROOL level in all six dimensions than the tablet treatment or 
combined treatment (tablet and insulin) groups. 
Using HROOL measures in studies of diabetic interventions may assist in gaining a 
view into the effects of the intervention on the patient's health related quality of life. 
This information may be helpful in assessing and developing intervention 
programmes that achieve good control of diabetes and its complications while 
maximiSing patient's well-being in relation to health. 
In diabetic patients, some studies of health related quality of life have been performed 
using several generic (Hanninen et aI., 1998; Hiltunen and Keinanen-Kiukaanniem, 
1999; Klein and Klein, 1998; Weinberger et aI., 1994) or diabetes-specific 
questionnaires (Boyer and Earp, 1997; Bradley et aI., 1999; DCCT Research Group, 
1988; Goddijn et aI., 1999) or with both (Anderson et aI., 1997; Jacobson et aI., 1994) 
and patients with Type 1 or Type 2 (Hiltunen et aI., 1999; Klein and Klein, 1998) or 
only with Type 2 (Boyer and Earp, 1997; Bradley et aI., 1999; Goddijn et aI., 1999; 
Hanninen et aI., 1998; Jacobson et aI., 1994; Weinberger et aI., 1994). 
1.4.3.1 Generic health related quality of life instruments 
There are a number of generiC health related quality of life instruments currently 
available for assessing the impact of treatment on quality of life. These instruments 
have been developed for use in any population regardless of the specific disease. 
The main limitations of such instruments are that they may be less sensitive to 
changes in specific conditions, may not cover the appropriate areas of interest in 
sufficient detail, and their validation may be inappropriate for a particular study. 
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Conversely the use of a generic instrument allows for unexpected effects by taking a 
broad approach and allows for comparisons to be made across different studies, 
health care programmes, and patient groups (Guyatt et aI., 1993; Anderson et aI., 
1997). Table 1.1 provides examples of widely used generic health related quality of 
life measures. 
Table 1.1 Summary of generic QOL measures and examples of clinical trials In 
which they were used 
Measure 
Sickness 
Impact Profile 
(SIP) 
Nottingham 
Health Profile 
(NHP) 
Characteristics 
Clinical trial 
Population 
Sample size 
No. of domains 
Name of domains 
No. of items 
Response scale 
Mode of administration 
Validity 
Reliability 
Language 
Clinical trial 
Population 
Sample size 
No. of domains 
Name of domains 
No. of items 
Response scale 
Mode of administration 
Validity 
Reliability 
Language 
Details 
Oeyo et al., 1983 
Outpatients with rheumatoid arthritis 
79 patients 
12 
Physical: ambulation, mobility, body care 
and movement 
Psychosocial: communication, alertness, 
emotional behaviour, social interaction 
Independent categories: sleep and rest, 
eating, work, home management, 
recreation and pastimes 
136 
Tick if item applies 
Self-administered 
Criterion validity 
Test-retest reliability 
US version 
O'Brien et aI., 1993 
Cardiac patients at 6 months after 
myocardial infarction 
185 patients 
6 
Energy, pain, sleep, physical mobility, 
social isolation and emotional reactions 
38 
Yes/no response 
Self-administered 
Construct validity: Spearman correlations 
with the New York Heart Association 
(NYHA) ranged from 0.30 to 0.52 
Spearman correlations among domain 
scores ranged from 0.32 to 0.70 
British version 
Table 1.1 continues overleaf 
Measure 
Medical 
Outcome Study 
(MOS) Short-
Form General 
Health Survey 
(SF-36) 
World Health 
Organisation 
Quality of life 
(WHOQOL-100) 
Characteristics 
Clinical trial 
Population 
Sample size 
No. of domains 
Name of domains 
No. of items 
Response scale 
Mode of administration 
Validity 
Reliability 
Language 
Clinical trial 
Population 
Sample size 
No. of domains 
Name of domains 
No. of items 
Response scale 
Mode of administration 
Validity 
Reliability 
Language 
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Details 
Brazier et aI., 1992 
Patients aged 16-74 years randomly 
selected from two general practices in 
Sheffield 
1,980 patients 
8 
Physical functioning, role limitations due 
to physical health problems, bodily pain, 
social functioning, general mental health, 
role limitations due to emotional 
problems, vitality, and general health 
perceptions 
36 
2-,3-,4-,5- or 6-point Likert scales 
Self-administered 
Construct validity, the SF-36 was able to 
detect low levels of ill health in patients 
who had scored 0 on the NHP 
Internal consistency: Cronbach's alpha 
greater than 0.85 
Test-retest reliability: reliability coefficient 
greater than 0.75 for all dimensions 
except social functioning 
British version 
Bonomi et aI., 2000 
The study population consisted of three 
groups: healthy adults, childbearing 
women, and chronically ill participants 
443 participants 
6 
Physical health, psychological state, level 
of independence, social relationships, 
environment, and spirituality 
100 
5-point Likert scale 
Self-administered 
Construct validity: Pearson correlations 
with the SF-36 and Subjective Quality of 
Life Profile were moderate to high (r > 
0.45). 
Internal consistency: the alpha coefficient 
for each domain exceeded 0.80 (range 
0.82-0.95). 
Test-retest: Intraclass correlation 
coefficient exceeded 0.70 for all domains 
(range 0.83-0.96). 
US version 
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Sickness Impact Profile (SIP) 
The SIP was developed in the United States as a behaviourally based assessment of 
the impact of illness on everyday life (Bergner et aI., 1981). It consists of 136 yes/no 
items describing behaviour related to health within 12 dimensions (Table 1.1). It 
emphasises the impact of health upon activities and behaviour, including social 
functioning, rather than on feelings and perceptions. Scores range from 0 to 100, 
with higher scores reflecting lower quality of life. 
The SIP appeared to be a generally well constructed, reliable and valid measure of 
functional status, though its length is not an advantage (Bergner et aI., 1981; de Bruin 
et aI., 1992). The summary by de Bruin et al. indicated alpha coefficients ranging 
from 0.91 to 0.95 for the overall score, from 0.84 to 0.93 for dimension scores, and 
from 0.60 to 0.90 for category scores. In term of validity, almost all correlations of the 
SIP overall score compared with 13 other health measures exceeded 0.50. However, 
it cannot be assumed as valid for all conditions. The estimated time to complete the 
136 items is 20-30 minutes (de Bruin et aI., 1992; Weinberger et aI., 1991). For 
chronically or acutely ill patients it is likely to take even longer and this may lead to a 
reduced response rate. 
Nottingham Health Profile (NHP) 
The NHP was developed in the UK as a measure of generic health related quality of 
life (Hunt et aI., 1981). The design and content of the NHP was influenced by the SIP, 
but includes questions about feelings and emotions directly rather than via changes 
in behaviour. It is divided into two parts. The first part consists of 38 items grouped 
into six dimensions (Table 1.1). The second part contains seven items that measure 
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the effects of health problems on paid employment, jobs around the house, social life, 
home life, sex life, hobbies, and holidays. This part is optional as some items, such 
as work and sex life, may not be applicable. Yes/no responses are used throughout 
the questionnaire. It is self-administered and takes approximately 10-15 minutes to 
complete. 
Test-retest reliability is adequate, with correlations ranging from 0.77 and 0.85 in 
patients with chronic illness (Hunt et aI., 1981). The advantages of the NHP over 
other generic health related QOL are that it is short, easy to administer, and easily 
understood by patients (Jenkinson, 1991). The NHP has been shown to be 
responsive in a variety of patient groups, but it tends to emphasise severe disease 
states and is perhaps less sensitive to minor changes in health state (Hunt et aI., 
1981; Jenkinson, 1991; Brazier et aI., 1992). 
Medical Outcomes Study (MOS) Short-Form General Health Survey 
The MOS instrument includes physical, social and role functioning scales to detect 
behavioural dysfunction caused by health problems. The 20-item shortened form of 
the MOS instrument, SF-20, was published in 1988 (Stewart et al.,1988), and the SF-
36 was designed later in 1992 0/Vare and Sherbourne, 1992) in response to criticisms 
that SF-20 was too limited in scope to detect changes in health status. 
The SF-36 includes multi-item scales to measure eight domains (Table 1.1). Each 
domain is transformed to a 0 to 100 scale, with higher scores indicating higher 
HRQOL. The instrument is self-administered and generally takes five to ten minutes 
to complete while an average of 15 minutes may be required for elderly respondents 
0/Veinberger et aI., 1991). 
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The strengths of the instrument include its brevity and its applicability to a variety of 
disease states. The SF-36 has undergone reliability and validity testing in many 
countries, including the United Kingdom (Brazier et aI., 1992). It has been found to be 
reliable and valid in general populations, and populations with chronic diseases 
(Stewart et aI., 1988; Stewart et aI., 1989; Ware and Sherbourne, 1992). However, as 
with any brief generic health related QOL instrument, it remains possible that some 
aspects of life are not covered. Some have commented on the limitations of the SF-
36 in that there is no assessment of cognitive function or distress (Hays and Shapiro, 
1992), and that the physical activities items focus only on gross activities such as 
walking, bending, and kneeling, but do not cover coordinated actions (Anderson et 
aI., 1993). 
World Health Organisation Quality of Life (WHOQOL-100) 
WHoaOL-100 is a newer generic health related quality of life instrument, which was 
developed through collaborative work to assess quality of life across various disease 
types, severities, and cultural subgroups (WHOQOL group, 1995). Fifteen centers 
around the world partiCipated in the development and piloting of the WHOaOL pilot 
form (WHOaOL group, 1995). Each center explored the important aspects of quality 
of life and ways of asking about quality of life. There was high agreement about what 
aspects of life were considered important and these fell into six domains (Table 1.1). 
These domains contain 24 four-item facets (subscales), for a total of 96 items, plus 
one additional facet (four items) regarding global aOL and general health. The 
scores of each facet and domain are transformed to a 0 to 100 scale, a higher score 
represents better aOL (Bonomi et a/., 2000). It was noticed that some aspects, such 
as safety of the environment in which they live, and their current spiritual status, are 
not included in other instruments. WHOaOL-100 was tested to assess its validity and 
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reliability in each of the centers and it was shown to be reliable and valid across 
cultures. 
The instrument is self-administered taking generally about 10-20 minutes to complete 
(Bonomi et aI., 2000). Although the WHOQOL can be used successfully for a 
comprehensive assessment of QOL in many clinical studies, its length is considered 
to be unsuitable for use on a daily basis and in longitudinal studies (Saxena and 
Orley, 1997). 
The WHOQOL group recently developed a brief 24-item version, the WHOQOL-Brief 
(WHO, 1997). The WHOQOL-Brief contains four domains: physical, psychological, 
social relationships, and environment. Its reliability and validity evaluation is currently 
being tested in multiple countries (WHO, 1997). 
1.4.3.2 Diabetes-specific quality of life instruments 
Although there are well-designed generic health related quality of life instruments, 
these may not be specific enough to address some aspects of quality of life in 
diabetes such as hypoglycaemia, insulin injections, self-monitoring of blood glucose, 
dietary restrictions, and diabetic complications which may be critical to an individual's 
health related quality of life (Bradley, 1994). There have been studies measuring 
health status of patients with diabetes using generic measures of QOL, such as SF-
36, compared to diabetes-specific measures (Jacobson et aI., 1994; Anderson et aI., 
1997). It is important to note that whilst generic measures allow comparisons across 
different studies and disease groups, their need to cover a wide range of issues can 
make them less sensitive in identifying disease related problems and less responsive 
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to therapeutic effects, especially when the effects result in differences in lifestyle 
rather than functional health status. 
There are a rather limited number of valid diabetes-specific quality of life measures 
(Bradley, 1994). The DQOl (Diabetes Quality of Life) was the first diabetes-specific 
measure to be used in a number of studies (DCCT Research Group, 1988; Jacobson 
et aI., 1994; Parkerson et aI., 1993). Alternative diabetes-specific quality of life 
measures include the DHP (Diabetes Health Profile), Diabetes-39, and ADDQol (The 
audit of diabetes-dependent quality of life) all of which have recently been developed 
and validated. Table 1.2 describes clinical trials in which diabetes-specific measures 
have been studied in term of validity, reliability, and characteristics of the measures. 
Chapter 1: Review of Literature 27 
Table 1.2 Summary of diabetes-specific QOL measures and examples of 
clinical trials in which they were used 
Measure 
Diabetes Quality 
Of Life (DQOl) 
Diabetes Health 
Profile (DHP) 
Characteristics 
Clinical trial 
Population 
Sample size 
No. of domains 
Name of domains 
No. of items 
Response scale 
Mode of administration 
Validity 
Reliability 
Language 
Clinical trial 
Population 
Sample size 
No. of domains 
Name of domains 
No. of items 
Response scale 
Mode of administration 
Validity 
Reliability 
Language 
Details 
Jacobson et aI., 1994 
Adult Type 1 or Type 2 diabetes patients 
from the outpatient department of the 
Joslin Diabetes Center in Boston 
240 patients 
4 
Satisfaction, impact of diabetes, 
diabetes-related worry, and social and 
vocational worry 
46 
5-point Likert scale 
Self-administered 
Construct validity: Pearson correlations 
with the SF-36 were modest (range of 
correlations: -0.003 to 0.60). 
Internal consistency: Cronbach's alpha 
coefficients ranged from 0.47 to 0.87. 
US version 
Goddijn et aI., 1966 
Dutch Type 2 diabetes patients referred 
by their GPs for insulin therapy 
99 patients 
3 
Psychological distress, barriers to 
activity, and disinhibited eating 
32 
4-point Likert scale 
Self-administered 
Construct validity: Spearman correlations 
with the RAND-36 were moderate to high 
(r> 0.45). 
Internal consistency: Cronbach's alpha 
for each domain exceeded 0.70 (range 
0.72-0.79). 
Dutch version 
Table 1.2 continues overleaf 
Measure 
Diabetes-39 
The Audit of 
Diabetes-
Dependent 
Quality of Life 
(ADDQoL) 
Characteristics 
Clinical trial 
Population 
Sample size 
No. of domains 
Name of domains 
No. of items 
Response scale 
Mode of administration 
Validity 
Reliability 
Language 
Clinical trial 
Population 
Sample size 
No. of domains 
Name of domains 
No. of items 
Response scale 
Mode of administration 
Validity 
Reliability 
Language 
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Details 
Boyer and Earp, 1997 
Adult diabetic patients from general 
practice and a group of outpatients from 
a hospital diabetes clinic 
427 
5 
Energy and mobility, diabetes control, 
anxiety and worry, social burden, and 
sexual functioning 
39 
7 -point rating scale 
Self-administered 
Construct validity: correlations with the 
SF-36 were weak (weakest, r = 0.15) to 
strong (range 0.48-0.71). 
Internal consistency: Cronbach's alpha 
for each domain exceeded 0.70 (range 
0.81-0.93). 
US version 
Bradley et al.. 1999 
The Cambridge sample (outpatient 
diabetes clinic attenders at 
Addenbrooke's hospital) and the Bromley 
sample (diabetes patients attending an 
educational programme) 
52 outpatients with diabetes and 102 
patients attending diabetes education 
13 
Employment/career, social life, family 
relationships. friendships, sex life, 
sport/leisure, travel, future (own), future 
of family, motivation, physical activities, 
other fussing, and enjoyment of food 
13 diabetes-specific items and two 
general items 
7 -point rating scale for domain questions 
and 4-point rating scale for importance 
rating to allow weighting of scores 
Self-administered 
Construct validity: the ADDQoL score 
correlated significantly with the number 
of complications (Spearman r = -0.21). 
Internal consistency: Cronbach's alpha 
coefficient for each domain exceeded 
0.80. 
British version 
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Diabetes Quality of Life (OQOl) 
The DeOl instrument was designed in the 1980s for use in the DeeT, comparing 
the efficacy of different insulin regimens on the development of chronic complications 
of Type 1 diabetes (DeeT Research Group, 1988). It was designed originally to 
evaluate the relative burden of an intensive diabetes treatment in comparison to 
standard treatment. It is particularly suited for use in diabetic populations taking 
insulin although it may be used in Type 2 diabetics who are on diet or oral 
antidiabetic treatment as demonstrated by the study of Jacobson et al. (1994). 
The DeOl instrument is a 46-item, multiple choice, self-administered assessment 
with four subscales (Table 1.2). It uses a 5-point Likert-type scale that ranges from 1 
(very satisfied, no impact, no worry) to 5 (very dissatisfied, high impact, very worried). 
To be more readily interpretable and less confusing, it was proposed by Jacobson et 
al. (1994) to transform DeOl scores to a 100 point scale where 0 represents the 
lowest possible quality of life, and 100 represents the highest possible quality of life. 
Jacobson et al (1994) measured patients' quality of life using the DeOl and SF-36 
instrument. In this study, 240 patients were assessed, of whom 111 had Type 1 
diabetes and 129 had Type 2 diabetes. Patients were 18 to 80 years of age and were 
not excluded if they had diabetic complications. The mean age of the Type 1 diabetes 
patients was 44 and the mean age of the Type 2 diabetes patients was 60. Thirty-
eight percent of the Type 2 diabetics were on an oral antidiabetic agent and 53% 
were treated with insulin. The DeOl instrument was shown to have a moderately 
strong correlation with SF-36 (Table 1.2), with the satisfaction and impact scales 
having the strongest relationships overall with the functional health status scales of 
the SF-36. The study also provided information about external validity with the OQOL. 
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Patients with different frequency and severity of diabetes complications were 
compared in term of their diabetes-specific quality of life. It was found that increasing 
severity and number of complications were associated with lower levels of 
satisfaction and greater impact of diabetes, while the worry scales were less sensitive 
to complications. As the instrument was designed for use with adolescents, 
Jacobson et aI., (1994) commented that the social and diabetes worry scales are less 
relevant for adults and elderly patients. 
However there was some doubt as to the sensitivity and discriminant validity of this 
instrument which became apparent in the DCCT (1996). Results showed no 
difference in quality of life between intensive and conventional diabetes treatment. 
Although it was concluded that intensive diabetes treatment did not lead to a 
deterioration in quality of life, there have been criticisms that the instrument should be 
able to detect differences in quality of life between the two patient groups because 
they had different levels of glycaemic control, different incidence rates of severe 
hypoglycaemia and complications (Bott et aI., 1998; Bradley et aI., 1999). 
As with any disease- specific measure, it is unlikely that the scope of the instrument 
will cover all elements of change relevant to the study. For example, there are no 
items regarding the impact on sexual functioning. In this case, it was suggested that 
questions could be added if an intervention being evaluated was expected to have 
this particular consequence and to score these separately (Bradley, 1994). 
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Diabetes Health Profile (DHP) 
The DHP was developed by Meadows et al. (1996) for the identification of 
psychological and behavioural dysfunctioning of adult insulin-dependent and insulin-
requiring patients in an ambulatory care setting. The DHP contains 32 items 
measuring three domains: psychological distress, barriers to activity and disinhibited 
eating (Table 1.2). The questions are provided with 4-point Likert-type scales rated 
from 0-3. Each subscale score is then transformed to a common score range of 0-
100, where 100 represents no function. The DHP is self-administered and takes 
approximately 15-20 minutes to complete (Bradley, 1994). 
The DHP contains some questions regarding fear of hypoglycaemia which are less 
relevant in Type 2 diabetes patients and also a question concerning insulin injection, 
which was omitted from the study of Goddijn et al. (1999) as the subjects in that 
particular study were not using insulin. This study demonstrated that the DHP was 
not very sensitive to changes in glycaemic control, treatment modality and change in 
hyperglycaemic complaints, while a generic questionnaire (RAND-36) was more 
sensitive in this aspect. 
Diabetes-39 
The Diabetes-39 instrument (Boyer and Earp, 1997) contains 39 items referring to 5 
domains (Table 1.2). It was developed for use with patients who have either Type 1 
or Type 2 diabetes, whether managed with insulin, oral antidiabetic agents or diet 
alone. It uses a 7 -point rating scale (from 'not at all' to 'extremely') to express how 
much of an influence each item has had on their health related quality of life. 
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Boyer and Earp (1997) reported internal reliability for the domains of the Diabetes-39 
as ranging from 0.81 to 0.93 (Table 1.2), which was sufficient to support claims of 
internal reliability. Correlations between the Diabetes-39 and the SF-36 ranged from -
0.15 to -0.64. Strong negative correlations were identified between "Energy and 
Mobility" and the SF-36 "Physical Functioning" scales; "Anxiety and Worry" and the 
SF-36 "Mental Health" scales; and "Social Burden" and SF-36 "Social Functioning" 
scales. 
Hirsch et al. (2000) evaluated QOL scales and divided these into 'burden' type and 
'satisfaction' type. They studied five QOL questionnaires, including SF-36 and 
Diabetes-39, in a sample of 144 patients with Type 2 diabetes who were given the 
questionnaires twice. In this study the Diabetes-39 instrument was classified as a 
'burden' type. The results demonstrated that the Diabetes-39 scales were not 
sensitive to different types of therapy. The physical burden scores increased very 
significantly with late complications, but the scale scores showed no changes after 
therapeutic intervention. 
The Audit of Diabetes-dependent Quality of Life (ADDQoL) 
The ADDQoL was developed in the UK for use in patients with either Type 1 or Type 
2 diabetes by Bradley et al. (1999). It consists of 13 diabetes-specific items and two 
general items (Table 1.2). Some selected items have 'not applicable' options, which 
are not used in the ADDQoL weighted mean. Within each diabetes-specific domain, 
respondents rate both impact of diabetes on each item and also the importance of 
those items for their health related quality of life. Impact ratings are multiplied by the 
corresponding importance rating to provide a score from -9 to +9 for each domain. 
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The ADDQoL is self-administered however no completion time has been reported 
(Bradley et aI., 1999; Kinmonth et aI., 1998). 
The ADDQoL is a recently developed diabetes-specific QOL measure, and there is 
only preliminary evidence for its validity (Bradley et aI., 1999). However, in terms of 
construct validity, results show differences between patients treated with insulin 
versus those on oral antidiabetic agent or diet treatment. Insulin users reported 
significantly greater negative impact of diabetes on most domains. In addition, people 
with greater reported complications had greater QOL impairment. Reliability for the 
ADDQoL has been reported: range 0.81-0.84 for Cronbach's alpha coefficient if item 
deleted, suggesting highly satisfactory internal consistency and reliability. Evidence 
for sensitivity to change of the ADDQoL has been drawn from a finding that diabetes 
had greater reported impact on diabetes-specific domains (such as enjoyment of 
food, worried about future and travel) than on standard QOL domains (such as work 
and social life). 
1.4.4 Targets for glycaemic control and relevant measures 
In 1989 the St Vincent declaration made recommendations for the care of patients 
with diabetes, including targets for the reduction of diabetic complications. The World 
Health Organisation (WHO) and the International Diabetes Federation (IDF) have 
drawn up a data set to monitor progress in reaching the targets of the St. Vincent 
declaration (Anonymous, 1990). The Desktop Guide for the management of Type 2 
diabetes by the European Diabetes Policy Group (Anonymous, 1999a) recommends 
HbA1c (DCCr standardised) ~ 6.5% and blood pressure <140/85 as a low risk group 
for diabetic complications. 
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The clinical practice recommendations of the American Diabetes Association (ADA) 
(1998c) suggest a treatment HbA1c standard of <7% and a blood glucose self-
measurement target of 80-120 mgldl before meals and of 100-140 mgldl at bedtime 
in patients who do not have severe or unrecognised hypoglycaemia, and suggest 
therapeutic action when HbA 1 c exceeds 8%. 
Diabetes UK, formerly the British Diabetic Association (Diabetes UK, 1999), in the 
light of the UKPDS results, has suggested that HbA1c level of 7.0% or below and 
fasting blood glucose levels of 4-7 mmolll should be the target for glycaemic control 
in diabetic patients. 
In March 1996 the Scottish Intercollegiate Guidelines Network (SIGN) published a 
national clinical guideline for the prevention of visual impairment in diabetes (SIGN, 
1996). Further guidelines followed on the management of cardiovascular disease in 
diabetes (SIGN, 1997a), diabetic foot disease (SIGN, 1997b) and diabetic renal 
disease (SIGN, 1997c). 
1.4.5 Targets for blood pressure lowering in diabetes 
In the hypertension subgroup of the UK Prospective Diabetes Study (UKPDS Group, 
1998a), those with Type 2 diabetes (Mean BP of 160/94 mmHg) was randomised to 
intensive or conventional antihypertensive treatment. The average BPs achieved 
were 144/82 mmHg in the intensive group and 154/87 mmHg in the conventional 
group. In the intensive group, treatment of hypertension was associated with a 
reduction in the risk of stroke (44%), deaths related to diabetes (32%) and 
microvascular disease (37%). 
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The Hypertension Optimal Treatment (HOT) study (Hansson et aI., 1998) 
demonstrated the benefits of lowering BP to ;s; 140/85 mmHg in patients with 
hypertension. In patients with diabetes, there was a 51% reduction in major 
cardiovascular events (non-fatal MI, non-fatal stroke, and cardiovascular death) in the 
group with target diastolic BP < 80 mmHg, as compared to the group with a target of 
<90 mmHg. 
Based on the significantly elevated risk of cardiovascular disease in patients with 
Type 2 diabetes, both the American Diabetes Association (1998c) and the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC VI) (Anonymous, 1997) recommend a blood pressure of less 
than 130/85 mmHg as a goal in diabetic patients. It should be noted that the 
approximate level of systolic blood pressure achieved (144 mmHg) with intensive 
treatment in the UKPDS (144/82 mmHg) was higher than the ADA recommendation 
of 130 mmHg, although the diastolic blood pressure (82 mmHg) was lower than 85 
mmHg. However, it has been suggested that more aggressive treatment of high 
blood pressure might be useful in patients with microalbuminuria (Marshall 1999). 
According to the World Health Organisation/lnternational Society of Hypertension 
guidelines (Anonymous, 1999b), blood pressure in patients with diabetes should be 
reduced to below 140/90 mmHg. In the UK Diabetes UK (1999) has suggested that 
140/80 mmHg should be the target blood pressure in diabetic patients. 
In addition, aspirin treatment should be considered in patients with diabetes as a 
means of primary prevention of CVD. The HOT study (Hansson et aI., 1998) showed 
that aspirin significantly reduced the frequency of major cardiovascular events by 
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15% and all MI by 36%. The benefit of aspirin was the same in the groups of patients 
with diabetes and ischaemic heart disease as it was in the whole HOT population. 
1.5 Pharmaceutical Care in Type 2 diabetes 
1.5.1 Concepts of Pharmaceutical Care 
The process of pharmaceutical care has the patient as the main focus for activity. 
Pharmaceutical care has been defined as -the responsible provision of drug therapy 
for the purpose of achieving definite outcomes that improve a patient's quality of life." 
(Hepler and Strand, 1990). The purpose of this practice philosophy is to ensure that 
individual patients receive the right drug, in the right dose, in the right form at the right 
time and to ensure that medication related health outcomes are optimised for the 
patient (Hepler, 1987; Hepler and Strand, 1990). In providing pharmaceutical care 
consistent with this philosophy, pharmacists become involved in three major functions 
which include identifying actual and potential drug related problems (DRPs), resolving 
actual DRPs, and preventing potential DRPs (Hepler and Strand, 1990). 
Expanding from the traditional compounding role of pharmacists, the provision of 
pharmaceutical care has required pharmacists to optimise patient's therapy and to 
increase their relationships with patients and collaboration with other health care 
providers (Cipolle, 1998). This broader view of pharmacists' activities has been 
advanced, not only in the US, but also in many other countries (Foppe van Mil, 1999; 
Gilbert, 1995; Ibrahim, 1997). In the UK, pharmacists were familiar with the field of 
clinical pharmacy, the provision of information to patients, and cooperation with 
doctors. The philosophy articulated by Hepler and Strand (1990) for the development 
of pharmaceutical care was adopted in the UK in order to increase awareness of 
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pharmacists' responsibilities with respect to individual patients. The United Kingdom 
Clinical Pharmacy Association (UKCPA) (1996) launched a statement on 
pharmaceutical care intended to encourage the development and evaluation of new 
services to patients. 
The benefits of pharmaceutical care models on patient outcomes of several disease 
states have been previously documented. Knoell et al. (1998), for example 
demonstrated a positive impact of a pharmacist-provided comprehensive education 
programme in an asthma outpatient clinic. A study by Varma et al. (1999) also 
showed improved outcomes in exercise capacity, compliance with drug therapy, 
knowledge of drug therapy and fewer hospital admissions in elderly patients with 
congestive heart failure who received education from a pharmacist, compared with 
control patients. 
1.5.2 Interventions to improve diabetes management from previous 
studies 
In term of diabetes management, a literature review revealed a limited number of 
published studies on the impact of a pharmacist intervention on patients with diabetes 
(Berringer et aI., 1999; Coast-Senior et aI., 1998; Hawkins et aI., 1979; Huff et aI., 
1983; Jaber et aI., 1996; Schilling, 1977, Wilcock, 2000). Studies during the 1970s 
and 1980s have primarily focused on the impact of diabetes education, and 
increasing patient compliance. Although disease-specific outcome measures were 
not consistently obtained, these studies demonstrated that pharmacist-oriented 
services produced a favourable impact. Since the 1990s studies have focused on 
drug therapy monitoring and disease outcomes and have paid closer attention to the 
issue of pharmaceutical care services. However, few studies have been conducted 
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in the UK, with those conducted mostly in the community pharmacy setting. Table 1.3 
provides a summary of pharmacist interventions in the management of diabetes. 
Table 1.3: Summary of pharmacist interventions in diabetic patients 
References Characteristics 
Schilling, 1977 Population 
Sample size 
Site 
Research design 
Intervention 
Outcome measure 
Hawkins et aI., Population 
1979 Sample size 
Site 
Research design 
Intervention 
Outcome measure 
Huff et aI., 1983 Population 
Sample size 
Site 
Research design 
Intervention 
Outcome measure 
Details 
Diabetic patients 
Not stated 
58-bed Indian Health Service Hospital 
Intervention without either randomisation 
or control group 
Pharmacist ran clinic (education, 
compliance assessment, monitoring, dose 
adjustment and referral) 
Not stated 
Hypertensive and diabetic patients 
349 intervention and 280 control 
Medical follow-up clinic at the hospital in 
San Antonio, Texas 
RCT 
Clinical pharmacist with physician review. 
Details not stated 
BP and fasting blood sugar levels, kept-
clinic-appointment rate, frequency of 
hospital admissions 
Diabetic patients 
Not stated 
Three ambulatory-care centers 
Intervention without either randomisation 
or control group 
Diabetes-patient education 
Not stated 
Table 1.3 continues overleaf 
References Characteristics 
Van Veldhuizen- Population 
Scott et aL, 1995 
Sample size 
Site 
Research design 
Intervention 
Outcome measure 
Jaber et aL, 1996 Population 
Sample size 
Site 
Research design 
Intervention 
Outcome measure 
Coast-Senior et Population 
aL, 1998 
Sample size 
Site 
Research design 
Intervention 
Outcome measure 
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Details 
Patients attending the educational 
programme at the Regional Diabetes 
Center in Lafayette, Indiana, from May 
through December 1993 
41 patients (13 intervention group 1, 14 
intervention group 2, 14 control) 
Diabetes center 
RCT 
Additional small group or individual 
supplementary education with follow-up 
telephone contact by the pharmacist 
Changes in blood glucose levels, 
responses on a pretest and posttest 
questionnaire 
African-American Type 2 diabetes 
patients 
39 patients (17 intervention, 22 control) 
Outpatient clinic 
RCT 
Diabetes education, medication 
counselling, instruction on dietary 
regulation, exercise, and home glucose 
monitoring, and evaluation and 
adjustment of antidiabetes drug regimen 
Fasting plasma glucose and glycated 
haemoglobin concentrations 
Patient with Type 2 diabetes who 
received insulin and were willing to 
perform self-monitoring of blood glucose 
23 patients 
Primary care clinics 
Intervention without either randomisation 
or control group 
The pharmacists provided diabetes 
education, medication counselling, 
monitoring, and insulin initiation and/or 
adjustments. 
Changes from baseline in glycosylated 
haemoglobin, fasting blood glucose, and 
random blood glucose measurements. 
Table 1.3 continues overleaf 
References Characteristics 
Berringer et aI., Population 
1999 ,; 
Wilcock, 2000 
Sample size 
Site 
Research design 
Intervention 
Outcome measure 
Population 
Sample size 
Site 
Research design 
Intervention 
Outcome measure 
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Details 
Type 1 or Type 2 diabetes patients 
receiving prescription services from two 
independently owned community 
pharmacies in Richmond, Virginia 
52 patients 
Community pharmacy 
Intervention without either randomisation 
or control group 
Routine monitoring using 'Diabetes 
Checklist', chart review, and identify drug-
related problems and develop plan 
Self-monitoring blood glucose (SMBG) 
results, 5MBG frequency, and 
antidiabetes agent adherence rates 
People receIving a service from 
community pharmacies during three-
month period. 
Not stated 
Community pharmacies in Cornwall 
Intervention without either randomisation 
or control group 
Pharmacist identified diabetes-related 
problem, resolved the problem within the 
pharmacy or made GP referral if 
appropriate. 
Number of patients given a referral slip, 
number of patients with pharmacist 
intervention 
Schilling (1977) described a pharmacist involvement in a programme for monitoring 
and treating diabetic patients in hospital. Patients were seen by the pharmacist 
instead of a doctor for routine diabetes management including education, compliance 
assessment, alteration of medication doses based on blood and urine glucose 
readings and referral when appropriate. Although the report described the 
programme in specific details, no outcome measures were provided. 
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Hawkins et al. (1979) reported a randomised controlled trial assessing the 
effectiveness of a clinical pharmacist intervention on the management of patients with 
hypertension and diabetes in a pharmacist-run clinic setting. The study results 
indicated that the experimental group experienced higher patient satisfaction 
attributed to higher kept-clinic appointment and lower drop-out rates. No evidence 
was provided to support the claim that attendance rates equated to patient 
satisfaction. Fasting blood glucose in patients with diabetes were not significantly 
changed by the pharmacist interventions. No analysis of HbA 1 c was provided for 
comparison of longer term glycaemic control measurement. The only clinical endpoint 
which was reported as statistically significant was systolic blood pressure which was 
reported to be lower in the control group (143 to 141) compared to the intervention 
group from baseline to follow up (145 to 147). 
Huff et al. (1983) described a reimbursed pharmacist-managed educational service 
successfully provided over a 10-year period. The pharmacist-educators' 
responsibilities included assessment, planning, instruction, and follow-up. However, 
objective assessment of the impact of these services on disease outcome was not 
published. 
Van Veldhuizen-Scott et al. (1995) described a randomised, controlled study where 
the patients in two treatment groups received additional small group (n=13) or 
individual supplementary education (n=14) with the pharmacist for a two-month 
period. Control patients (n=14) received the standard educational programme. The 
authors claimed lower average weekly blood glucose levels and a decreased 
incidence of hyperglycaemic episodes in the treatment groups compared with the 
control group. However when adjusted for baseline values there was no significant 
difference between intervention and control groups in percentage change of glucose 
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over the eight weeks (P = 0.796). Analysis of HbA1c was not available due to the 
short duration of the study. In addition no significant change between pre-test and 
post-test responses was identified in general knowledge of diabetes or in 
perceptions/attitudes towards diabetes in general when comparing control and 
intervention patients (P = 0.776). Severe limitations of this study were the small 
numbers involved the short two month follow up and the reliance of self reported 
blood glucose values with only 8 patients (25%) being able to confirm self-
documentation exactly as reported by their meter memory printout. 
Jaber et al. (1996) reported the results of a study assessing the effectiveness of a 
pharmaceutical care model in African-American patients with Type 2 diabetes in an 
ambulatory care setting. Patients were randomised to either a pharmacist intervention 
or control group and followed over a 4-month period. Patients in the intervention 
group (n = 17) received diabetes education, medication counselling, instructions on 
diet, exercise, and home glucose monitoring, and evaluation and adjustment of their 
hypoglycaemic regimen. Follow-up was conducted on a scheduled weekly basis until 
targeted glycaemic control (FBG ~ 6.6 mmolll and 2-hour postprandial blood glucose 
< 10.0 mmolll) was reached. Thereafter, patients came to the clinic every 2-4 weeks 
for the duration of the study. Patients in the control group (n = 22) continued to 
receive standard medical care provided by their doctors. 
The authors claimed significant improvement in glycaemic control was achieved in 
the intervention group as evidenced by glycosylated haemoglobin and fasting plasma 
glucose. Fasting glucose levels at baseline and 4 month follow up were 12.7 and 11.0 
for the control group and 11.1 and 8.5 in the intervention group. HbA 1 c values at 
baseline and 4 month follow up were 12.2 and 12.1 for the control group and 11.5 
and 9.2 for the intervention. Although this latter decrease (P = 0.003) is considered 
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statistically significant it has to be cautiously interpreted. It is notable that only one 
hundred and fifty-six patients (17.5%) met the strict inclusion criteria and that only 
forty five (29%) agreed to take part with thirty nine (87%) patients completing the 
study. Six patients (26%) in the intervention group dropped out of the study compared 
to no dropouts in the control group. Of the six patients who dropped out four found it 
difficult to comply with the frequency of clinic visits, one was discharged due to 
unstable angina and one was lost to follow up. It is likely that selective exclusion of 
non-compliant patients in the intervention group introduced a significant bias and that 
the result may not have been found to be significant if an intention to treat analysis 
had been employed. 
No significant changes in blood pressure control, lipid profile, renal function 
parameters, weight, or quality of life measures were noted within or between groups. 
However, a study with larger numbers of subjects and of longer duration needs to be 
carried out for further evaluation. In terms of the high frequency of attendance with 
this intensive approach, it might be difficult to apply this model into routine practice. 
Coast-Senior et al. (1998) reported a study of clinical pharmacists working in two 
primary care clinics managing patients with Type 2 diabetes who either were 
currently treated with insulin or were initiated on insulin therapy by the pharmacists. 
All patients were referred to the pharmacist by their primary care providers with the 
aim of improving glycaemic control. The pharmacists provided diabetes education, 
medication counselling, monitoring and insulin initiation and/or adjustment. Twenty-
three patients completed the study; fifteen (65%) were initiated on insulin by the 
pharmacists and eight (35%) were already using insulin. The mean length of follow-
up was 27 weeks. Mean HbA 1 c was 11.1 ± 1.6 at baseline for control compared to 
8.9 ± 1.4 at follow up for intervention. Although this was statistically significant (P < 
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0.0005) and of clinical importance the study design did not include a control group 
therefore it is likely that the improvement in HbA 1 c noted was due to the introduction 
of insulin. The study has many limitations in that the total number of patients were not 
reported only those completing the study. HRQOL was not evaluated and it is notable 
that 35% of patients reported hypoglycemic symptoms. Finally the study is not 
generalisable due to its very narrow inclusion criteria with all Type 2 patients requiring 
insulin. 
Berringer et al. (1999) reported outcomes of a year-long pharmacist-led programme 
in two independent pharmacies in Richmond, Virginia. During the first 6 months of the 
programme, enrolled patients experienced an average decrease in their glucose 
values from 178.6 mg/dl to 159.3 mg/dl. Remarkably, over the 12-month study period, 
participants had an average adherence rate of 90% for their use of diabetes 
medications. One limitation of this study was that it relied on patient self report of 
blood glucose measure with no attempt to validate the method of self-report. As 
already highlighted the study by Van Veldhuizen-Scott et al. (1995) found only 8 out 
of 32 patients had readings which were supported by glucose meter memory records. 
Another limitation was that only patients reporting 0, 6 and 12 month blood glucose 
levels were included in the analysis. This is likely to bias the sample as such patients 
may also be more compliant with therapy. No control group was included therefore 
we cannot rule out other factors which may have influenced the blood glucose levels. 
HbA 1 c values would have provided a more accurate measure of glucose control 
which would have been ideal for the six monthly reviews included in this study. A final 
limitation of the high adherence rate reported is the method used to evaluate 
adherence which calculated this by dividing the 'actual days supply' with the 
'prescribed days' supply' where 'actual days supply' was calculated by number of 
Chapter 1: Review of Literature 45 
units purchased over the time and 'prescribed days' supply' was calculated on 
prescription issued over the period. 
Wilcock (2000) reported an evaluation of pharmacists' intervention in community 
pharmacies in Cornwall. Eighty-one community pharmacists from 70 pharmacies (out 
of 86) attended a two-and-a-half-hours diabetes training programme. They were 
given a package of resources including referral forms for referring patients to a doctor 
or practice nurse if appropriate, and a documentation book for recording 'in-house' 
intervention made by pharmacists. Forty-nine pharmacies participated in the study. 
After a three-month period, there were only 23 patients referred back to the surgery. 
The top four reasons for referral included 'further advice on diet' (n=5), 'symptoms 
due to low/high blood glucose' (n=3), 'potential interaction with prescribed medication' 
(n=3), and other reasons (not specified in the report) (n=12). A total of 300 patient 
intervention forms were recorded from 37 pharmacies, with 12 pharmacies having no 
intervention recorded. Monitoring of the condition was the most common reason for 
advice (38% of patients), followed by advice on avoiding inappropriate over-the-
counter medication (20%). However, this study did not analyse clinical outcomes 
such as HbA 1 c to assess glycaemic control, and took place over a short period of 
only three months. In addition outcomes of the referrals were not stated. 
Conclusion 
None of the studies to date have provided robust evidence of patient outcomes to 
support the delivery of pharmaceutical care to diabetic patients. The gold standard is 
normally a randomised controlled trial design. However of the three randomised 
controlled trials reviewed each has their limitations. 
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In the first RCT (Hawkins et aI., 1979) a large number of subjects were reviewed over 
29 months. However there was no measure of HbA 1 c or HRQOL. The assumption 
was made that attendance rates at the clinic equated to patient satisfaction. Even the 
attendance rates for the control group were estimates rather than actual values. 
The second RCT (Van Veldhuizen-Scott et aI., 1995) included very small numbers 
with only a two-month follow up. There was no measure of HbA 1 c, HRQOL and drug 
related problems. The authors claimed lower blood glucose in the intervention group 
however when adjusted for baseline values no difference was noted (P = 0.796). 
The third ReT (Jaber et aI., 1996) covered small numbers over a short four-month 
follow up. This study did measure HbA 1 c, blood pressure and QOL. No significant 
changes in blood pressure, lipid profile, and QOL. However the mean HbA 1 c for the 
intervention group at the end of the study was 9.2 ± 2.1, therefore it is unlikely to be 
clinically significant. Also this data has to be interpreted with caution as 6 (26%) 
patients were removed from the intervention group, four of whom could not cope with 
the strict regimen. No such consideration was given to removing patients from the 
control group therefore it is likely that we have bias in the reporting of outcomes 
which is likely to be significant given the small numbers. 
Further research is therefore required to evaluate the impact of pharmaceutical care 
models in a diabetic population. 
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1.6 Hypothesis 
Pharmaceutical care delivered by community pharmacists can improve patient 
outcomes of Type 2 diabetics in a primary care setting, as indicated by changes in 
HbA 1 c, systolic blood pressure (SSP), health related quality of life (HROOL) and drug 
related problems (DRPs). 
1.7 Aim of the present study 
The aim of this study is to compare the impact of a pharmaceutical care diabetic clinic 
within a primary care setting to standard care on clinical, humanistic and process 
outcomes in Type 2 diabetics. 
1.8 Objectives 
1. To develop a practical pharmaceutical care model for patients with Type 2 
diabetes. 
2. To develop and validate suitable data collection forms to support the 
pharmaceutical care model. 
3. To implement a pharmacist managed diabetic clinic for patients with Type 2 
diabetes using the pharmaceutical care model. 
4. To evaluate the pharmaceutical care model and compare clinical (HbA1c, SSP) 
and humanistic (HROOL) patient outcomes in the active group receiving the 
pharmaceutical care model, in addition to standard care, versus the control group 
receiving standard care only. 
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5. To investigate the number and types of DRPs identified by the pharmacist, the 
percentage of recommendations accepted by the physician and the status of the 
DRPs at follow up. 
6. To obtain feedback from the pharmacists to inform future service delivery. 
Objective 1-2 will be covered in the pilot study, with objectives 3-6 being met in the 
main study. 
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Chapter 2 
General Methodology 
2.1 Literature review 
A review of the literature was conducted using the electronic databases MEDLINE 
(1966-2000) and International Pharmaceutical Abstracts (1990-2000). The search 
terms used included pharmacist intervention (any of community pharmacist, clinical 
pharmacist, pharmacy service), pharmaceutical care,· ambulatory care, 
pharmacotherapy, diabetes, quality of care, quality of life, outcomes, and clinical 
outcomes. Bibliography searches were conducted of some articles obtained, 
including reviews. In addition a hand search of other relevant literature was 
undertaken. 
2.2 Study setting 
It was intended that all of the pharmaceutical care clinics would take place within 
general medical practice settings within Greater Glasgow Health Board area (GGHB), 
Scotland. 
2.3 Project funding 
The programme was funded by the Greater Glasgow Primary Care Trust through a 
prescribing development fund. 
Chapter 2: General Methodology 50 
2.4 Ethics committee approval 
Separate applications were made for both the pilot and the main studies to the ethics 
committee of the Greater Glasgow Community/Primary Care Local Research Ethics 
Committee. Approval was granted (Appendix I and II). 
The pilot study was carried out in the eight recruited general practices during July and 
August 1999. The main study was carried out in nine different general practices over a 
12-month period from March 2000 to February 2001. 
2.5 Study team 
Overall there were eight members of the study team, some of whom had joint 
responsibilities. There was a supervisory research team who focussed on research 
aspects of the study and a project team which co-ordinated day to day operational 
aspects of the study and together these two groups comprised the study team. 
The supervisory team comprised two experts in pharmaceutical care (CAM,DS) and a 
pharmacologist (DMcC). The project team comprised CAM (principal investigator), 
two clinical pharmacists (AM & RL) and a clerical assistant (KB). In addition a medical 
adviser (ANC) who was a consultant phYSician and a specialist in diabetes, was also 
appOinted to the study team. The research student (SS) worked with both teams and 
was responsible for independently reporting on all aspects of the study. 
In the main study the study team also included an experienced research pharmacist 
(ALe) to independently follow up patient outcomes at the end of the study. 
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2.6 Recruitment of general medical practices 
The pilot study involved a convenience sample of eight out of twenty two practices 
currently participating in medication review clinics. The main study sample was drawn 
from the GGHB list of two hundred and nineteen practices excluding the eight pilot 
sites. Random numbers were used to identify the practices. However fifteen practices 
were approached in order to recruit nine practices with sufficient patient numbers to 
meet the predetermined study power. 
2.7 Recruitment and training of pharmacists 
All twenty-two pharmacists currently running general Medication Review Clinics in 
Glasgow were invited to participate in the pharmaceutical care diabetic clinics and 
required to attend a training programme. All the pharmacists who participated in the 
study were registered pharmacists and subject to the Royal Pharmaceutical Society 
of Great Britain code of ethics. 
Six community pharmacists were recruited to provide the clinics in the pilot study. In 
addition two project pharmacists (AM & RL) also participated in the pilot clinics. All 
eight pharmacists received the training programme provided and had previously been 
working in the medication review clinics. 
There were nine pharmacists who participated in the main study. All nine pharmacists 
completed the training programmes provided before the model was implemented. Of 
these, six participated in the pilot study while the remaining three were not involved in 
the pilot but participated only in the main study. 
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The training programme involved three evening sessions in November 1998, January 1999 
and June 1999, and a one-day session in February 1999. The study team and appropriate 
specialists provided training for the pharmacists. 
The first session involved a lecture providing on overview of Type 2 diabetes, 
pharmaceutical care of diabetic patients, and an introduction to the diabetes project, 
delivered by the research student. The pharmacists received a package of materials 
including relevant papers to support the pharmaceutical care aspects of Type 2 
diabetes (BOA, 1997; SIGN, 1996; SIGN, 1997a; SIGN, 1997b; SIGN, 1997c; Strand 
et aI., 1990; UKPOS, 1998a; UKPOS, 1998d). 
The second training session was a problem-based learning workshop regarding Type 
2 diabetes. This aimed to enhance the pharmacist's ability to develop diabetic care 
plans and solve related clinical problems. There was an interactive discussion at the 
end of the session. The last part of the session included practice on the use of the 
blood glucose meter and measuring blood pressure. 
The third training session included a presentation on the diabetes clinic procedures 
and role playing in diabetes case scenarios. The role playing part was aimed to 
ensure that the pharmacists completed the data forms correctly and were able to: 
comply with study procedures; perform the fingerstick technique for blood glucose 
monitoring; measure blood pressure correctly; identify a list of drug related problem 
and outline a plan of action for each problem. 
The fourth training session was concerned with reinforcing the study procedure and 
data collection methods and included a review of drug management and patient 
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education in Type 2 diabetes. This was presented by a specialist in diabetes (ANC) 
from the AYR Hospital NHS trust and the researcher (SS). 
2.8 Data analysis and statistical methods 
Statistical analyses were performed in both the pilot and the main study using the 
Statistical Package for Social Sciences (SPSS) programme version 9.0 and 10.0 for 
Windows. All data was entered on a SPSS database by the researcher (SS). Patients 
and pharmacists were all coded to ensure confidentiality. No names or address were 
recorded on computer profiles. The following analyses were generally considered: 
1. Demographic and clinical characteristics of patients and data on the medical 
conditions, drugs prescribed and drug related problems were examined using 
descriptive statistics. Values are expressed as number, percentage, mean ± SO, and 
median values, as appropriate. 
2. The Pearson Chi-square or Fisher' Exact test was used for nonparametric 
analysis to compare categorical variables. 
3. Continuous variables were compared between groups using Independent-Sample 
T test or the Mann-Whitney U-test, in the case of skewed variables. 
A two-tailed P value less than 0.05 was regarded as statistically significant. 
Chapter 3 
Pilot Study 
3.1 Aim and objectives 
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The aim of the pilot study was to develop a pharmaceutical care model and 
documentation system for use in the main study. 
The objectives of this pilot study were to: 
1. Develop a practical pharmaceutical care model for patients with Type 2 diabetes. 
1.1 Develop a practical pharmaceutical care model to be used in the main study. 
1.2 Estimate the number of patients required for the main study. 
1.3 Identify and investigate problems arising from the implementation of the 
above process in order to improve the model. 
2. Develop and validate suitable data collection forms to support the pharmaceutical 
care model. 
2.1 Develop suitable data collection forms. 
2.2 Test two previously validated quality of life measures and determine the 
most appropriate disease specific quality of life measure for the main study. 
2.3 Obtain the participating pharmacists' comments on the model and data 
collection forms during the pilot. 
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3.2 Methodology 
3.2.1 Study setting 
The project was conducted in a convenience sample of eight general practices in the 
Greater Glasgow Health Board area (GGHB). The practices were recruited from a total of 
twenty-two general practices running pharmacist led medication review clinics at the time 
the project began in July 1999. Each practice had one pharmacist running a clinic one 
day per week. A convenience sample was selected because the pharmacists were 
willing to participate in the training programme and were available one day per week for 
the 12 - 18 month period of the project. In addition the practice had to agree to 
participate in the pilot study and provide a suitable consultation room. 
3.2.2 Patient recruitment 
Patients aged 18 years and older who were diagnosed as suffering from Type 2 
diabetes and receiving oral antidiabetic drugs (based on their medical record) were 
eligible for inclusion. They were excluded from the study if any of the following criteria 
were present: 
(1) patients unable to provide informed consent due to cognitive or severe sensory 
impairment such as dementia, hearing, speech, or severe visual impairment, or 
(2) serious acute or terminal illness. 
A letter together with a consent form (Appendix III) was sent to prospective patients 
inviting them to attend the pharmaceutical care diabetic clinics. Written informed 
consent was obtained from all subjects before admission to the study. Within 2 weeks 
patients were telephoned and an appointment made, if appropriate. Patients who did 
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not attend a scheduled appointment were contacted again and a second clinic 
appointment allocated. If they did not attend the second clinic no further contact was 
made. 
3.2.3 Development of documentation to support the pharmaceutical 
care model 
A Medication Review Form (MRF) was used (Appendix IV, Mackie et aI., 1999) to 
collect general data. The eight clinic pharmacists had previous experience of this MRF 
as it was used as a standard in all Medication Review Clinics in Glasgow. In addition a 
draft Diabetes Data Collection Form (DDCF) was developed by the researcher (SS) to 
collect additional diabetic specific information. The DDCF was presented on two pages 
(Appendix V). The first page included the following: demographic patient information, 
medical history, attendance at diabetic clinics, use of glucose monitoring, clinical 
objective data, history of foot examination, history of eye examination, previous 
therapy, and diabetic education provided at interview. This included information mainly 
obtained from medical records. Information not available in medical records was 
requested by the pharmacist directly from the patient at interview. The second page 
presented a list of questions for the pharmacist to ask the patient, a table in which to 
record the time spent on the activities in the clinic, and finally space for general 
comments from the pharmacists. A patient information leaflet (Appendix VI) was 
designed using 'plain' English providing information about diabetes with some basic 
advice about diabetes care. 
As a measure of content validity, the draft DDCF was sent to the study team. 
Comments were sought in relation to whether the wording in the form was clear and 
whether any important areas had been omitted. Minor changes were subsequently 
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made to the form, which was then sent to the study team and six pharmacists for the 
pilot study. 
After completing the training programme (see Chapter 2), the pharmacists were given a 
package of materials including data collection tools namely a Medication Review Form 
(Appendix IV), and Diabetes Data Collection Form (Appendix V), patient information 
leaflet (Appendix VI), two quality of life questionnaires (Appendix VII and VIII), and a 
GP referral form (Appendix IX). 
The two quality of life questionnaires, the Audit of Diabetes Dependent Quality of Life 
(ADDQoL) (Appendix VII) and Diabetes-39 (Appendix VIII), were selected as they had 
been previously validated in Type 2 diabetic patients (Boyer, 1997; Bradley, 1999). 
These two questionnaires were used in the pilot study by permission from the authors. 
3.2.4 Pharmaceutical care model 
Six patients were booked into the pharmaceutical care clinic, which ran one day per 
week. Pharmacists prepared for the clinic in the morning and interviewed patients in 
the afternoon. The overall aim was to identify actual and potential DRPs where a 
DRP was defined as 'any undesirable event experienced by the patient that involves 
or is suspected to involve drug therapy and that actually or potentially interferes with 
desired patient outcomes' (Strand et aI., 1990). 
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3.2.4.1 Morning session 
During the morning session, the medical notes and computer records of all scheduled 
patients were reviewed in order to gather background patient information and 
complete the first page of the DOCF and MRF. The pharmacist explained the new 
type of clinic to the reception staff and supplied him/her with questionnaires and 
patient consent forms for every patient booked into the clinic. 
3.2.4.2 Afternoon session 
Patients were invited to attend the clinic in the afternoon session. Patients were 
asked to fill in the QOL questionnaires (either ADDQoL or Diabetes-39 allocated 
randomly) at the reception area before meeting with the pharmacist. At the clinic, the 
pharmacist introduced him/herself to the patient and explained the reason for the 
clinic to patients and answered all the questions about the study the patient may 
have. The pharmacist also obtained the completed QOL questionnaire and consent 
form from the patient at the start of the interview. Then the pharmacist interviewed the 
patient asking general and specific questions about diabetes and completed the MRF 
and the DDCF. During the clinic, the pharmacist educated the patient regarding DRPs 
which were relevant and gave the patient a diabetes leaflet. The pharmacist recorded 
the time spent at each step and added comments relating to the protocol and the data 
collection form, if appropriate. 
After the clinic, the pharmacist reviewed all of the data to identify DRPs and 
completed a GP referral form (Appendix IX), if required. 
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3.2.5 Process outcomes 
After completing the pilot study at the end of August 1999, the pharmacists were 
given a pharmacist feedback survey form (Appendix X) which asked them to 
comment on the clinic protocol, data collection forms, and training programme. The 
pharmaceutical care model was then revised based on this written feedback from the 
pharmacists, discussion at the training session, and peer review by the study team. 
3.3 Results 
3.3.1 Characteristics of patients recruited to the pilot study 
Computerised records were searched in eight general practice settings in Greater 
Glasgow Health Board area and following screening for exclusions by the practice 
manager, 138 patients were identified who met the inclusion criteria. Of those, 21 
(15%) refused to participate in the study and 4 (2.9%) were not contactable. Sixteen 
patients (12%) agreed to participate but did not subsequently attend the clinic. The 
remaining 97 (70%) patients participated in the study by attending the clinic of whom 
96 patients completed the quality of life questionnaire. 
Demographic data is provided in Table 3.1. There were approximately equal numbers 
of male and female patients. The majority of patients was over 60 years of age, with a 
mean age of 67 ± 11 years (mean ± SO). 
Table 3.1: Characteristics of pilot participants 
Characteristic 
Age 
40-50 years 
51-60 years 
61-70 years 
> 70 years 
Gender 
male 
female 
Number 
(n=97) 
12 
16 
38 
31 
48 
49 
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Percentage 
12 
16 
39 
32 
50 
50 
Clinical data, where available, is provided in Table 3.2. Most patients were attending 
diabetic clinics (92.8%) and using self-glucose monitoring at home (75.3%). Sixty-six 
percent of the patients were obese (8MI >27 kg/m2), with a mean 8MI of 30 ± 6.1. In 
addition, 34% had a history of eye problems while 11 % had a history of foot 
problems. An indicator of glycaemic control, the HbA 1 c value, was 8.0 ± 2.1 %. 
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Table 3.2: Clinical data of patients included in the pilot study 
Characteristic Number Percentage 
Attendance at diabetic clinics 
Currently attend at hospital 44 46 
Currently attend at surgery 13 14 
Currently attend both 33 34 
Had ever attended at hospital in the past 2 2.1 
Never attended diabetic clinics 4 4.2 
Last diabetic clinic attendance 
< 1 year 78 94 
> 1 year 5 6.0 
Self-glucose monitoring 
Using blood glucose monitoring 20 21 
Using urine glucose monitoring 53 55 
Never use 23 24 
8MI (kg/m2) 
< 25 kg/m2 14 16 
25-27 kg/m2 9 10 
>27 kg/m2 64 74 
History of foot exam 
normal 61 85 
foot problem(s) 11 15 
History of eye exam 
normal 50 60 
eye problem(s) 33 40 
HbA1c value 
HbA1c > 8 % 44 46 
HbA1c 7- 8 % 15 16 
HbA1c<7% 37 38 
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3.3.2 Documentation system and missing data 
There were 97 data collection forms, 48 GP referral forms, 48 Diabetes-39 
questionnaires, and 48 ADDQoL questionnaires returned to the researcher. Of the 97 
data collection forms, there were missing clinical data as shown in Table 3.3. 
Table 3.3: Top ten missing data In the forms returned 
Missing data 
Liver function test 
Albumin 
Fasting/random blood glucose 
Renal function (creatinine) 
Lipid profile 
Blood pressure 
History of foot exam 
Last date of attendance 
History of eye exam 
8MI 
59 
58 
58 
47 
45 
45 
25 
14 
14 
10 
Number of missing records 
3.3.3 Time required to deliver the pharmaceutical care model 
The time required to deliver the pharmaceutical care model is shown in Table 3.4. 
Overall the participating pharmaCists took approximately one hour in retrieving patient 
information from the medical records, completing the data collection forms, 
interviewing the patient, and providing patient education. 
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Table 3.4: Time required for the pharmaceutical care clinic 
Activity Time per patient 
Pre-interview 
Interview 
Patient education 
<10 mins 
0 
2 
49 
10-20 mins 
33 
37 
30 
Note: underlined values are the most frequently observed times. 
3.3.4 Quality of life questionnaires 
21-30 mins >30 mins 
48 16 
43 3 
1 0 
A summary of comparable issues between ADDQoL and Diabetes-39 is displayed in 
Table 3.5. In addition to the details presented in the table, it was found that there was 
some difficulty in score interpretation using the Diabetes-39 questionnaire. This was 
due to the fact that the scale was not discrete and depended on positioning of a 
cross. 
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Table 3.5: Comparison between Diabetes-39 and ADDQoL 
Issues to be considered Diabetes-39 ADDQoL 
Number of questions to be 39 diabetes-specific questions 13 diabetes-specific questions 
completed plus two overall rating plus two overall rating 
questions questions 
Study participant Validated in two samples 
(Iowa and Carolina study) of 
adults in the United States. 
Evidence of reliability and Yes 
validity 
Scale score for each question 0-100 
Domains and number 
questions for each domain 
Missing data 
(higher score indicates worse 
quality of life) 
of Diabetes control 
12 questions 
Anxiety and worry 
4 questions 
Social burden 
5 questions 
Sexual functioning 
3 questions 
Energy and mobility 
15 questions 
If in total more than 4 items 
are missing (excluding missing 
items sexual function scale 
and independent of the scale) 
the questionnaire will be 
excluded from the analysis 
Valid completion (from the 81% 
pilot study) 
Validated in two samples 
(Cambridge and Bromley 
sample) of adults in the United 
Kingdom. 
Yes 
-9 to 9 
(higher score indicates better 
quality of life) 
Employment/career 
Social life 
Family relationships 
Friends 
Sex life 
Sport/leisure 
Travel 
Future (own) 
Future of family 
Motivation 
Physical activity 
Others fussing 
Enjoyment of food 
(one question/domain) 
Provides N/A option in some 
domains. This is excluded 
from the scoring. 
92% 
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3.3.5 Drug related problems 
3.3.5.1 Total number of drug related problems (ORPs) 
One hundred and twenty seven DRPs were noted by the pharmacists for 47 (48%) of 
the 97 patients. DRPs most frequently involved monitoring laboratory tests (34%), 
changing of regimens (19%), and adjusting dose (13%). The pharmacists obtained 
complete GP agreement to 90 (71%) of the resolutions recommended for the drug 
related problems, and partial agreement to a further 26 (20%). Partial agreement was 
defined as GP agreeing to the recommendation but requiring to see the patient 
before making a change to therapy. Overall 9% of GP referrals were rejected. 
3.3.5.2 Diabetes related and diabetic complication related ORPs 
The pharmacist made suggestions to the GP regarding 71 diabetes related DRPs in 
97 patients. The GP completely agreed with 46 out of 71 diabetes related changes 
(65%). 
3.3.6 Summary of comments from pharmacists 
The eight clinic pharmacists returned a feedback questionnaire regarding data 
collection forms, the package of materials, and the training programme. 
3.3.6.1 Comments about the pharmaceutical care model and documentation 
All eight pharmacists responded. Table 3.6 presents the pharmacists' responses to 
the survey questionnaire. Generally the pharmacists responded that the form was 
Chapter 3: Pilot Study 66 
easy to use and a useful guide when preparing the care plan and GP referral. They 
suggested reducing the number of records of objective data to the 3 most recent due 
to the difficulty and time taken in retrieving all data. In addition, the difficulty of 
establishing a normal range of HbA 1 c and some other laboratory data was also 
raised. 
Table 3.6: General questions about the model - questionnaire completed by 
pharmacists after pilot study 
No. 
1. 
Question 
Comments about the data 
collection form 
Answer 
1. The form itself is relatively easy to fill and very 
useful when preparing GP referral form. 
2. The boxes of objective data were not split properly 
and there was not enough space provided. 
3. It was difficult to get relevant readings especially if 
the patient attended a hospital clinic because 
although they apparently make measurements they 
are not recorded in the surgery notes. 
4. Five readings of the objective data were too much 
and found it was quite time consuming. 
2. Data to be included or Exclude: 
excluded in the form 1. What is the patient's reading' in the part about 
glucose monitoring 
Include: 
1. Present diabetic medication 
2. Clarify 'attendance at clinics' e.g., regularly, never. 
3. Were the given package of 1. One answered 'inadequate' 
documents and training 2. Seven answered 'adequate' 
programme adequate or 
inadequate? 
4. How many patients on average 1. All answered six patients 
have you booked in for each 
clinic? 
5. Is this number too little, too 1. Six pharmacists answered 'about right' 
many or about right? 2. Two did not answer and gave a reason that there 
was high non-attendance rate. 
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The pharmacists rated number of patients booked per clinic 'about right' in the sense 
that when all attended there was adequate time for paper work between patients. 
One pharmacist said she could manage seven patients easily at one clinic. In the 
pilot study there was 88% attendance. Two pharmacists complained about the high 
non-attendance rate and therefore could not respond on whether the number of 
patients per visit was appropriate. 
The pharmacists commented on HbA 1 c records. They noted that hospital results of 
HbA 1 c did not provide normal range data and the 5 readings examined in patients' 
notes were usually a mixture of hospital and GP readings. One pharmacist suggested 
excluding 'What is the patient's reading' in the part about glucose monitoring giving 
the reason that it was too ambiguous. It was also suggested that documentation of 
the liver function test data should change because most results were given as a 
range of enzymes. There was no simple way of documenting this in a single row 
within the table. 
It was also suggested that if reception staff are handing out the QOL questionnaires, 
care must be taken to ensure that they can communicate all the necessary 
information to allow the patients to feel comfortable about taking part in the study and 
to appreciate the importance of their contribution. 
The feedback from the pharmacists was discussed within the study team and some 
minor modifications of the data collection tools were undertaken. 
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3.3.6.2 Comments about the training programmes 
Most of the pharmacists found the training programme and documentation provided 
useful and reported that it was adequate. One pharmacist indicated she was not 
satisfied and that she required more information, especially about the use of insulin in 
Type 2 diabetes. 
3.4 Discussion 
3.4.1 Study setting 
In choosing a convenience sample, the study team recognised that the data would 
not be generalisable. However, the objective of the pilot study was to develop the 
model and data collection tools and this is best done by a team with an established 
relationship to prevent additional strain on team members. 
3.4.2 Pharmaceutical care model and data collection forms 
The pilot study was designed as a single intervention aimed primarily at arriving at a 
pharmaceutical care model appropriate and practical for the main study. Data from 
the pilot study allowed a number of points to be identified as important in revising the 
protocol and data collection tools. The forms were revised in term of the space and 
layout, the order of questions, and some items, which it was not practical to retrieve 
and use, were omitted. 
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It is important that patients actually complete the quality of life questionnaire and so 
the number of questions has to be considered in order to encourage completion. In 
this case we chose the shorter questionnaire, ADDQoL which had a 92% completion 
rate, for use in the main study. The other reasons for choosing the ADDQoL included 
ease of self-administration, and interpretation of questions and a straightforward 
scoring system. 
The case load of approximately six patients per clinic was considered manageable for 
the pharmacists, with the interview lasting 20-30 minutes plus 10 minutes for patient 
education. This was useful information for determining the clinic schedule in the main 
study. It was considered likely, however that time spent would be shorter in the 
follow-up clinic. This duration is comparable to the study by Veldhuizen-Scott et al. 
(1995) who found that a one-on-one counselling intervention time took a mean time 
of 40 minutes. 
3.4.3 Pharmacists' comments on the model and data collection form 
Most of the pharmacists accepted that the training programme and materials 
provided were adequate to allow them to fulfill the role of the pharmacist in the 
diabetic clinic. However, to ensure consistency in the main study, a peer review team 
consisting of experienced clinical pharmacists will continue to review all GP referrals 
made by the pharmacists. Educational needs were also identified and would be 
addressed by a series of workshops to include treatment of diabetes, and further 
training in measuring blood pressure. Pharmacists who wished to continue to deliver 
the pharmaceutical care model in the main study were encouraged to enroll in 
ongoing peer review sessions throughout the study. These peer review sessions 
allowed pharmacists to discuss problem cases with their colleagues once a fortnight. 
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3.4.4 Problems to be solved 
It was found that the normal range of HbA 1 c values varies between laboratories 
because of the lack of standardisation of the assay method. It is not possible to 
directly compare HbA 1 c values generated in different laboratories. It is therefore 
essential that the same laboratory is used throughout the main study and the normal 
reference values for this particular laboratory are used when assessing patients' 
glycaemic control. 
The recommendations on drug related problems made by the pharmacists in this pilot 
study were well accepted by physicians, as indicated by the fact that 71 % of the 
recommendations obtained complete GP agreement. Co-operation of the medical 
team is a critical factor in making this model work. Therefore, this is a positive finding 
with regard to the implementation of the model and future collaboration with the 
medical team in the main study. 
3.4.5 Sample size for the main study 
To calculate the sample size required for the main study, the study was powered to 
detect a clinically meaningful difference of 1.0 unit change in mean HbA 1 c value. 
From the data collected in the pilot study, the standard deviation (SO) of the mean 
HbA 1 c is 2.1. The sample size estimate was calculated on the basis of the 
assumption of a 2-tailed test for which the (l error is 0.05 and power is 0.90. The 
standardised difference = clinical significant difference/SO = 1.0/2.1 = 0.48. Reading 
from the nomograph (Altman, 1991), gives a sample size of 170. 
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Therefore the minimum sample size in the main study should be 170 patients. Due to 
the 30% drop-out rate estimated from the pilot and the need for three visits, it was 
estimated that we would have to recruit many more patients into the main study, 
which is a randomised controlled trial design. However compared to other studies 
(Fischer et aI., 2000; Jaber et aI., 1996), participation rate in the pilot study was high. 
Jaber et al. (1996) studied the impact of pharmaceutical care model on Type 2 
diabetes patients comparing active and control groups at baseline and a 4-month 
visit. The study was done in an outpatient clinic in a university hospital. Of a total of 
156 eligible patients, 45 (29%) patients participated in the study. After randomisation 
into active and control groups, 6 of 45 patients (13%) dropped out, leaving 39 (87%) 
patients completing the study. The participation rate in Fischer et al. (2000) study was 
46% at the initial visit. This study involved pharmaceutical care evaluation in patients 
with chronic disease in community pharmacies. Therefore in order to have 170 
patients complete the main study we would require 370 patients to allow for a 46% 
follow up. 
3.5 Conclusion 
All the suggestions made by the pharmacists and medical adviser were incorporated 
into the model for the main study which was undertaken as a randomised controlled 
trial. The newly designed pharmaceutical care model and documentation were 
finalised for use in a large-scale trial to allow investigation of the impact of the 
pharmaceutical care model in Type 2 diabetic patients compared to standard care. 
Documentation to support the Pharmaceutical Care model in the main study, is given 
as follows: 
Appendix VII 
Appendix XI 
Appendix XII 
Appendix XIII 
Appendix XIV 
Appendix XV 
Appendix XVI 
Appendix XVII 
Appendix XVIII 
Appendix XIX 
Appendix XX 
Appendix XXI 
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ADDQoL 
Patient diabetes information leaflet (Revised) 
GP referral form (Revised) 
Patient information about the study (new) 
Patient consent form (Revised) 
Medication review form (Revised) 
Update medication review form (New) 
Diabetes data collection form (Revised) 
Update diabetes data collection form (New) 
Letter of thanks to patient after attending clinic 1 (new) 
Letter of thanks to patient after attending clinic 2 (new) 
Letter of thanks to patient after attending clinic 3 (new) 
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Chapter 4 
Method - Main Study 
4.1 Aim 
The aim of the study is to assess the impact of pharmaceutical care delivered by 
community pharmacists on the management of Type 2 diabetes using a randomised 
controlled trial study design. 
4.2 Objectives 
1. Implement a pharmacist managed diabetic clinic for patients with Type 2 
diabetes using the pharmaceutical care model developed in the pilot study. 
2. Evaluate the pharmaceutical care model and compare clinical (HbA 1 c, S8P) and 
humanistic (HRQOL) patient outcomes in the active group receiving the 
pharmaceutical care model in addition to standard care versus the control group 
receiving standard care only. 
3. Investigate the number and types of drug related problems (DRPs) identified by the 
pharmacist, the percentage of recommendations accepted by the physician and the 
status of DRPs at follow up. 
4. Obtain feedback from the pharmacists to inform future service delivery. 
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4.3 Study design 
The study was conducted as a randomised controlled trial, doubled blinded at the first 
clinic visit. Pharmacists were blinded to the allocation at first visit only. Patients and 
GPs were blinded up to the point of amendment to care if one was actually made 
(Figure 4.1). 
Pharmacists provided pharmaceutical care during a 12-month period from March 2000 
to February 2001. Pharmacists received no additional payment for participating in the 
study, but were remunerated for running the clinics using standard rates in place at the 
time of the study (£2S/hour). Participating practices and individual GPs received no 
payment for the study. 
Patients were stratified by age, gender, and practice and then randomised into the 
active or control group. The enrolled patients in the control group received a 
pharmacist interview and usual medical care from GPs whilst the patients in the active 
group received usual medical care, pharmacist interview and pharmacist intervention 
(Figure 4.1). All patients were invited to a pharmacist run clinic within their general 
practice surgery for three clinic visits at approximately three-month intervals. 
To determine the impact of the pharmacist intervention, the following outcomes were 
measured: changes in mean HbA 1 c level, changes in mean systolic blood pressure, 
and patient QOL, number and type of DRPs identified, and the percentage of 
recommendations accepted by the GP. 
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Figure 4.1: Flow chart of study protocol 
Step 1 
Pre-clinic 
session 
Step 2 
Clinic 
visit 1 
Step 3 
Post-clinic 
session 
I Eligible patients 
~ 
Randomisation 
(Stratified by age, gender and practice) 
I 
1- .. 
Active group Control group 
• Pharmacist gathers background information and completes both 
the medication review form and diabetes data collection form. 
• Receptionist provides quality of life questionnaire to patient for 
completion. 
• Pharmacist discusses nature of study and receives informed 
consent and the completed quality of life questionnaire. 
" 
• Patient interview (documented on medication review form) 
• confirm details of all drugs and dosage taken. 
• confirm indications still valid. 
• assess compliance, knowledge and suitability. 
• identified drug related problems. 
• Patient interview (documented on diabetes data collection form) 
• Ask patient about self glucose monitoring. 
• Ask patient about signs/symptoms of diabetic complications. 
• Ask patient about diabetic medication and OTC medication. 
• Weigh patient and measure height. Calculate body mass index. 
• Measure blood pressure. 
• Take a finger prick blood sample and post the sample to the office for 
HbA 1 c analysis. 
Week 1-2 
, 
" 
• Record HbA1c result in diabetes data collection form. 
• Draft GP referral where appropriate. 
• All referrals peer reviewed by a member of the project team. 
• Pharmacist and peer reviewer still blinded to allocation (active/control). 
1 Week 2-4 
Next page 
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Pharmacis tis Active group Control group 
unblinded to f 1 the group of ~ 1 patients 
Clinic visit 2 
• Referral form is sent to GP. • Referral form is held until 
• Contact patient to obtain the end of the study. 
agreement, make changes, • Contact patient to make 
counselling and next appointment next appointment (by 
(by phone). phone). 
• Send a letter of thanks to patient, • Send a letter of thanks to 
confirm implementation of patient, provide diabetes 
changes, if appropriate, provide leaflet and book next 
diabetes leaflet and book next appointment. 
appointment. 
Week 8-12 , 
Step 1: Pre-clinic session 
• Pharmacist documents any change of patient details on 'update 
pharmaceutical care medication review form' and 'diabetes data 
continuation form'. 
• Receptionist provides quality of life questionnaire to patient for 
completion. 
• Pharmacist receives the completed quality of life questionnaire. 
Step 2: Clinic session 
• Interview patient and complete document. 
• Weigh patient and measure height. Calculate body mass index. 
• Measure blood pressure. 
• Take a finger prick blood sample and post the sample to the office for 
HbA 1 c analysis. 
Step 3: Post-clinic session 
• Record HbA 1 c result in diabetes data collection form. 
• Draft GP referral where appropriate. 
• All referrals peer reviewed by a member of the project team. 
Active group 
• Referral form is sent to GP 
• Contact patient to obtain 
agreement, make changes, 
counselling and next apPointment 
(by phone). 
• Send a letter of thanks to patient, 
confirm implementation of 
changes, if appropriate, provide 
diabetes leaflet and book next 
appointment. 
Control group 
• Hold any further referral to 
GP until the end of next 
visit. 
• Contact patient to make 
next appointment (by 
phone). 
• Send a letter of thanks to 
patient, provide diabetes 
leaflet and book next 
appointment. 
1 
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Clinicv isit 3 Active group Control group 
I I 
Repeat all three steps as before. 
,r r 
Active group Control group 
Make further referral to GP for Review and make referrals of all 
continuing care. outstanding drug related problems 
from first and second GP referral 
forms which were held back. 
,Ir 
I GP continuing care 
At the end of the study, the pharmacists were asked to rate how they felt about the 
clinics on a score of 0 (not confident) to 10 (very confident) before and after the study. 
A copy of the questionnaire is provided in Appendix XXII. This questionnaire was sent 
six months after the last clinic, together with a thank you card and a £20 Marks and 
Spencer voucher plus stamped envelope for returning the questionnaire. No reminder 
was sent. 
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4.4 Study setting 
The study was conducted in nine general practices in Greater Glasgow Health Board 
area, Scotland as described in section 2.6 of the General Methods. 
4.5 Patient selection 
4.5.1 Eligibility criteria for participants 
Patients were eligible for study if they: 
1) had a diagnosis of Type 2 diabetes mellitus and were currently using an 
oral antidiabetic agent and 
2) were aged 18 years or over and 
3) had been receiving primary care from a general practitioner in one of the 
study practices. 
4.5.2 Exclusion criteria 
Patients were excluded if they met any of the following criteria: 
1) Unable to obtain informed consent due to cognitive or severe sensory 
impairment such as dementia, hearing, speech, or severe visual 
impairment. 
2) Serious acute or terminal illness. 
These patients were identified by the practice manager from a list of eligible patients. 
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A final list of eligible patients was drawn up which included names, address, and 
telephone numbers. The clerical assistant (KB) contacted each patient by telephone, to 
briefly describe the study and ask whether they would like further information. The 
research office then mailed packages containing a description of the study (Appendix 
XIII) and patient consent form (Appendix XIV), The clerical assistant then followed up 
the patients by telephone to arrange an appointment within 1-2 weeks. Patients were 
asked to bring all their medicines (prescribed and OTC) plus the consent form to their 
first visit. 
4.5.3 Size of the study population 
It was hypothesised that the pharmacist intervention would have an impact on 
improving glycaemic control. Based on this hypothesis and the results from the pilot 
study, for a 1.0 unit drop in HbA 1 c values, it was estimated that 170 patients were 
required to complete the study. This figure was revised to 370 to take into account 
likely dropout rates (see 3.4.4). 
4.6 Intervention in the active group 
Patients enrolled in the active and control groups were seen by a community 
pharmacist at a clinic run within the general practice. All patient records were reviewed 
and patients were interviewed to obtain additional information required to identify drug 
related problems. In the active group a GP referral was made where appropriate and a 
patient information leaflet provided. The GP referrals were peer reviewed prior to 
submission to the GP. All referrals agreed by the GP were then implemented by the 
pharmacist unless the GP indicated otherwise. In the control group drug related 
problems were recorded and a patient information leaflet was provided but no other 
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intervention was made. Referrals were stored until the end of the study when they 
were actioned if appropriate (Figure 4.1). A total of nine pharmacists provided care to 
patients in this study. The study design (Figure 4.1) indicates that the patients should 
have up to three visits with the pharmacist over the course of the study. All patients 
continued to receive their usual care from the practice throughout the study. 
4.7 Data collection 
A summary of the contents of the various data collection tools used in this study is 
shown in Table 4.1. After the third clinic, data collection was continued to obtain the 
information regarding GP referral at last visit in both active and control groups. The 
data collection forms returned to the researcher were reviewed and transferred to a 
summary sheet. Information transferred to this sheet was independently checked and 
coded by a member of the study team (ALe). To ensure updated patient information, 
this pharmacist also verified the information in the patient record at the surgery and 
added any updated data, wherever possible, to the summary sheet. 
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Table 4.1: Data collection tools and information collected 
Data collection tools Type of information collected 
Medication Review Form • Patient demographic data 
• Relevant medical history 
• Current/Previous drug therapy, 
dosage, indication 
• Relevant investigations 
• Details of current secondary care 
monitoring 
• Monitoring by practice 
Identified drug related problems, 
action plan and outcome. 
Update Medication All new information at the second 
and third clinic visits about medical 
history, drug therapy and any other 
relevant changes 
Review Form 
Diabetes Data Collection • Relevant medical history 
Form (related to diabetes) 
Diabetes 
Continuation Form 
• Specific objective diabetes data 
• Attendance at diabetic clinics 
• Foot exam 
• Eye exam 
Interview about self-glucose 
monitoring, smoking habit, 
signs/symptoms of diabetic 
complications, diabetic medication 
and OTC medication. 
Data All new information at the follow up 
clinic visits about diabetes 
GP referral form Drug related problems 
Proposed action 
GP response 
ADDQoL questionnaires Diabetes specific quality of life 
Primary data 
source 
• Surgery computer 
• Patient medical 
record 
• Patient interview 
• Surgery computer 
• Patient medical 
record 
• Patient interview 
• Patient medical 
record 
• Patient interview 
• HbA1c resultfrom 
DIASTAT analysis 
• Patient medical 
record 
• Patient interview 
• HbA 1 c result from 
DiaST AT analyser 
• Recorded and 
signed by 
pharmacist. 
• Responded and 
signed by GP. 
• Self-administered 
by patient. 
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4.8 Outcome measures 
Outcome measures included HbA 1 c, systolic blood pressure, health related quality of 
life, DRPs and the percentage of pharmacist recommendations accepted by GP. 
4.8.1 Clinical outcome: Haemoglobin A1c (HbA1c) 
The study was powered to detect a clinically meaningful difference of 1.0 unit change 
in mean HbA1c values (see 3.4.4). 
The HbA 1 c value obtained on the day of first visit was considered the patient's 
baseline measurement. HbA 1 c measurements were also obtained at the second and 
third clinic for the purpose of documenting changes in glycaemic control. There was a 
minimum interval of 3 months between visits. 
To assess HbA 1 c the pharmacist collected a capillary sample of the patient's blood 
(Appendix XXIII), placed it in a polypropylene tube containing aqueous solution of 
EDT A and potassium cyanide, and then mailed it to the laboratory where glycosylated 
haemoglobin A 1 c (HbA 1 c) was determined by the researcher (55) using a Biorad 
Automated HbA1c Analyser, DiaSTAT (Biorad Laboratories Ltd., Herts, UK). The 
DiaST AT analyser is a low pressure liquid chromatography system designed for the 
rapid and fully automated measurement of HbA1c in a small laboratory. The 
manufacturer's quoted range was 3.8 - 7.3% ± 0.50 (SD), 4.0 - 6.3% (95% confidence 
limits), n = 130 normal patients. 
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Transport of samples 
The HbA 1 c measurement was performed at the office in Glasgow. The samples from 
each site were sent to the office by first class Royal Mail service at the end of each 
clinic. Samples were stored at room temperature for up to 7 days before assay. 
Quality Assurance 
At every 100 assays performed, Lypochek Diabetes Control (Biorad, Herts, UK) was 
used to monitor the precision of the DIASTAT testing procedure, as recommended by 
the manufacturer. 
4.8.2 Clinical outcome: Blood pressure 
Systolic and diastolic blood pressure was recorded by using the automatic blood 
pressure measuring device, OMRON 705CP. The mean value of two sitting and two 
standing readings was used. In the case where the two systolic readings differed by 
more than 15 mmHg, a third reading was made and the mean of the two closest 
readings was used for analysis. Pharmacists were given instructions on how to use the 
OMRON 705CP (Appendix XXIV). 
Machines were checked at 6 months by the electronics laboratory at Department of 
Bio-Medical Physics and Bio-Engineering, University of Aberdeen to ensure that they 
were working in accordance with the manufacturer specifications. 
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4.8.3 Humanistic outcome: Diabetes specific QOL assessment 
Diabetes-specific QOL was assessed via the Audit of Diabetes Dependent Quality of 
Life, (ADDQoL) measuring the perceived impact of diabetes on different areas of 
patients' lives, weighted by importance to the individual (Bradley et aI., 1999). 
The ADDQoL was administered to patients in both groups at all three clinic visits. The 
questionnaire was self-administered. The study patients completed the ADDQoL at the 
reception area while waiting for their clinic appointment. 
The ADDQoL has 13 domain-specific items rated by the respondent on an impact score 
scale ranging from -3 (very much worse) to 3 (very much better) and importance rating 
scale ranging from 0 (not at all important) to 3 (very important). In addition, there were 
two overview items with a scale ranging from -3 to 3 at the beginning of the 
questionnaire. There were 'not applicable' options for four selected domains: 
employment/career, family relationship, sex life, and future of family. Those non-
applicable domains were excluded from the ADDQoL scoring. In the situation where the 
patient missed> 5 domains (including non-applicable domains) the questionnaire was 
excluded from the analysis. 
4.8.4 Process outcome: Drug related problems (DRPs) 
The type of drug related problem (Table 4.2), type of intervention (Table 4.3), GP 
response (Table 4.4), immediate outcome (Table 4.5) and final outcome (Table 4.6) 
classification system was adapted from Strand et al. (1990) and validated by Mackie 
and Campbell (2001) and subsequently used in this study to categorise DRPs and 
outcomes related to them. 
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Table 4.2: Drug related problem classification system 
Type of drug related problem 
1. No indication apparent 
2. Ineffective 
3. Adverse Drug Reaction 
4. Contraindication 
5. Admitted non-compliance, 
counselling required 
6. Drug Interaction 
7. Monitoring required 
8. Unnecessary therapy 
9. Untreated indication 
10. Repeat file inaccurate 
11. Generic substitution/cost issue 
12. Inappropriate choice of therapy 
13. Inappropriate dose/dosing 
schedule 
14. BP monitoring required 
15. HbA 1 c monitoring required 
Description 
Patient is taking a medication for no medically valid 
indication. 
Therapy is not adequately controlling the indication 
for which it has been prescribed or being prescribed 
at doses which are sub-optimal for improving disease 
control. 
Patient is taking a medication that should not be 
taken because of potential or actual adverse drug 
reaction or adverse effect. 
Patient is receiving a medication that is 
contraindicated. 
Patient is not receiving a medication or is not 
complying with the treatment due to economic, 
psychological, sociological, or pharmacological 
reasons. 
Patient is taking drugs that should not be combined 
together because of potential or actual drug 
interactions. 
Testing may be requested for monitoring purposes or 
because previous monitoring indicates a potential 
ADR, untreated indication or ineffective therapy. 
Patient currently has no indication for the therapy or 
duplicate therapy. 
Patient needs a treatment and is not receiving it. 
Repeat prescription on surgery computer is not 
accurate. 
Generic or less expensive drug is available. 
Patient has a drug indication but is taking the wrong 
drug, or is taking a drug that is not the most 
appropriate for the special needs of the patient. 
Alternatively the drug is correct but the dosage form 
or formulation is inappropriate. 
Patient is receiving too high or too Iowa dosage, 
inappropriate frequency or inappropriate duration. 
Blood pressure measurement may be required for 
monitoring therapy or because previous monitoring 
indicates untreated indication or ineffective therapy. 
HbA 1 c measurement may be required for monitoring 
therapy or because previous monitoring indicates 
untreated indication or ineffective therapy. 
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Table 4.3: Pharmacist intervention classification system 
Type of intervention 
Change drug same group 
Change drug new group 
Decrease dose 
Increase dose 
Stop therapy 
Initiate therapy 
Change directions 
Change formulation/device/brand 
Counsel 
Monitoring required 
Clinical review 
Update records 
Confirm indication/dose 
Table 4.4: GP response classification system 
Type of response 
Completely agreed 
Partially agreed 
Rejected, no action 
Description 
GP completely agrees to pharmacist's recommendation. 
GP agrees to pharmacist's recommendation with 
minor adjustment to the purposed action or GP requires 
patient's further review before making decision on therapy 
as recommended. 
GP rejects pharmacist's recommendation, no action taken. 
Chapter 4: Method· Main Study 87 
Table 4.5: Immediate outcome classification system 
Type of immediate outcome 
Actioned & accepted by patient 
Rejected by patient 
Not actioned • change in patient status 
Not actioned • no reason apparent 
Agreed GP to action 
Monitoring detects abnormality 
No further patient contact required 
Notes not available at follow up 
Description 
Action taken by pharmacist. Both patient and 
GP accept the change. 
GP agreed but patient does not 
agree to the change. No change made. 
Patient status changed. No action taken. 
GP and patient agreed but no action taken 
without explanation. 
GP require further review. Action taken after 
review. 
Patient's medical record is not available in 
surgery during pharmacist's working hours 
Table 4.6: Final outcome classification system 
Type of final outcome 
DRP resolved 
DRP remains 
Patient lost to follow up 
Description 
DRP resolved due to action taken or 
DRP resolved itself, no longer relevant or 
DRP resolved by alternative action. 
DRP remains as before despite action or 
DRP remains as before, action not taken or 
DRP addressed but not fully resolved. 
Patient died or left practice or patient's notes 
not available at follow up. 
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4.8.5 Ethical issues related to the control group 
In the case of a potentially life threatening issue identified for a control patient, this was 
referred to an independent medical adviser (ANC) for confirmation and removal of the 
patient from the study if appropriate. 
At the end of the study, all draft GP referrals for the control group were reviewed and 
where appropriate brought to the attention of the GP. The study team has not included 
any outcome measures for this group following this intervention. Analysis of this data is 
outwith the scope of the present study. 
4.9 Validation and quality assurance 
In order to minimise variation on HbA 1 c and blood pressure measurements, standard 
equipment was used. As there was a different normal range of HbA1c values from 
different laboratories, HbA1c was carried out in a single laboratory using the DiaSTAT 
machine. The pharmacists were trained in using the SOFTCLIX PRO LANCING device 
for taking blood samples and in using the automatic blood pressure measuring device, 
OMRON 705CP. To confirm the BP record on the data collection form, the pharmacist 
was requested to attach blood pressure printouts to the form. 
All GP referrals (both active and control groups) were peer reviewed by one of the 
project pharmacists (AM or RL) to assure that the GP referral was appropriate. The 
allocation of the patient to the active or control group was revealed after the peer 
review process in order to reduce bias. 
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Control patients were also seen by pharmacists in this study. Pharmacists were 
blinded at first visit only. At follow up visits to prevent contamination by pharmacists, for 
control patients, printed lists of control patients were provided to pharmacists and also 
'C' marked on the clinic appointment forms. 
4.10 Data analysis and statistical methods 
Comparisons of outcome measures were made within and between the active and 
control groups using T-Tests. In addition to comparison of absolute values of individual 
parameters, the number of patients in each group whose HbA 1 c and blood pressure 
were within target during the course of the study was compared using Chi-square. The 
extent of blood pressure and HbA 1 c control classed as good or poor control were 
stratified according to the following scheme: 
• Glycosylated haemoglobin (HbA 1 c) 
Good control 
Poor control 
<8.0% 
~8.0% 
• Systolic blood pressure targets for Type 2 diabetes: 
Good control ~ 140 mmHg 
Poor control > 140 mmHg 
To score a weighted rating of the ADDQoL, the patient's rating on the unweighted 
impact score (-3 to +3) was multiplied by the importance rating (0 to 3) for each 
domain. From this, unimportant domains score 0 regardless of magnitude of effect of 
diabetes and domains unaffected by diabetes score 0, regardless of their importance 
for QOL. The sum of weighted ratings of applicable domains divided by the number of 
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applicable domains provided the ADDQoL score. Therefore, the scores vary from -9 
(maximum negative impact of diabetes) to +9 (maximum positive impact of diabetes). 
The researcher (88) coded medication data using BNF chapter (Number 35, March 
1998) and Read codes to code diseases. At the end of the study two members of the 
study team (ALe and CAM) independently coded DRPs, pharmacist intervention, GP 
response, immediate and final outcomes. 
No attempt has been made to analyse new DRPs identified at clinics 2 and 3 due to the 
confounding factors and extensive double counting that would take place in the control 
group with each DRP being counted again at each visit. 
Chi-square test, relative risk (RR), absolute risk reduction (ARR) and number needed 
to treat (NNT) were calculated to compare the final outcomes of DRPs at clinic visit 1 to 
2 and clinic visit 1 to 3. Relative risk (RR) was used to calculate the effect size and the 
confidence interval (95%CI) used as a measure of its precision. The difference 
between the proportions with the outcomes caused by an intervention or a new 
treatment (PN) and no intervention or a standard treatment (Ps) is called the absolute 
risk reduction (ARR = PN - Ps). The NNT is the inverse of the ARR and is the estimated 
number of patients who need to be treated with the new treatment rather than the 
standard treatment to prevent one additional adverse outcome, and can be obtained for 
any trial that has a reported binary outcome (Altman, 1999). 
Chapter 5 
Results 
5.1 Practice setting 
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The nine practices had a total population of 38,613 patients of whom 387 (1.0%) 
were Type 2 diabetics (;~18 years old) taking an oral antidiabetic drug, indicating a 
prevalence of Type 2 diabetes in this population which is comparable with that 
reported by other studies (Khunti et aI., 1999). 
5.2 Participant flow 
Of the 387 patients identified, 19 (4.9%) met the exclusion criteria leaving 368 
potential participants who were eligible for inclusion in the study. They were stratified 
by practice, age, and gender, and then randomised into the active (188 patients) or 
control group (180 patients) (Figure 5.1). Blinding was achieved using a closed 
envelope technique. Overall 198 (54%) patients signed informed consent and 
attended the interview. After interview the pharmacist completed a GP referral form if 
appropriate following which the pharmacist was notified of active and control status. 
The overall number of patients attending the second clinic was 160 patients (81%, 
Figure 5.1). There were 21 patients (11%) who agreed but did not attend the clinic 
with the reason of work commitment (9, 43%), illness (6, 29%), taking care of other 
people (1, 4.8%) and no specific reason (5, 24%). In addition 8 (4.0%) patients 
declined the invitation, 4 (2.0%) patients left the practice or were away from home 
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during the appointment period and 2 (1.0%) patients died. The remaining three 
patients in the control group were withdrawn from the study, two with a potential 
serious illness and the one with a serious diabetic related problem. All 3 patients 
were removed from the study by the independent medical adviser in accordance with 
the study protocol. These three patients are described in more detail later in this 
chapter (see 5.4.9). Overall 82 (51 %) patients attended all three clinic visits, 45 (28%) 
patients agreed but did not attend the clinic with the reason of work commitment (12, 
27%), illness (8, 18%), and no specific reason (25, 55%). In addition 27 (17%) 
patients were not able to make the appointment within the study period due to a 
minimum three-month interval between visits (Figure 5.1). The remaining six patients 
(3.7%) include one who left the practice, one who died, and four who were unable to 
attend due to serious illness. 
The average time between clinic visit 1 and 2 was 19 weeks, and between clinic visit 
1 and 3 was 32 weeks. Patients who agreed but subsequently did not attend the 
second clinic were invited to attend another clinic together with other patients who 
were attending for clinic visit 3. Therefore the average time period between clinic visit 
1 and 2 was extended from the planned 12 weeks for these patients. 
There were 198 patients who attended the clinic at least once for the clinic visit 1 and 
160 who attended the clinic visit 1 and at least one of clinic visit 2 or 3. Of these 198 
patients, there were 38 (19%) patients who attended only one clinic, 78 (39%) 
patients who attended two clinics, and 82 (41%) patients who attended three clinics. 
The analysis was completed for the 160 patients (83 active patients, 77 control 
patients) who had the first clinic visit and at least one of clinic visit 2 or 3. 
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Figure 5.1: Flow diagram of participants through the trial 
I Assessed for eligibility (n=387) 
Excluded (n=19) 
... • Serious acute illness (n=11) 
• Resident of nursing home (n=6) 
• Dementia (n=2) 
" 
Randomised 
(n=368) 
~ ---------.. 
Active group (n=188) Control group (n=180) 
Did not receive intervention Did not receive interview 
(n=86) (n=84) 
• Declined (n=36) ~ r+ • Declined (n=33) • Did not attend (n=19) • Did not attend (n=25) 
• Died (n=5) • Died (n=3) 
• Away from homelleft • Away from homelleft 
practice (n=10) practice (n=6) 
• Not contactable (n=16) • Not contactable (n=17) 
, 
" Received allocated Received interview 
intervention (n=102, 54%) (n=96,53%) 
Total n=19 
Total n=19 
• Did not attend (n=11) 
• Did not attend (n=1 0) 
• Away from homelleft 
• Away from homelleft ~ r-. practice (n=1) practice (n=3) 
• Declined (n=3) 
• Declined (n=5) 
• Died (n=1) 
• Died (n=1) 
• Other (n=3) 
" " 
Followed up at 19 ± 4.9 Followed up at 19 ± 5.5 
weeks (n=83, 81%) weeks (n=77, 80%) 
Total n=44 Total n=34 
• Did not attend (n=25) 
<4- r-. • Did not attend (n=20) 
• Unable to make appt. • Unable to make appt. 
within study period within study period (n=11) 
(n=16) • Left practice (n=1) 
• Died (n=1) • Other (n=2) 
• Other (n=2) 
~, 
" Final follow up at 32 ± 2.7 Final follow up at 32 ± 3.4 
weeks (n=39, 47%) weeks (n=43, 56%) 
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The number of patients attending three clinic visits, and average time between visits 
did not differ significantly (P > 0.05) between the active and control groups. 
Patients who attended two or more clinics were categorised as having completed the 
study with the remainder categorised as not completing the study (:S; 1 clinic visit). 
5.3 Patient characteristics at baseline 
At baseline (clinic visit 1), patient demographics and clinical characteristics of the 160 
patients who completed the study are given in Table 5.1 and 5.2 respectively. The 
data show that the groups were comparable with respect to age distribution, sex, 
body mass index, smoking status, glycaemic control (HbA 1 c), blood pressure, total 
cholesterol, number of concurrent medical conditions, and number of drugs 
prescribed. 
Similar results were found between active and control patients who attended three 
clinic visits (39 active and 43 control). There was no significant difference between 
groups in patient demographics and clinical characteristics (P> 0.05). 
Chapter 5: Results 95 
Table 5.1: Baseline demographic characteristics of participants in active and 
control groups who completed the study 
Characteristic Active Control Pvalue 
n =83 n =77 
Mean age, years (±SO) 65 (10) 66 (10) 0.366 
No. of female gender (%) 43 (52) 35 (46) 0.422 
Mean body mass index, kg/m2 (±SO) 30 (6.6) 29 (9.2) 0.850 
No. of patients with body mass index 49 (64) 50 (71) 0.452 
> 27 kg/m2 (%) # 
Smoking status: 
Current tobacco smokers (%) 18 (22) 19 (25) 0.761 
Ex-smoker (%) 31 (37) 28 (36) 
Non-smoker (%) 34 (41) 30 (39) 
# 77 active and 70 control had a reading recorded in notes. 
Table 5.2: Baseline clinical characteristics of participants who completed the 
study 
Characteristic Active Control 
n=83 n=77 
Mean HbA1c level, %, (± SO) 8.3 (1.5) 8.4 (1.8) 
No. of patients with HbA1c ~ 8.0% (%)# 44 (53) 42 (55) 
No. of patients using glucose monitoring 
at home (%) 47 (57) 52 (67) 
Mean systolic blood pressure, mmHg 
(± SO) 149 (24) 149 (19) 
Mean diastolic blood pressure, mmHg 
(± SO) 82 (15) 82 (11) 
No. of patients with blood pressure 
within target, <140/80 mmHg, (%) 27 (32) 23 (30) 
Mean total cholesterol, mmollL (± SO) 5.4 (1.1) 5.3 (1.0) 
No. of drugs prescribed, median (range) 5.0 (1-13) 6.0 (1-16) 
No. of concurrent medical conditions, 4.5 (2.2) 4.7 (2.1) 
mean (± SO) 
# 79 active 75 control had a reading obtained from DiaSTAT analyser 
* T-test 
** Chi-square 
*** Mann-Whitney U-test 
Pvalue 
0.546 * 
0.929 ** 
0.156 ** 
0.835 * 
0.728 * 
0.369 ** 
0.969 * 
0.066 *** 
0.443 * 
Baseline characteristics were compared between those who completed the study and 
those who did not (Table 5.3). It shows that age, percentage of female and baseline 
HbA 1 c level did not differ significantly between both groups. 
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Table 5.3: Comparison of baseline characteristics between those who 
completed study and those who were randomised and did not complete the 
study 
Characteristic 
Mean age, years (±SO) 
No. of female gender (%) 
Mean HbA 1 c level, %, (± SO)# 
Number of clinics attended 
~ 2 clinics ~ 1 clinic 
n = 160 n = 208 
65 (10) 
78 (50) 
8.4 (1.7) 
64 (15) 
127 (61) 
8.1 (2.1) 
Pvalue 
0.703 
0.388 
0.413 
# 155 completed the study and 37 who did not complete the study had HbA 1 c value 
obtained from OIASTAT. 
From the pilot study sample size was estimated based on a change of 1.0 unit HbA 1 c 
to give the study a power of 90% to detect a difference if one existed. The mean 
value of Hba1c in total participants (n = 160) was 8.3 ± 1.7 and clinical significant 
difference was 1.0 units decrease in HbA 1 c, therefore the standardised difference = 
1.0/1.7 = 0.59. From Altman's nomogram (Altman, 1991), 160 patients participated in 
the study giving a 96% power of detecting a 1.0 unit difference in HbA1c value 
between two groups at the 5% level of Significance. However, there were 82 subjects 
who attended three clinics throughout the trial giving 77% power. 
The age and gender distributions of those who completed the study are presented in 
Table 5.4. Most of the partiCipants were aged 60 or over. The age distribution was 
7.5% aged less than 50 years, 20% aged 50-59, and 73% aged 60 or more. They 
were equally distributed between gender in active and control groups. 
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Table 5.4: Distribution of age and gender at baseline for those who completed 
the study 
Age range 
(years) 
31-49 
50-59 
60-69 
~70 
Total (%) 
Male 
3 
9 
16 
12 
40 (25) 
Active 
Female 
4 
7 
16 
16 
43 (27) 
5.3.1 Medical conditions recorded 
Control 
Male 
o 
11 
13 
18 
42 (26) 
Female 
5 
5 
12 
13 
35 (22) 
Total (%) 
12 (7.5) 
32 (20) 
57 (36) 
59 (37) 
160 (100) 
A total of 284 medical conditions were recorded for the active group and 283 for the 
control group. Table 5.5 shows the number of medical conditions identified from 
patient records in both the active and control groups. The most common diabetic 
complications recorded in the medical notes were cardiovascular diseases which 
include hypertension (19% in active and 17% in control), ischaemic heart disease, 
cardiac failure and arrhythmia (11% in active and 12% in control), and 
hyperlipidaemia (7.7% in active and 6.4% in control). Vascular diseases were 
associated with 45% of the medical conditions in the active group and 43% in the 
control group. For nonvascular diseases the most common was arthropathy (6.3% in 
active and 6.0% in control) which included both osteoarthritis and rheumatoid 
arthritis, obesity (6.0% in active and 4.9% in control) and gastrointestinal disorder 
(4.2% in both groups). Overall diabetic related complications were present in 55% 
and 53% of active and control patients respectively. 
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Table 5.5: Medical conditions recorded 
Medical condition Active (0/0) Control (0/0) Significant 
Hypertension # 55 (19) 47 (17) NS 
Ischaemic heart disease! Cardiac 
failure! Arrhythmia # 32 (11) 35 (12) NS 
Hyperlipidaemia # 22 (7.7) 18 (6.4) NS 
Arthropathy 18 (6.3) 17 (6.0) NS 
Obesity # 17 (6.0) 14 (4.9) NS 
Gastrointestinal disorder 12 (4.2) 12 (4.2) NS 
StrokelTlA # 11 (3.9) 14 (4.9) NS 
Urological problem 11 (3.9) 11 (3.9) NS 
COAD!asthma 10 (3.5) 16 (5.6) NS 
Peripheral vascular disease # 9 (3.2) 8 (2.8) NS 
Peripheral neuropathy # 8 (2.8) 7 (2.5) NS 
Depression and other 
Psychological disorders 7 (2.5) 7 (2.5) NS 
Hypo-!hyperthyroidism 6 (2.1) 5 (1.8) NS 
Renal failure! nephrectomy! 
Nephropathy # 3 (1.1) 5 (1.8) NS 
Miscellaneous 66 {22} 63 {23} NS 
Total 287 {100} 279 (100} 
# Diabetic related complications 
NS = not significant 
5.3.2 Current drugs prescribed 
Nine hundred and sixty-three prescribed drugs were reviewed by the pharmacist 
during patient interviews at clinic visit 1. Table 5.6 provides information on BNF 
chapter and number of drugs prescribed for both the active and control group. 
Table 5.6: Number of drug prescribed In BNF category 
BNF category (chapter number) 
Cardiovascular system (2) 
Endocrine system (6) 
Central nervous system (4) 
Gastro-intestinal system (1) 
Musculoskeletal and joint disease (10) 
Skin (13) 
Respiratory system (3) 
Others 
Total {n = 963) 
NS = not significant 
Active (0/0) 
167 (37) 
131 (29) 
51 (11) 
26 (5.8) 
24 (5.4) 
12 (2.7) 
11 (2.5) 
24 (5.4) 
446 (100) 
Control (0/0) 
188 (36) 
125 (24) 
66 (13) 
42 (8.1) 
23 (4.4) 
8 (1.5) 
37 (7.2) 
28 (5.4) 
517 POO} 
Significant 
NS 
NS 
NS 
NS 
NS 
NS 
P< 0.05 
NS 
Chapter 5: Results 99 
Apart from drugs in the endocrine system category, overall 63% of all prescribed 
drugs were accounted for by four BNF chapters namely: cardiovascular (37%); 
central nervous system (12%); gastro-intestinal (7.1 %) and musculoskeletal and joint 
disease (4.9%). The two groups were well matched for prescribed drugs with the 
exception of respiratory drugs which were more commonly prescribed in the control 
group (P < 0.05). 
Table 5.7 summarises the number of antidiabetic drugs prescribed in each of the two 
groups. The majority of patients were treated with a single drug (48% in active group 
and 53% in control group). As monotherapy, gliclazide was the most common choice 
of sulphonylurea in both groups. Metformin was the second drug most commonly 
used as a single agent and was also used most frequently in combination with a 
sulphonylurea especially gliclazide. Ten patients were prescribed glibenclamide (5 
active and 5 control), a long-acting sulphonylurea, and none were prescribed 
chlorpropamide at the baseline. Other drugs used as single drug included glipizide (1 
contrOl), glimepiride (1 control) and acarbose (1 control). 
Table 5.7: Number of antidiabetic drugs prescribed 
Drug No. (%) of patients receiving drug Significant 
Single drug 
Two-drug combination 
Triple-drug combination 
Total 
NS = not significant 
Active 
48 (58) 
33 (40) 
2 (2.4) 
83 (100) 
Control 
53 (69) 
24 (31) 
o (0) 
77 (100) 
NS 
NS 
NS 
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5.4 Outcome measures 
There were four outcome measures namely HbA 1 c, systolic blood pressure, HRQOL 
and DRP. Table 5.8 and 5.9 summarises the first two outcome measures at clinic visit 
1 and 2 and clinic visit 1 and 3 respectively. In addition to testing the significance of 
the differences in the means of clinic visit assessments, the number of patients 
whose diabetic condition and blood pressure were within target during the study was 
also evaluated and shown in Table 5.10 through 5.13. 
5.4.1 HbA1c 
HbA1c values were not available for all 160 patients who completed the study. Of 
these 160 patients, 6 patients in the active group and 4 patients in the control group 
had no HbA 1 c result available at clinic 1 or 2 for technical reasons such as too little 
blood sample and missed posting samples. Overall there were 150 (76 active 
patients, 74 control patients) patients reviewed for analysis as shown in Table 5.8, 
5.10 and 5.12. 
The study was powered to detect a meaningful clinical difference of 1.0 unit HbA 1 c. 
The HbA 1 c (mean ± SD) did not change significantly in either the active or the control 
groups (P > 0.05) from clinic visit 1 to 2 and between groups (Table 5.8). 
Similarly, there were no significant differences in the proportion of patients who had 
HbA1c value changed from poor (~8.0%) to good control « 8.0%) at the clinic visits 
1 and 2 between active and control groups (P > 0.05, Table 5.12). The analysis was 
repeated for the 82 patients (39 active, 43 control) who attended all three clinic visits. 
Table 5.8: Summary of outcome measures in patients who attended 2 or more clinics (83 active, 77 control) 
Measure Clinic 1 Clinic 2 
Active Control Active Control 
HbA1c (%) 8.3 ± 1.5 8.4 ± 1.8 8.4 ± 1.5 8.6 ± 1.7 
(7.9,8.6) (8.0,8.8) (8.1,8.8) (8.2,9.0) 
Systolic BP 149 ± 24 149 ± 19 140 ± 19 141 ± 19 
(mmHg) (144,155) (142, 151) (136, 144) (136, 145) 
Note: data is shown as (mean ± SD), A = active, C = control 
• Normal range = 3.8 -7.3% 
.. Significant difference 
Pvalue 
Size of change from 
clinic 1 to 2 
(mean ± 95%CI) 
Active 0.2 (-0.1 - 0.4) Active (1 st vs 2no) 0.486 
Control 0.1 (-0.2 - 0.4) Control (1 st vs 2nd) 0.516 
Change 1st to 2nd (A vs C) 0.628 
Active -9.3 (-14 - (-4.5» Active (1 st vs 2no) 0.007·· 
Control-6.2 (-12 - (-0.3» Control (1 st vs 2nd) 0.060 
Change 1st to 2nd (A vs C) 0.409 
Table 5.9: Summary of outcome measures in patients who attended three clinics (39 active, 43 control) 
Measure . Clinic 1 Clinic 3 
Active Control Active Control 
HbA1c (%) 8.1 ± 1.5 8.5 ± 1.6 8.2±1.4 8.7 ± 1.5 
(7.6,8.6) (8.0,9.0) (7.7,8.7) (8.3,9.4) 
Systolic BP 151 ± 20 149 ± 19 136 ± 16 144 ± 17 
(mmHg) (144,157) (143,155) (131,142) (138,149) 
Note: data is shown as (mean ± SD). A = active, C = control 
• Normal range = 3.8 - 7.3% 
•• Significant difference 
Size of change from Pvalue 
clinic 1 to 3 
(mean ± 95%CI) 
Active 0.1 (0.3 - 0.5) Active (1 st vs 3~) 0.857 
Control 0.1 (-0.2 - 0.5) Control (1 st vs 3~) 0.823 
Chanae 1st to 3rt! (A vs C) 0.819 
Active -14 (-8.2 - (- 20» Active (1 st vs 3~) o.oof'-
Control-5.7 (-0.6 - (-11» Control (1 st vs 3~) 0.151 
Change 1st to 3rt! (A vs C) 0.030·· 
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Table 5.10: Number of patients who attended two or more clinic visits by group 
and HbA1c category 
Category Clinic 1 Clinic 2 Pvalue* 
Active Control Active Control 
No. of patients with 
HbA1c ~ 8.0% 42 42 43 45 NS 
No. of patients with 
HbA1c < 8.0% 34 32 33 29 NS 
* Chi square 
NS = not significant 
Table 5.11: Number of patients who attended two or more clinic visits by group 
and systolic blood pressure category 
Category Clinic 1 Clinic 2 Pvalue* 
Active Control Active Control 
No. of patients with 
SSP> 140 mmHg 52 46 45 35 NS 
No. of patients with 
SSP:s; 140 mmHg 29 28 36 39 NS 
* Chi square 
NS = not significant 
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Table 5.12: Number of patients who attended two or more clinic visits by group 
and change of HbA1c category 
Change of HbA1c from Number of ~atient {%} Significant 
clinic 1 to 2 Active Control 
Good control, no change 24 (32) 22 (30) NS 
remained within target 
Poor control, within target 10 (13) 7 (9.5) NS 
at baseline only 
Good control, high at 9 (12) 7 (9.5) NS 
baseline, now within target 
Poor control, no change at 33 (43) 38 (51) NS 
baseline and follow up 
NS = not significant 
Good control: HbA1c < 8.0% 
Poor control: HbA1c ~ 8.0% 
Table 5.13: Number of patients who attended two or more clinic visits by group 
and change of systolic blood pressure category 
Change of Systolic BP from 
clinic 1 to 2 
Good control 
SBP remains ~ 140 mmHg 
Poor control 
SBP ~ 140 mmHg at baseline, 
now> 140 mmHg 
Good control 
SSP> 140 mmHg at baseline, 
now ~ 140 mmHg 
Poor control 
SSP remains> 140 mmHg 
Number of patient (%} 
Active Control 
23 (28) 21 (28) 
6 (7.4) 8 (11) 
22 (27) 18 (24) 
30 (37) 27 (36) 
NS = not significant, SSP = systolic blood pressure 
Significant 
NS 
NS 
NS 
NS 
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No significant difference in HbA 1 c values were found from clinic visit 1 to 3 and 
between groups (P > 0.05, Table 5.9). 
Four patients in the active group were switched over to insulin therapy during the 
study period. The HbA1c values were in the range of 9.9 - 12.6% at the time of 
starting insulin. HbA 1 c value decreased by 3.8%, 1.3%, 0.5% and 0.4% in the 
patients in the first 3-4 months of insulin therapy. 
In the active group, 48 (58%) patients had no hyperglycaemic complaints between 
clinic visit 1 and 2, compared to 40 (52%) in the control group (X2 = 0.35, 1df, P > 
0.05). No hyperglycaemic event occurred that required professional medical 
intervention. 
5.4.2 Blood pressure 
Table 5.8 provides the results for blood pressure which shows a significant reduction 
in average systolic blood pressure from clinic visit 1 to 2 in the active group (P = 
0.007) whilst no significant differences were found in the control group (P = 0.060) 
and between groups (P = 0.409). 
Of the 82 patients who attended all three clinics (Table 5.9), a significant reduction 
was noted for systolic blood pressure change within the active (P = 0.001) and 
between the active and control (P = 0.030) whilst no difference was noted in systolic 
blood pressure change within the control (P = 0.151). 
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There was no significant difference in the proportion of patients who had systolic 
blood pressure >140 mmHg changed to ~ 140 mmHg at clinic visit 1 to 2 between 
active and control groups (P>0.05, Table 5.13). 
Diastolic blood pressure was also measured and is reported for information. There 
was an apparent reduction in average diastolic blood pressure from clinic visit 1 to 2 
in the active and control groups but this was not statistically significant (80 ± 12, 78 ± 
10 in active; 82 ± 12, 79 ± 10 in control for clinic 1 and 2 respectively; P > 0.05). In 
addition no significant differences were found in the change between groups. 
There was no significant difference in the proportion of patients who had diastolic 
blood pressure > 80 mmHg changed to ~ 80 mmHg at clinic visit 1 to 2 between 
active and control groups (P > 0.05). No significant differences were found in the 
mean diastolic blood pressure, and the number of patients who had changed diastolic 
blood pressure> 80 mmHg to :::;; 80 mmHg between the clinic visit 1 to 3 and between 
groups (P > 0.05). 
5.4.3 Health related quality of life: ADDQoL 
A total of 112 patients (70%, 60 active and 52 control) completed the ADDQoL 
questionnaires at clinic visit 1 and 2. Three patients (1.9%) did not complete 
questionnaires at clinic visit 1 and 45 patients (28%) did not complete questionnaires 
at clinic visit 2. Of these 48 patients, 38 patients did not fill in the questionnaire and 
gave no reason, 6 patients did not bring their spectacles and 4 patients could not 
read English. Of these 112 patients, data from 98 patients (54 active, 44 control) 
were included in the analysis. Questionnaires from the remaining 14 patients could 
not be used for the following reasons: 4 active patients did not complete 'importance 
rating' questions and 1 answered only general questions; 6 control patients did not 
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complete 'importance rating' questions and 3 patients answered less than 3 
questions. 
Thirty-eight of 98 (39%) patients at clinic visit 1 and 49 of 98 (50%) patients at clinic 
visit 2 responded to every question in the questionnaires. Table 5.14 shows the 
number of patients who responded to each question at baseline and follow up. Some 
omissions appeared to be due to simple oversight, which seemed particularly 
apparent when a page of the questionnaire was left blank (the printing format resulted 
in 3 questions being printed on each page). Two questions (no. 1 and 5) had 
relatively high rates of missing values (43 and 27 at baseline, 38 and 21 at follow up, 
respectively). Question related to employment and career (Question no. 1) may have 
been considered not applicable by patients who were not employed at the time of the 
questionnaire administration, including most patients in the study who were aged 60 
or over. In addition several patients did not respond to the question concerning sex 
life (no.5). 
Table 5.14: Number of respondents to each domain of ADDQoL 
Domain Number of respondents 
Clinic 1 Clinic 2 
1) Employment/career 55 60 
2) Social life 91 88 
3) Family relationships 90 90 
4) Friends 94 95 
5) Sex life 71 77 
6) Sport/leisure 94 95 
7) Travel 90 93 
8) Future (own) 88 92 
9) Future of family 80 91 
10) Motivation 86 93 
11) Physical activities 89 92 
12) Other fussing 86 94 
13) Enjoyment of food 93 93 
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At clinic visit 3, there were 30 patients (77%, 30/39) in the active group and 31 
patients (72%, 31/43) in the control group who completed the questionnaire. Of 
these, 2 questionnaires were invalid as only three questions were filled in. A total of 
59 (72%) patients completed ADDQoL questionnaires at all three clinic visits. 
Table 5.15 provides overall scores for HRQOL. Patient's diabetes related quality of 
life, as reflected by total score on the ADDQoL, did not change significantly for either 
the active or control groups from clinic visit 1 to 2. 
A trend of improved mean QOL in the active group (+ 0.3) and a reduced mean QOL 
in the control group (- 0.3) can be seen, however this does not reach statistical 
significance (P = 0.064). 
Table 5.15: ADDQoL total score between clinic visit 1 and 2 
Group ADDQoL score 
Clinic 1 Clinic 2 Pvalue* 
Mean±SD Median (range) Mean ±SD Median (range) 
Active 
-2.3 ± 1.9 -2.0 (-7.4-0) -2.0 ± 1.6 -2.0 (-5.3-0.1) 0.588 
Control 
-1.5±1.9 -0.8 (-8.7-0) -1.8 ± 2.0 -1.2 (-7.9-0) 0.800 
* Compare means using T-test 
Changes from clinic visit 1 to 2 for the 13-domain ADDQoL subscores are shown in 
Table 5.16. Patients in the active group scored better in most domains (9/13), except 
family relationships, friends, future of family, and motivation. There was a general 
decline in ADDQoL scores (worse quality of life) across most domains from baseline 
to follow up in the control group, except for the sex life domain. 
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Table 5.16: Change from baseline in ADDQoL domain scores 
Domain Change from clinic visit 1 to 2 
Active, Control, Difference 
Mean (range)" Mean (range)' between 
Employment/career 0.56 (-6-9) -0.69 (-5-3) 
Social life 0.16 (-9-9) -0.43 (-7-6) 
Family relationships -0.47 (-9-6) -0.37 (-6-5) 
Friends -0.15 (-4-3) -0.20 (-6-9) 
Sex life 0.43 (-5-7) 0.15 (-5-6) 
Sport/leisure 0.65 (-9-6) -0.40 (-9-9) 
Travel 0.10 (-6-9) -0.64 (-5-4) 
Future (own) 0.42 (-6-7) -0.86 (-9-4) 
Future of family -0.27 (-6-9) -0.77 (-9-5) 
Motivation -0.06 (-5-7) -0.23 (-4-4) 
Physical activities 0.10 (-9-7) -0.49 (-5-4) 
Other fussing 0.55 (-6-9) -0.37 (-9-9) 
Enjoyment of food 0.25 (-9-9) -0.46 (-7-9) 
# Figure with minus sign means decrease in quality of life. 
groups 
1.25 
0.59 
-0.10 
0.05 
0.28 
1.05 
0.74 
1.28 
0.50 
0.17 
0.59 
0.92 
0.71 
Pvalue 
0.107 
0.341 
0.855 
0.906 
0.656 
0.009 
0.148 
0.036 
0.444 
0.489 
0.303 
0.234 
0.351 
Comparison of score changes reveals a difference between active and control groups 
on two items: sport/leisure domain (P = 0.009) and future (own) domain (P = 0.036). 
The largest change in average score between groups was for the future (own) 
domain, for which the active group scores increased by 0.42 units but the control 
group value declined on average by 0.86 units. A Bonferroni correction would indicate 
that a significant result would require a P value of < 0.0038. Therefore the differences 
observed would not reach statistical significance. 
In the general quality of life question (question A, Appendix VII), the median score at 
clinic visit 1 was -1.0 (range -3 to 2) in the active group, and -1.0 (range -3 to 1) in the 
control group. The median score was the same in both groups at the clinic visit 2 
(-1.0 (range-3 t01) in both the active and the control groups). The median score in 
diabetes related general quality of life (question B, Appendix VII) at clinic visit 1 was 
-2.0 (range -3 to1) in the active group, -1.0 (range -3 to 0) in the control group. The 
median score remained the same in active and control groups at clinic visit 2. 
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5.4.4 Number of DRPs identified 
Tables 5.17 and 5.18 provide further details of type of DRPs for the active and control 
groups. It should be noted that the number of drug related problem at the second and 
third clinic visits includes both newly identified problems and unresolved problems. 
Table 5.17: Classification and number of DRPs in active and control groups at 
clinic 1 and 2 
Description Active Control 
Clinic 1 Clinic 2 Clinic 1 Clinic 2 
Clinical DRP 154 98 151 165 
Administrative DRP 23 13 28 22 
Total 177 111 179 187 
Table 5.18: Classification and number of DRPs in active and control groups at 
clinic 3 
Description Active Control 
ClinicalDRP 43 100 
Administrative DRP 4 12 
Total 47 112 
At the first clinic visit, some 356 DRPs were identified of which 177 related to the 
active patients and 179 to the control patients. The number of DRPs identified 
decreased by 37% in the active group and increased by 4.5% in the control group at 
the second clinic visit (Table 5.17). Of the 82 patients (51 %) who attended a third 
clinic visit, the number of DRPs identified was significantly higher in the control group 
than the active group (Table 5.18). 
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Within clinical DRPs there were 101 (34%) and 154 (37%) DRPs related to diabetes 
in the active and control groups respectively. The average number of DRPs per 
patient is shown in Table S.19. 
Table 5.19: Mean number of DRPs per patient in active and control groups 
Patient group Mean±SD Range 
Active 
Clinic visit 1 (n = 83) 2.1 ± 1.6 0-6 
Clinic visit 2 (n = 83) 1.3 ± 1.4 O-S 
Clinic visit 3 (n = 39) 1.2 ± 0.9 0-3 
Control 
Clinic visit 1 (n = 77) 2.3 ± 1.4 0-5 
Clinic visit 2 (n = 77) 2.4 ± 1.4 0-5 
Clinic visit 3 (n = 43) 2.6 + 1.S 0-6 
Figures 5.2 - 5.4 provide detailed information on the number of patients and number 
of DRPs in the active and control groups at clinic visit 1, 2 and 3 respectively. At the 
first clinic visit, 67 (81 %) of patients in the active group and 69 (90%) of patients in he 
control group had one or more DRPs identified (l = 3.22, df = 1, P> O.OS). However, 
there was a significantly lower number of patients who had one or more DRPs at the 
second clinic visit in the active group (y: = 6.87. df = 1, P < 0.01) and at the third 
clinic visit (X2 = 7.44, df = 1, P < 0.01). 
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Figure 5.2: Number of patients and number of DRPs at clinic visit 1 (N = 160) 
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Figure 5.3: Number of patients and number of DRPs at clinic visit 2 (N = 160) 
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Figure 5.4: Number of patients and number of DRPs at clinic visit 3 (N = 82) 
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5.4.5 Clinical drug related problems 
5.4.5.1 Categories of clinical DRPs Identified 
The drug related problems of each category were classified independently by two 
members of the study team (AC and CAM). The results were matched for 97% of all 
DRPs identified and the results presented in the tables were obtained after final 
unanimous agreement of the 3% amongst members of the project team (AC, CAM, 
and 88). 
The distribution of the DRP categories in the active and control groups is shown in 
Table 5.20. The five most common clinical DRPs were: ineffective therapy (37%), 
monitoring required (19%), untreated indication (16%), inappropriate choice of 
therapy! dose! dosing schedule (9.8%), and admitted noncompliance! counselling 
required (7.4%). 
Only three DRPs (31713, 0.4%) were classified under 'other', which suggests that 
there was a sufficient range of categories. Two DRPs in the active group related to 
patient's concern regarding bleeding after dilatation and curettage procedures and 
patient's colour blindness which made a difficulty reading Diastix. Another DRP in the 
control group was about removing Canesten pessaries from the repeat list and 
advising the patient to request a supply specifically so that the use could be better 
monitored. 
Table 5.20: Number of clinical DRPs identified by pharmacist at first clinic (n=160), second clinic (n=160) and third clinic (n=82) 
Category of clinical DRP Total Active Control 
(%) Clinic 1 Clinic 2 Clinic 3 Clinic 1 Clinic 2 Clinic 3 
Ineffective 267( 37) 58 47 20 52 52 38 
Monitoring! BP monitoring! HbA 1 c monitoring 
required 133(19) 31 17 10 31 28 16 
Untreated indication 113(16) 24 10 6 23 28 22 
Inappropriate choice of therapy/ dose/ dosing 
schedule 70(9.8) 16 6 3 18 18 9 
Admitted noncompliancel counselling 
required 53(7.4) 12 9 3 12 13 4 
Unnecessary therapy 37(5.2) 8 3 0 7 16 3 
ADRI drug interaction 23(3.2) 2 1 0 8 7 5 
No indication apparent 5(0.7) 2 2 0 0 1 0 
Formulation/delivery 5(0.7) 0 3 0 0 1 1 
Contraindication 2(0.3) 0 0 0 0 0 2 
Other 3(0.4) 1 0 1 0 1 0 () 
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5.4.5.2 BNF categories for drugs with clinical DRPs 
The pharmacists reviewed 964 and 1,033 drugs at the clinic visit 1 and 2 for the 160 
patients interviewed. The BNF categories for these are given in Table 5.21. Of the 
964 drugs reviewed at clinic visit 1, 256 (26%) were associated with clinical drug 
related problems and of 1,033 drugs reviewed at clinic visit 2, 199 (19%) were 
associated with clinical drug related problems. 
Overall there were found to be 27 DRPs per 100 drugs reviewed at clinic visit 1 
compared to 19 DRPs per 100 drugs reviewed at clinic visit 2. However there was a 
large variation in the number of DRPs associated with different BNF chapters. For 
example, 36 DRPs were noted for every 100 cardiovascular drugs reviewed at clinic 
1 compared to only 6 DRPs per 100 central nervous system drugs reviewed and 2 
DRPs per 100 respiratory drugs reviewed. 
Table 5.21: SNF categories and cllnlcallJRl's 
BNF category (chapter 
number) 
Number of drugs reviewed Number of drugs related to 
(%) DRP(%) 
Clinic 1 Clinic 2 Clinic 1 Clinic 2 
Cardiovascular system (2) 355 (37) 405 (39) 129 (51) 91 (46) 
Endocrine system (6) 240 (25) 247 (24) 90 (35) 75 (38) 
Central nervous system (4) 133 (14) 135 (13) 8 (3.1) 12 (6.1) 
Gastro-intestinal system (1) 68 (7.1) 71 (6.9) 10 (3.9) 8(4.1) 
Respiratory system (3) 48 (5.0) 50 (4.8) 1 (0.4) 2 (1.0) 
Musculoskeletal disease( 10) 47 (4.9) 53 (5.1) 11 (4.3) 4 (2.0) 
Others 72 (7.5) 70 (6.8) 6 (2.3) 5 (2.5) 
Total 964 (100) 1033 (100) 256 (100) 199 (100) 
Number of patients: 83 active, 77 control 
DRPs per 100 drugs 
reviewed 
Clinic 1 Clinic 2 
36 22 
38 30 
6 9 
15 11 
2 4 
23 8 
8 7 
27 19 
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5.4.5.3 Clinical DRPs linked to diabetes 
There were some DRP categories related to the condition of diabetes itself, i.e. DRPs 
regarding HbA 1 c monitoring required, other monitoring required, and admitted 
noncompliance! counselling required. HbA 1 c monitoring was required in the cases 
where new diabetic treatment was commenced or where the dose of diabetic 
medication was adjusted. HbA 1 c measurement was needed to assess the 
effectiveness of the revised diabetic treatment. Examples of monitoring required 
included failure to received routine screening including feet and eye examinations. 
Examples of noncompliance and counselling required included monitoring blood and 
urine glucose levels and compliance with diabetic medications. 
5.4.5.3.1 Clinical DRPs related to antidiabetic drugs 
Of the 711 clinical DRPs, 171 (24%) were identified specifically related to antidiabetic 
drugs, the distribution of the most common categories of DRPs are shown in Table 
5.22. Gliclazide and metformin are the most common antidiabetic drugs found to be 
associated with clinical DRPs. The most prevalent clinical DRPs associated with 
antidiabetic drugs were related to ineffective therapy (79%). 
All referrals for the active group were passed to the GP for consideration while in 
control group no referrals were made in accordance with the planned protocol. 
Therefore it is possible for the pharmacist to identify a DRP in the control group 
repeatedly at the later clinic visits, if the problem remained as before. Of the 89 DRPs 
related to antidiabetic drugs in the control group, 28 (31%) DRPs were repeated at 
the later clinic visits. 
Table 5.22: Antidiabetic drug. a •• ocIAttd with clinicAl DRP. 
Drug Number 
prescribed 
Number of Category of DRPs 
associated Ineffective Admitted non- Inappropriate Inappropriate 
clinical DRPs therapy compliance choice of dose/dosing 
(%) therapy schedule 
Gliclazide 125 74 (59) 58 6 7 2 
Metformin 88 61 (69) 49 6 2 2 
Glibenclamide 25 13 (52) 6 0 0 4 
Acarbose 16 6 (37) 6 0 0 0 
Insulin 15 9 (60) 9 0 0 0 
Glipizide 8 2 (25) 2 0 0 0 
Other 12 6(50) 6 0 0 0 
Total (%) 246 171 (69) 136 (79) 12 (7.0) 9 (5.3) 8{4.7} 
Includes patients attending clinic visit 1 (n=160). clinic visit 2 (n=160) and clinic visit 3 (n=82) and includes DRPs identified in the 
pending GP referral in the control group. 
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5.4.5.3.2 Clinical DRPs related to blood pressure 
Overall 100 (14%) of the 711 clinical DRPs were linked to blood pressure control. 
Pharmacists identified 59 (29 active, 30 control) DRPs related to 'ineffective therapy' 
in 47 (23 active, 24 control) hypertensive patients. Twenty-six blood pressure 
monitoring requests (14 active, 12 control) were made by pharmacists in 23 patients 
(13 active, 10 control). Untreated hypertension was identified in 12 patients (5 active, 
7 control). Inappropriate choice of hypertensive treatment was identified in 3 active 
patients, each of these related to inappropriate use of frusemide for the management 
of hypertension. 
5.4.5.3.3 Clinical DRPs related to lipid levels 
There were 85 (12%) of the 711 clinical DRPs associated with dyslipidaemia and 
regular lipid control. Thirty seven of these (43%, 19 patients in the active group and 
11 patients in the control group) were categorised as monitoring required due to no 
regular lipid check or re-check after change of the lipid-lowering drug and 26 (31%, 9 
patients in the active group and 11 patients in the control group) which were 
categorised as untreated indication. Other lipid related DRPs included 9 issues 
categorised as ineffective therapy (5 active, 4 control), 8 issues categorised as 
inappropriate dose/dosing schedule (3 active, 5 control), 3 issues involving adverse 
drug reaction (1 control), and 2 issues where choice of therapy was inappropriate (2 
active). 
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5.4.5.3.4 Clinical DRPs related to aspirin therapy 
Of the 711 clinical DRPs, pharmacists recommended a low dose of aspirin for 
primary and secondary cardiovascular prevention resulting from 46 (6.5%) DRPs (18 
active, 28 control) in 38 patients (20 control, 18 active patients) who had Type 2 
diabetes with coronary heart disease or who were at high risk of coronary heart 
disease, without a contraindication to using aspirin. These were categorised as 
untreated indication. The patients were prescribed plain aspirin 75mg daily for this 
indication, as recommended by the pharmacists. 
5.4.5.3.5 Clinical DRPs related to urinary protein and electrolytes 
Of the 711 clinical DRPs, pharmacists requested 34 (4.8%) urinalysis and electrolytes 
checks (16 active, 18 control) in 26 patients (14 active, 12 control). Overdue 
monitoring was the most common reason for requesting a urinalysiS test (21/34 
issues, 62%). Other reasons included monitoring renal function before and during 
treatment with angiotensin-converting enzyme inhibitors, diuretics, and metformin. 
5.4.5.3.6 Clinical DRPs related to foot and eye examinations 
Overall 6 (0.8%) of 711 clinical DRPs were related to foot and eye examinations. 
Pharmacists recommended referral of 4 patients (1 active, 3 control) to a chiropodist 
and referral of 2 patients (1 active, 1 control) to an ophthalmologist for further 
examination. 
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5.4.5.3.7 Miscellaneous 
Liver function tests were requested in 3 patients (2 active, 1 control) who were 
already receiving or were about to commence statins. This test was also 
recommended in 2 patients (1 active, 1 control) before they started pioglitazone and 
rosiglitazone respectively. 
5.4.5.4 Proposed actions to resolve clinical DRPs 
A summary of the actions recommended by the pharmacists to resolve the clinical 
DRPs is provided in Table 5.23. The pharmacists made 711 recommendations over 
all three visits in both groups. Of these, recommendations 'initiate therapy' and 
'increase dose' were the two most common categories totalling 170 (24%) and 151 
(21 %) respectively. 
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5.4.5.5 GP response to proposed actions to resolve clinical DRPs In the active 
group 
Overall of the 295 clinical DRPs referred in the active group, 235 (80%) resolutions 
were completely agreed, 53 (18%) partially agreed and 7 (2%) rejected by the GP. At 
clinic visit 1, 154 active patient referrals were made of which 123 (80%) were agreed, 
28 (18%) were partially agreed and 3 (1.9%) were rejected. At clinic visit 2, there 
were 96 active referrals of which 80 (82%) were agreed, 16 (17%) were partially 
agreed and 2 (1.3%) were rejected. At clinic visit 3, there were 45 active referrals of 
which 32 (71%) were agreed, 11 (24%) were partially agreed and 2 (4.4%) were 
rejected. 
Table 5.24 provides a summary of GP responses to the clinical DRPs. Generally a 
high level of agreement was noted for all categories of clinical DRPs although GPs 
appeared more likely to reject no indication apparent (25%) and unnecessary therapy 
(18%) but the numbers are too small to interpret. 
Table 5.24: Summary of GP responses to recommendations regarding clinical DRPs in the active group at all clinic visits 
DRP 
Ineffective therapy 
Routine monitoring I HbA 1 c monitoring 
required 
Untreated indication 
Inappropriate choice of therapy Idose! dosing 
schedule 
Admitted noncompliance I counselling required 
Unnecessary therapy 
No indication apparent 
AD RID I 
Other 
Total (%) 
Completely agreed (ty.) Partially agreed W.) Rejected (0/0) 
95 (76) 27 (22) 3 (2.4) 
54 (93) 4 (6.9) 0(0) 
30 (75) 10 (25) 0(0) 
18 (72) 6 (24) 1 (4.0) 
23 (96) 1 (4.2) o (O) 
6 (55) 3 (27) 2 (18) 
3 (75) o (0) 1 (25) 
2 (67) 1 (33) 0(0) 
4 (80) ~~1 .. (2~QL .. _ _--=-O ........ (0'-L) __ -'--
235 (80) 53 (18) 7 (2) 
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5.4.6 Administrative drug related problems 
5.4.6.1 Categories of administrative DRPs Identified 
There were 102 administrative DRPs of which 83 (81%) were categorised as 'repeat 
file inaccurate' and 19 (19%) which were identified as 'generic substitutionl cost 
issue'. 
5.4.6.2 GP response to proposed actions to resolve administrative DRPs In the 
active group 
Of the 40 administrative DRPs in the active group from all three clinic visits, 
recommendations on 39 (98%) were fully agreed and in only 1 case (2.5%) was 
further review requested. This DRP was related to the cost issue of the drug 
prescribed. 
5.4.6.3 Outcome of administrative DRPs 
Outcome data for administrative DRPs identified at clinic 1 was noted at clinic 2 and 
are provided in Table 5.25. Overall 96% of DRP were resolved in the active group 
versus 46% in the control group (P < 0.001). 
Table 5.25: Number of administrative DRPs with outcome (clinic 1 to 2) 
Outcome Active 
DRP remaining Yes 1 
No 22 
Total 23 
r: = 14.2, 1 df, P < 0.001 
RR = 0.08 (95%CI: 0.01 to 0.57), ARR = 0.5, NNT = 2 
Control 
15 
13 
28 
Total 
16 
35 
51 
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5.4.7 Outcome for all drug related problems 
5.4.7.1 Immediate outcome 
Table 5.26 provides details of the immediate outcomes resulting from all DRPs 
(clinical and administrative) in the active group at all three clinic visits. The majority of 
the agreed actions (239, 71 %) were accepted by the patient and implemented by the 
pharmacist. None of the pharmacist recommendations were subsequently rejected by 
patient. The GP was left to action only 36 (11 %). Details of the remainder are 
provided in Table 5.26. 
-Table 5.26: Immediate outcome resulting from intervention in the active group at clinic 1 (n=160), clinic 2 (n=160) and clinic 3 
(n=82) 
Outcome 
Actioned and accepted by patient 
Not actioned, change in patient status 
Not actioned, no reason apparent 
Agreed GP to action 
No further patient contact required 
Monitoring detects abnormality 
Notes not available 
Clinic 1 Clinic 2 Clinic 3 
125 (71) 87 (78) 27 (57) 
1 (0.6) 3 (2.7) 0 (0) 
17 (9.6) 5 (4.5) 5 (11) 
22 (12) 8 {7.2} 6 (13) 
3 (1.7) 6 (5.4) 3 (6.4) 
6 (3.4) 1 (0.9) 2 (4.2) 
3 (1.7) ~ J(Q.9L . ~ 4 (8.5) 
Total (%) 177 (100) 111 (100)_~__ 47 (100} 
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5.4.7.2 Final outcome 
Outcome data for DRPs identified at clinic 1 was noted at clinic 2 and are provided in 
Table 5.27. Overall 62% of DRP were resolved in the active group versus 36% in the 
control group (P < 0.001). A significant difference was noted with a RR of 0.59 (0.48 
to 0.74), an ARR of 0.26 and NNT of 3.85. However chi-square assumes 
independence of DRPs which may not be the case. 
Table 5.27: Number of DRPs with outcome at clinic 2 (Clinic 1 to 2) 
Outcome Active Control Total 
DRP remaining Yes 67 114 181 
No 110 65 175 
Total 177 179 356 
-l = 23.8, 1 df, P < 0.001 
RR = 0.59 (95%CI: 0.48 to 0.74), ARR = 0.26, NNT = 3.85 
Table 5.28 provides details of patients on the number of DRPs remaining. A 
significant difference was noted with a RR of 0.80 (0.66 to 0.96), an ARR of 0.17 and 
NNTof5.88. 
Table 5.28: Outcome data for patients and DRPs remaining (clinic 1 to 2) 
Outcome Active Control 
No. of patients with Yes 55 64 
one or more DRPs No 28 13 
Total 83 77 
x2 = 5.95, 1 df, P < 0.02 
RR = 0.80 (95%CI: 0.66 to 0.96), ARR = 0.17, NNT = 5.88 
Total 
119 
41 
160 
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Eighty-two patients attended all three clinics and Table 5.29 provides final outcome 
data for all DRPs identified at clinic 1 which were followed up at clinic 3. Overall 62% 
of DRP were resolved in the active group versus 37% in the control group (P < 
0.001). A significant difference was noted with a RR of 0.60 (0.44 to 0.82), an ARR of 
0.25 and NNT of 4.0. 
Table 5.29: Number of DRPs with outcome at clinic 3 (clinic 1 to 3) 
Outcome Active Control Total 
DRP remaining Yes 31 67 98 
No 51 39 90 
Total 82 106 188 
x2 = 11.96, 1 df, P < 0.001 
RR = 0.60 (95%CI: 0.44 to 0.82), ARR = 0.25, NNT = 4.0 
Table 5.30 provides data on individual patients on the number of DRPs remaining at 
clinic visit 3. A significant difference was noted with a RR of 0.76 (0.61 to 0.96), an 
ARR of 0.22 and NNT of 4.5. 
Table 5.30: Outcome data for patients and DRPs remaining (clinic 1 to 3) 
Outcome Active Control 
No. of patients with Yes 27 39 
one or more DRPs No 12 4 
Total 39 43 
x2 = 6.0, 1 df, P < 0.02 
RR = 0.76 (95%CI: 0.61 to 0.96), ARR = 0.22, NNT = 4.5 
Total 
66 
16 
82 
Table 5.31 provides examples of DRPs and outcomes in the order of categories 
described in method section 4.8.4. 
Table 5.31: Examples of DRPs identified by the pharmacists 
Patient 
code 
no. 
H05D 
H16D 
I05DA 
H07D 
Category 
No indication 
apparent 
Ineffective therapy 
Ineffective therapy 
Adverse drug 
reaction 
l18DA Contraindication 
Drug related problem 
Description Intervention Outcome 
Taking frusemide for ankle Stop frusemide and GP accepted, patients no longer had 
symptom. oedema. monitor. 
History of hypertension. 
BP not controlled. 
Taking metformin for 
controlling diabetes. 
HbA1c over 8.0% 
Patient complaint of cold 
hands and feet and 
breathlessness, possible 
side effect of propranolol. 
Taking metformin 500mg 
twice a day. Patient had 
hepatiC impairment and 
alcohol dependence. 
Consider enalapril 2.5 mg 
initially and titrate dose. 
Increase dose of Metformin 
GP accepted, enalapril was prescribed. 
Actioned BP now controlled 
GP accepted, Pharmacist increased 
dose of metformin. HbA 1 c decreased 
but still over 8.0%. 
Stop propranolol and review GP accepted. Patients had now no 
symptoms. Start atenolol symptoms and BP controlled. 
and recheck BP. 
Stop metformin. GP accepted, prescribing gliclazide for 
alternative. 
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Patient Category 
No. Description 
I06DA Admitted non-
compliance 
Patient was asked about 
monitoring blood/urine 
glucose levels. She does 
not monitor at the moment 
but has urine stix 
prescribed in the past. Her 
daughter bought a blood 
glucose monitor. She was 
reluctant to monitor. 
A26D 
G21D 
K31D 
Counselling required Patient thought 
glibenclamide making her 
put on weight. Pharmacist 
noted that she was 
possibly not taking the 
glibenclamide dose which 
was increased by GP 
three months earlier. 
Counselling required Patient was very unclear 
about directions for 
prescribed medications. 
Monitoring required Started on pioglitazone by 
diabetic clinic. 
Drug related ~roblem 
Action Outcome 
Discuss reasons for 
monitOring and for elevated 
results. Further discussion 
at next diabetic appointment 
with GP. 
GP accepted, patient was using blood 
glucose monitoring at home. 
Counsel patient on GP accepted. 
importance of taking tablets. 
Clarify directions on GP accepted. 
repeated medication list. 
Check LFT's GP accepted. LFT's checked. Result 
was normal. 
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Patient Category 
No. 
L060 Monitoring required 
L020 
J22D 
H10D 
K22D 
Monitoring required 
Unnecessary 
therapy 
Untreated indication 
Untreated indication 
Description 
Patient has never had foot 
examination since 
diabetes diagnosed. 
No diabetic monitoring 
since 1997. There were no 
recent HbA 1 c, lipid profile, 
blood pressure, feet and 
eyes examinations. 
Increase in bisoprolol dose 
to relieve angina 
symptoms. Also taking 
captopril for hypertension. 
BP 95/62. 
BP 150nO on 2100 and 
166/80 on 3/00 and 
untreated for 
hypertension. History of 
gout. 
BP 170/60 last clinic visit 
and currently 153n1. No 
history of hypertension. 
Drug related problem 
Action 
Request a patient referral to 
chiropodist. 
Outcome 
GP accepted. No referral with no 
reasons apparent. Care issue remained 
as before. 
Request a patient referral to GP required further review. The 
diabetic clinic. monitoring results were obtained after 
review. 
Recommend decrease 
captopil dose to 
accommodate increase in 
bisoprolol dose and monitor 
BP. 
Consider enalapril 2.5mg 
daily. Recommend 
monitoring U&Es and ECG. 
Consider bendrofluazide 
and monitor for 
effectiveness in one month. 
GP accepted. Captopril dose was 
decreased as suggested. BP was within 
normal range. 
GP accepted. Initiated captopril as 
suggested. BP still high (164/103). 
Further increased enalapril dose and 
monitor BP. 
GP accepted. BP now 146/60. 
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Patient Category 
No. 
Drug related problem 
Description Action 
J24D Untreated indication Primary prevention of 
cerebrovascular disease. 
History of hypertension 
and diabetes. No CII for 
aspirin. 
Start aspirin 75 mg daily 
and counsel patient on 
lifelong therapy. 
M15D 
E12D 
L18D 
K06 
K35 
Repeat file 
inaccurate 
Generic 
substitution/cost 
issue 
Generic 
substitution/cost 
issue 
Inappropriate choice 
of therapy 
Metformin dose changed 
by diabetic clinic. 
Amend metformin dose on 
computer repeat list. 
Taking enalapril10mg two Change to enalapril20mg 
times a day. once daily. 
(Cost £22.03/month) (Cost £13.1 O/month) 
Taking Monocor 10rng. 
Taking glibenclamide at 
maximum dose. Creatinine 
level 169 flrTlolIl. 
Change to generic 
bisoprolol 10mg. 
Switched to gliclazide as 
gllibenclamide is less 
suitable with renal 
impairment. 
Inappropriate choice Total cholesterol coming Change statin to 
of therapy down on simvastatin atorvastatin as it has better 
therapy but triglyceride still efficacy for mixed 
high. hyperlipidaemia. 
Outcome 
GP accepted. Aspirin initiated. 
GP accepted. Metformin dose on 
computer list is now correct. 
GP accepted. 
GP accepted. 
GP accepted. 
GP accepted. Triglyceride still high but 
has started to come down slightly. 
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Patient Category 
No. 
E15D Formulation/delivery 
A37D Inappropriate 
dose/dosing 
schedule 
Description 
Prescribed verapamil SR 
240 mg. SR preparation 
should be prescribed by 
brand name to avoid 
variation in bioavailability. 
Taking simvastatin 10mg 
once in the morning as 
prescribed. 
Drug related problem 
Action 
Change verapamil SR to 
Securon SR. 
Outcome 
GP accepted, problem resolved due to 
action taken. 
Advise patient to take GP accepted. 
simvastatin at night and 
amend computer repeat list. 
o 
:J 
II) 
"S-
CI) 
"' ~ 
::0 
m 
c: 
iff 
-1 
(.oJ 
(.oJ 
Chapter 5: Results 134 
5.4.8 Pharmacist intervention rates and implications for future service 
delivery 
Nine pharmacists participated in the study, three of whom were not involved in the 
pilot study but had completed the training programme. All had experience of 
medication review clinics for at least one year. The mean age was 37 years. The 
majority of the pharmacists were female (7/9), had attained a bachelor's degree in 
pharmacy (9/9), graduated in the years between 1981-1989 (8/9), and currently 
practiced in a community pharmacy (7/9). One had attained a master's degree, two a 
postgraduate diploma in clinical pharmacy and one a diploma in health and social 
welfare. Four of them were working as full-time pharmacists at the time of the study. 
The pharmacists operated the pharmaceutical care clinic one day per week except 
one pharmacist who ran the clinic one day every two weeks. 
Appendix XXII provides a copy of questionnaire sent to the pharmacists six months 
after completion of the clinics, 100% response was obtained. Pharmacists rated their 
confidence in running the diabetes clinic on a scale of 0-10 with a median of 5.0 (3.0 
- 8.0) before the study and 9.0 (7.0 - 10.0) after the study (Wilcoxon Signed-Rank 
test, Z = -2.7, P = 0.008). One year after the study the majority of the pharmacists 
(8/9) have continued working in medication review clinics. 
The maximum number of patients interviewed at anyone site was 61; the minimum 
number was 35. The average number was 45. Active and control group enrolment 
was balanced in all sites. Table 5.32 provides details of number of patients with one 
or more DRPs and number of DRPs per patient across the nine pharmacists. 
Percentage of patients with one or more DRPs ranged from 51 to 94%. The 
distribution of common clinical DRPs across the nine pharmacists were further 
Table 5.32: Comparison of the number of DRPs Identified by each of the pharmacists (includes active and control patients) 
Pharmacist No. of patients No. of patients with one or Mean no. of DRPs per patient 
interviewed more DRPs (%) (range) 
A 51 44 (86) 2.3 (0-7) 
B 51 48 (94) 2.3 (0-4) 
C 36 29 (81) 1.7 (0-6) 
0 61 57 (93) 2.2 (0-5) 
E 43 27 (63) 1.1 (0-4) 
F 36 34 (94) 2.7 (0-7) 
G 38 23 (60) 0.9 (0-4) 
H 52 42 (81) 2.0 (0-7) 
35 18 (51) 0.7 (0-3) 
Total 403 322 (80) 1.8 (0-7) 
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examined in Table 5.33. Although ineffective therapy comprised 32% of the top five 
clinical DRPs, the values for individual pharmacists ranged from 22% to 56%. A 
similar variation can be noted for the remaining DRPs. 
The pharmacists recorded a total of 711 DRPs and recorded recommendations in 
both groups throughout the study. Three hundreds and five problems were identified 
at clinic visit 1, 263 problems at clinic visit 2 and 143 problems at the last clinic visit. 
Ten patients (six active patients and 4 control patient) had no DRP identified by the 
pharmacist. Table 5.34 provides information on GP acceptance of pharmacists' 
recommendation by practice for the 335 DRPs referred in the active group. The 
percentage of recommendations completely agreed ranged from 54% to 100% and 
rejected from 0% to 9%. 
Table 5.33: Comparison of the top five clinical DRP categories identified according to individual pharmacists DRPs 
(includes active and control patients) 
Pharmacist Total no. of DRP categories (Ofo} 
DRPs Ineffective Monitoring Untreated Inappropriate- Noncompliance 
identified therapy required* indication I counselling*-
A 134 30 (22) 25 (19) 22 (16) 20 (15) 12 (9) 
B 121 43 (35) 16 (13) 23 (19) 12 (10) 8 (7) 
C 67 20 (30) 11 (16) 3 (5) 0(0) 2 (3) 
0 149 57 (38) 17 (11) 23 (15) 21 (14) 2 (1) 
E 46 18 (39) 4 (9) 2 (4) 1 (2) 4 (9) 
F 102 24 (23) 23 (22) 13 (13) 4 (4) 10 (10) 
G 43 12 (28) 5 (12) 9 (21) 4 (9) 1 (2) 
H 124 43 (35) 35 (28) 12 (10) 8 (6) 11 (9) 
27 15 (56) o (O) 7 (26) o (0) 2 (7) 
----------
Total 813 262 {32} 136 (17} 114 {14} 70 (9} 52 {6} 
*Routine monitoring! BP monitoring! HbA 1 c monitoring required 
** Inappropriate choice of therapy! dosel dosing schedule 
*** Admitted noncompliancel counselling required 
Other 
25 (19) 
19 (16) 
31 (46) 
29 (20) 
17 (37) 
28 (28) 
12 (28) 
15 (12) 
3 (11) 
179 (22} 
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Table 5.34: Comparison of the number of recommendations regarding DRPs in the active group accepted by GP by each of the 
pharmacists . 
Pharmacist 
A 
8 
C 
o 
E 
F 
G 
H 
Total 
Total no. of DRPs with GP response to pharmacists' recommendation (%) 
GP referral Totally agreed~ Partially agreed Rejected, no action 
48 40 (83) 8 (17) 0(0) 
44 33 (75) 7 (16) 4 (9) 
17 17 (100) o (O) 0(0) 
61 42 (69) 19 (31) o CO) 
34 29 (85) 3 (9) 2 (6) 
55 50 (91) 5 (9) 0(0) 
13 7 (54) 6 (46) o CO} 
47 38 (81) 8 (17) 1 (2) 
16 16 (100) 0 (0) 0 (O) 
335 272 (81) 56 (17) 7 (2) (") 
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The total number of DRPs identified and amended by peer review in both the active 
and the control groups are shown in Table 5.35. Overall 14% (112 out of 795) of 
DRPs were amended by the peer review process with the highest rate noted at the 
first visit (20%) falling to 9% at clinic visit 2 and 3. 
Table 5.35: Number of DRPs Identified by Individual pharmacists and number 
of DRPs amended by subsequent peer reviewer 
Pharmacist Number of DRPs Identified by Number of DRPs amended by 
~harmacist ~eer reviewer {%} 
Clinic 1 Clinic 2 Clinic 3 Clinic 1 Clinic 2 Clinic 3 
A 59 45 21 5 (8.5) 1 (2.2) 3 (14) 
B 55 45 20 17 (31) 3 (6.7) 6 (30) 
C 28 22 17 7 (25) 4 (18) 1 (5.9) 
D 62 52 26 16 (26) 5 (9.6) 3 (11) 
E 12 24 10 1 (8.3) 6 (25) 1 (10) 
F 51 33 19 9 (18) 3 (9.1) 0(0) 
G 19 16 8 6 (32) 3 (19) 0(0) 
H 63 29 32 8 (13) 1 (3.4) 0(0) 
I 11 10 6 3 {27} o {O} o {O} 
Total (%) 360 276 159 72 (20) 26 (9.4) 14 (8.8) 
POOl {100} {100} 
5.4.9 Ethical Issues In the control group 
In the control group, there were 134 DRPs from 94 patients remaining at the end of 
the study. Of a total of 109 DRPs, the proposed resolutions to 94 (86%) were agreed, 
12 (11%) were partially agreed and 3 (2.7%) were rejected. In addition, 25 (19%) 
were from 10 patients for whom it was not possible to access the patient record due 
to either a change in patient status or the patient record not being available at the 
time. Final outcomes of these control referrals were not included in the data analysis 
as they are outwith the scope of the study. 
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The following illustrates 3 patients who were removed from the study In accordance 
with the predefined protocol after attending one clinic visit. 
Case 1 
A 70 year-old female diagnosed with Type 2 diabetes and hypertension. Gartnavel 
clinic recommended stopping diabetic medication on 6/6/00 (Glucobay 50 mg/day). 
The clinic did not recommend stopping doxazosin. However, the patient has stopped 
all medications. This included doxazosin 2 mg daily, which was being used to treat 
hypertension. 
BP history: 29/2/00: 160/100 --- doxazosin added 7/3/00 
15/3/00: 181196 
6/6/00: 164/97 -- doxazosin stopped by patient 
Current BP readings (26/6/00) --- 175/100, 176/93, 168/93 
As the patient's blood pressure is not under control, and the patient is not on any 
antihypertensive medication, and in our control group (no intervention from us until 
end of study), the medical adviser suggested to break the code and inform the 
patient's GP of the misunderstanding which has led to the discontinuation of 
doxazosin, and the resultant increase in blood pressure. The patient was removed 
from the study. 
Case 2 
A 75 year-old female with Type 2 diabetes. Currently taking gliclazide 160mg twice 
per day. HbA 1 c value within last four months was 11.1 %. Current HbA 1 c: 12.5%. 
As the patient's glycaemic value is not under control, and the patient did not attend 
the diabetic clinic for more than a year, and in our control group (no intervention from 
the pharmacist until the end of study), this patient was removed from the study and 
the patient's GP informed. 
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Case 3 
A 77 year-old male with Type 2 diabetes treated with metformin 500mg 1 tablet daily 
and gliclazide 80mg 1 tablet daily. Current HbA 1 c: 10.1 %. SP 1721110. Patient was 
removed from the study because of a stroke on 14/6/00, after attending only one 
clinic. 
5.5 Key results of the main study 
• Target of 1.0 unit change in HbA 1 c was not achieved. There was no change In 
HbA 1 c both between and within the active and control groups throughout the 
study. There was no change in HbA 1 c when patients were grouped according to 
poor or good control. 
• Overall the active group achieved a significant decrease in SSP at clinic visits 2 (9 
mmHg) and 3 (15 mmHg) within group; no such difference was noted in the 
control group. When comparing between groups there was no difference in mean 
change in SSP between the active and the control from clinic 1 to clinic 2 (P = 
0.409), however, this was significant at clinic 3 (P = 0.030). 
• There was no change in diastolic blood pressure between or within group at clinic 
2 and 3. 
• There was no difference in health related quality of life in terms of overall score 
however a trend was noted with the majority of domains producing a more 
favourable outcome in the active group than in the control. 
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• Overall 813 DRPs were identified (711 clinical DRPs and 102 administrative 
DRPs). Of these, 356 DRPs were identified at the first clinic visit, 298 DRPs at the 
second clinic visit and 159 DRPs at the third clinic visit. 
I 
• The top three common categories of clinical DRP were ineffective therapy (37%), 
monitoring required (19%), and untreated indication (16%). 
• Of the 711 clinical DRPs, 171 (24%) were identified specifically related to 
antidiabetic drugs, 100 (14%) to blood pressure, and 85 (12%) to lipids. 
• In the active group, the number of DRPs per patient was decreased from clinic 1 
(2.1 per patient) to clinic 3 (1.2 per patients) compared to the control group at 
clinic 1 (2.3 per patient) and at clinic 3 (2.6 per patient). 
• In the active group there was a significant decrease in the number of DRPs from 
clinic 1 to 2 compared to the control group (60% of active DRPs resolved vs 34% 
of control DRPs resolved). 
• At the first clinic visit, 136 (85%) patients had one or more DRP. In the active 
group there was a significant decrease in the number of patients with one or more 
DRPs from clinic 1 to 2 and clinic 1 to 3 compared to the control group. 
• The GPs completely agreed recommendations for resolving 235 (80%) clinical 
DRPs and 39 (98%) administrative DRPs at all three clinic visits. 
• The majority of the agreed actions were accepted by the patient and implemented 
by the pharmacist (71 %). 
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Chapter 6 
Discussion 
6.1 Aim and Objectives 
A pharmaceutical care model for patients with Type 2 diabetes was developed and 
successfully implemented in primary care. The effectiveness of the pharmaceutical 
care model was assessed in this randomised controlled trial in nine GP practices 
within a primary care setting. The results demonstrated a significant change in 
systolic blood pressure in the active group from clinic visit 1 to 2 and clinic visit 1 to 3 
but no change in HbA 1 c and HRQOL. There were 177 DRPs in the active group at 
baseline which decreased to 67 at clinic visit 2. Equivalent numbers of DRPs for the 
. 
control group were 179 and 114 respectively. The risk reduction In the active group 
was therefore 0.59 with a NNT of 4 (19 weeks). The results also demonstrated a high 
GP acceptance rate, as evidenced by 80% of recommendations from pharmacists 
being completely agreed and only 2% of the resolutions to DRPs being rejected. 
6.2 Methodological consideration 
6.2.1 ReT design 
The ReT is an experimental design used increasingly in patient care settings to 
compare the effectiveness of different interventions (Altman, 1996). The results 
provided by RCTs are of potentially higher validity and contribute more to clinical 
knowledge than traditional methods, such as case control and observational cohort 
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studies. The UKPDS is an example of a study using a RCT design. The study was 
able to establish the safety and efficacy of intensive blood glucose and blood 
pressure control in preventing complications (UKPDS Group, 1998a; UKPDS Group, 
1998d). 
The RCT has the unique advantage of using randomisation as a method of 
determining patient allocation between intervention and control groups, which 
eliminates selection bias (Altman, 1991; Bowling, 1997). The random allocation of the 
patients into two comparable groups allows the groups to be compared to 
demonstrate the effect of an intervention. Any imbalance between groups with 
.. 
respect to other variables can only arise by chance. Bias in the observation of 
outcomes or execution of the intervention can be minimised by the use of blinding 
procedures. Remaining variability can be reduced by increasing the sample size. 
In this study we conducted such a trial to compare the effect of a pharmacist 
intervention between the active and control groups. We hypothesised that the patient 
outcomes (HbA 1 c, blood pressure, HRQOL, DRPs identified and resolved) would be 
Improved in the active group compared to the control group according to the 
intervention. We believe that the RCT design facilitated the analysis of each of the 
outcomes directly attributable to the input from the pharmacists. A before and after 
comparison alone would not have been appropriate due to the dynamic nature of 
practice with new evidence informing rapidly evolving treatment guidelines. 
RCTs do however have their limitations when applied to health services research. 
Randomisation does not preclude the possibility that the population randomised may 
be atypical for the wider population of interest. Healthcare professionals who are 
willing to participate In RCTs may be unrepresentative of the rest of their profession. 
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In some cases, the criteria for inclusion of patients in RCTs may bear little 
resemblance to the real world, which will affect the generalisability of the study. In 
addition, RCTs can be difficult to set up because of professional resistance to them. 
For instance, some healthcare professionals perceive that it would be unethical to 
deny patients a new treatment or a new service, if it was believed to improve the 
outcome or the standard of treatment (Bowling, 1997). 
6.2.2 External validity· Generalisability 
This study was completed in Type 2 diabetes patients receiving oral antidiabetic 
drugs rather than the wider diabetes mellitus population including both Type 1 and 2 
diabetics. However, patients with Type 2 diabetes make up a large and important 
group in terms of numbers and risk of cardiovascular disease (Haffner et aI., 1998; 
Stratton et aI., 2000). The decision to focus only on Type 2 diabetes was based on 
the difference of treatment strategy between types of diabetes, which might affect the 
outcome of the study, if there was a significant difference in the number of patients 
recruited in each arm. Exclusion criteria were set to ensure patient safety at the 
outset of the study. 
The number of patients who refused to participate in the study after randomisation 
was 46%, leaving 54% of patients to enter the study. This number was comparable to 
the 58% participation rate in the study of Mackie et a!. (1999). A 54% recruitment was 
considered reasonable because details about the, study process were sent to patients 
before they gave their consent including the need to take blood samples at the clinic. 
A high percentage of patients (80%) who participated in clinic visit 1 returned for clinic 
visit 2. In addition, the allocated group (active or control) was not known when a 
patient was considered for entry into the study because this knowledge may have 
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influenced the patient participation and would have potentially increased the number 
of refusers within the control group. 
It was found that patients who declined to participate and those who did not complete 
the study were no different in certain baseline characteristics (mean age, gender 
distribution, and mean HbA 1 c value) suggesting that the intervention did reach nearly 
all of those who were eligible for the study. 
The number of patients lost to follow up was high at clinic visit 3 (78, 51%), showing 
the difficulty of undertaking ReT involving several clinic visits over 6 months or more 
in primary care. However, the proportion assessed in each group at all three visits 
was similar, reducing the risk of ascertainment bias (assessment of outcome) . 
. 
Although a random sampling method was used, our study may not be generalisable 
to patients in different primary care settings. A total of 15 out of 219 practices (7%) 
were approached in order to recruit 9 practices. This was considered a small sample 
size. Of these 15 practices, only 9 (60%) were willing to take part in the study. There 
was concern that GPs who did participate might not be typical of all GPs. Those who 
agreed to take part in the study may have been highly motivated and more likely to 
accept the intervention from the pharmaceutical care model. Extrapolating the results 
therefore to the general population might be misleading. 
In addition this study utilised pharmacists who had only recently received training In 
the pharmaceutical care model in Type 2 diabetes. They were therefore on the lower 
limb of a professional learning curve and may not be representative of experienced 
pharmacist specialists. In addition, like the GPs, these pharmacists may be 
particularly well motivated and receptive to the concept of delivering pharmaceutical 
Chapter 6: Discussion 147 
care in a general practice setting. The results obtained with these pharmacists might 
not be generalisable, therefore, to the wider group of community pharmacists. 
6.2.3 Internal validity 
In this study randomisation was used to allocate patients to groups in order to prevent 
bias. Stratified randomisation was conducted to ensure that the patients in each 
group were of similar age, gender and practice distributions, using computer 
generated random numbers. 
To avoid selection bias, group allocation for each patient was not revealed until the 
patient had been entered into the study. In addition the person who generated the 
allocation in this study (SS) was not the person who determined eligibility and entry of 
patients (RL, AM). 
Blinding represents an important methodological component for reducing results bias 
(ascertainment bias), intentionally or unintentionally, and so helping ensure the 
credibility of the study conclusion (Day and Altman, 2000). At the first clinic visit, both 
the patient and pharmacist were unaware of the group allocation (double blind). At 
the second and third clinic visits, double blinding became difficult. It was impossible to 
blind the pharmacist, as the intervention needed to be implemented in the active 
group. The single blinding at clinic visits 2 and 3 provided patient blinding to the 
group allocation only where patients had not received an intervention. In addition, the 
GPs were blinded to the patient allocation at all clinic visits to minimise possible bias 
in patient management. However, GP referrals in the active group would give a clue 
to patient's identity. In order to reduce this, no patient profiles, or GP referrals were 
stored with individual patient case notes during the period of the study. Also 
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randomisation was by patient rather than practice therefore the possibility of a 
washover effect was high between active and control patients registered with the 
same GP. 
6.2.4 Outcome measures 
Clinical outcome measures were changes in HbA 1 c and systolic blood pressure. 
Achieving good glycaemic control is important. The UKPDS proved that good 
glycaemic control in patients with Type 2 diabetes reduced the occurrence of chronic 
complications (UKPDS Group, 1998d). HbA1c is recognised as an important short-
,--
term parameter associated with long term outcomes (DCCT Research Group, 1993; 
UKPDS Group, 1998d). HbA 1 c is a reliable objective assessment method for 
metabolic control. Determinations of fasting or post -prandial blood glucose levels 
,. 
reflect only an instant in the course of the diabetic patient, while the levels of HbA 1 c 
relate to the blood glucose control during the previous two to three months (Gabbay 
et aI., 1977). 
Previous studies (Laakso, 1998; Turner, 1998; UKPDS Group, 1998d) emphasised 
the importance of combining monitoring and treatment of glycaemic control with that 
of other cardiovascular risk factors in diabetic patients: blood pressure and lipid 
profile. Systolic blood pressure was included as a clinical outcome in this study, and 
was measured using an electronic blood pressure machine. In addition, the study 
assessed diastolic blood pressure and reported the findings. There was a large 
number of missing records of lipid profile found in the pilot study and it was 
considered that it would be very difficult to obtain a lipid profile at all three clinic visits. 
In view of this, it was decided not to include lipid values as an outcome of this study 
from the outset. 
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Furthermore, to include the humanistic outcomes, health related quality of life was 
measured. Process outcomes were: the number and types of DRPs, the percentage 
of DRPs accepted by GPs, and the status of DRPs at follow up. These measures 
were included to provide information on the specific interventions made by the 
pharmacist, to gauge the GP response to suggested changes to therapy and, finally, 
to assess the effectiveness of the interventions. 
6.2.5 Procedures undertaken to enhance the reliability of outcome 
measurements 
6.2.5.1 HbA1c 
Since HbA 1 c values obtained from the different assays used in different practices 
vary in terms of the normal range, it was decided that values should be obtained from 
a single laboratory using the DiaSTAT machine (Biorad Laboratory Ltd., Herts, UK). 
Thus it was ensured that the data could be interpreted and compared in a meaningful 
manner. Furthermore, an electronic printout of HbA1c from DIASTAT was available to 
reduce operator bias and ensure the accuracy of recording the data. 
6.2.5.2 Blood pressure 
The auscultatory technique using a mercury sphygmomanometer for blood pressure 
measurement is troublesome, time consuming, and is subject to bias as it could not 
be established whether the pharmacist had measured and recorded the value 
accurately. In view of this an automated electronic device, OMRON 705CP, was 
preferred in this study. An electronic printout of blood pressure measurement, with 
the time and date of measurement, was generated and used to remove many 
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sources of bias associated with the conventional auscultatory technique and 
therefore improve the overall accuracy of the measurements (O'Brien et aI., 2001). 
Accordingly training in taking blood pressure using this device was provided for all the 
pharmacists in the study. The pharmacists were specifically trained on how to use the 
machine and the measuring technique (e.g., allow patient rest for 5 minutes before 
blood pressure measurement, and select appropriate cuff size for individual patient). 
However equipment problems still occurred, for example, the pharmacists reported 
that occasionally the first two readings differed by more than 15 mmHg, in which case 
a third reading was made and the mean of the two closest readings was recorded. 
6.2.5.3 Health related quality of life 
The previous validated instrument, ADDOoL (Bradley, 1999) was used to assess 
.. 
HROOL. Deyo et al. (1983) reported that the reliability of OOL instruments is 
influenced by day to day variations in patient response and mode of administration of 
the questionnaire amongst other factors. In order to reduced bias on the HRQOL, 
patients were asked by reception staff to self-complete the HROOL questionnaire 
prior to the clinic interview session. If patients had completed the HROOL during or 
after the Interview, it is likely that the interviewer or the clinic itself would bias the 
results. 
6.2.5.4 Drug related problem 
Drug related problems were recorded in the structured documentation developed in 
the pilot study. The free text format allowed the pharmacists to use their own words to 
describe the DRPs identified and actions recommended. DRPs were evaluated in a 
blinded fashion and then determined by unanimous decision. At the end of the study, 
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all identified DRPs, actions taken, and GP responses were coded according to the 
classification system described in Chapter 4 by an individual who was not involved in 
running the clinic (ALC). Peer review was undertaken for all DRPs identified in the 
active group before GP referral. The same peer review was also undertaken in the 
control group. The reviewer was initially blinded to group allocation (RL, AM) and 
intended to be blinded to the group at the follow up clinics, however, this blinding 
could not be guaranteed as there may have been some occasions when the 
pharmacist accidentally informed the reviewer. The peer reviewers were members of 
the project team. They were not involved, however, in running the clinics and 
analysing the data. 
It was realised that the decision to withdraw a patient from the study could easily be 
influenced by the pharmacist having knowledge of which group the patient had been 
assigned to. To avoid this patients considered to be at risk of life threatening DRPs 
were referred to the independent medical adviser (ADC) to the study team who was 
blinded to the patient allocation. He independently made the decision to withdraw 
three control patients from the study. 
A diabetes leaflet was posted to patients in both groups after the clinic session in 
order to minimise the influence of knowledge of diabetes on the study outcomes 
between the active and control groups. However, this may have introduced an 
intervention element to the control group and may have Influenced the control 
outcomes. The same GPs and community pharmacists provided standard care for 
both groups therefore they were not likely to be a source of variation. It is possible, 
however, that Involvement in the study may have influenced GP management of 
control patients who presented during the study. 
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6.2.6 Limitations of the study methodology 
Potential limitations of the study are detailed below. 
A high attendance rate of 80% was achieved at clinic visit 2, however, the 20% who 
did not return may have had poorer outcomes. The attendance rate of 51% (82 
patients) at clinic visit 3 restricted the generalisability of any findings. Restricting the 
clinic to once a week on a specific day may have curtailed the number of patients 
who were able to attend. The limited time for follow up of patients was also a problem 
with 27 patients not being invited to clinic 3 because three months had not passed 
since the second clinic visit by the end of the study period. In addition domiciliary 
visits were not available. A longer study period therefore might have led to an 
increased completion rate. 
The 160 patients successfully attending two clinic visits gave a satisfactory 96% 
power of detecting a 1.0 unit difference in HbA 1 c value, based on the mean value of 
HbA 1 c reported in the main study. Overall, 82 patients attended all three clinics 
giving lower study power at 77%. It was decided therefore to include the patients who 
attended two or more clinics in the main analysis of the study. However, as the study 
was planned on the basis of completion of three clinic visits, results of change in 
patient outcomes must be interpreted with caution, especially the process outcome 
which included actions recommended by the pharmacists. It is possible that the 
knowledge of having one further clinic visit to monitor the patient made a difference to 
the pharmacist's decision on the care plans at clinic visit 2. 
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The present study is a multi-practice study with a range of nine practices involved. 
The sample of practices was a random sample due to the detailed methodology 
applied (section 2.6). Overall there were 211 practices, of which 15 were approached 
in order to recruit 9 with sufficient patient numbers. The small number of practices 
and high refusal rate (40%) may have restricted the sample to practices with staff 
highly motivated to be involved in the study. As a result the data obtained cannot be 
extrapolated to the general population of practices in GGHB or further afield. This 
work should be replicated in greater numbers of representative practices. 
There was a delay in GP referral after the interview due to the time for posting the 
blood sample to the laboratory and analysing by the researcher (88). The 
pharmacists generally received the HbA 1 c result in approximately two weeks. This 
could possibly result in a delay in implementing changes in the active group which 
might effect the patient outcome and also result in a subsequent delay for the 
scheduling of the next clinic visit. 
It was possible that the pharmacists felt less confident in suggesting change in 
patient therapy at the first clinic as supported by their self assessment of confidence 
which was lower at the start than at the end of the study. There were also some 
difficulties for the pharmacist in dealing with the clinical procedures such as 
measuring blood pressure and taking blood sample for HbA 1 c test. In addition there 
were occasional technical problems in using the electronic blood pressure machine. 
Another issue that may influence the effect of the intervention is the Hawthorne 
effect, which is an effect of partiCipants being aware that they are in the study 
(Roethlisberger and Dickson, 1939). The knowledge of the study may influence the 
subjects' behaviour or they may change their behaviour because they know that they 
.. 
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are being tested in some way. As pharmacists and GPs were aware that the study 
was being conducted, a Hawthorne effect may be a potential source of bias. It is 
possible that the effect size could be overestimated in this way. This was because the 
GP was alerted to the fact that patients may have been reviewed by the pharmacist. 
In addition an improvement in active group prescribing by the GPs may develop after 
the pharmacists' recommendations were made at earlier clinic visits. Equally the 
effect size could be underestimated since the control group may receive better than 
standard care due to contamination as a result of the meeting with the pharmacist 
and GP intervention due to the Hawthorne effect. It is concluded that the effect 
observed represents the minimum difference between the two groups rather than a 
total effect size. • .. 
The peer review process was intended to assist in the development of a quality 
pharmaceutical care model. In this study DRP identified from both active and control 
groups were reviewed. However, the reviewer only reviewed the GP referral made by 
the pharmacists and not the actual patient profile. Therefore DRPs could have been 
missed by both the pharmacist and the peer reviewer. 
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6.3 Interpretation of findings 
6.3.1 Participants flow and characteristics 
Overall 160 (43%) patients completed the study out of a possible 368 eligible 
patients. Comparison of certain baseline characteristics (age, gender, HbA 1 c) found 
no difference between participants and non-participants. 
At baseline, in addition to age, gender and practice, which were criteria for 
randomisation to active and control groups, the groups also appeared to be closely 
matched in terms of number of concurrent medical conditions, number of drugs 
prescribed, body mass index, smoking status, and other clinical characteristics 
related to glycaemic control, blood pressure, and total cholesterol. However certain 
conditions may be underrecorded in the case notes as evidenced by recording of 
obesity in 31 patients but the pharmacist recording BMI > 27 Kg/m2 in 99 patients. 
This is supported by Whitelaw et al (1996). They highlighted the variation in recording 
morbidity data in general practice in Scotland. However, generally although only 75% 
complete it is highly accurate. In this study information from computer records was 
supplemented with paper based case notes and information obtained at patient 
interview. 
The use of cardiovascular drugs (BNF chapter 2) accounted for 37% of the total 
prescriptions in the subjects of the study. Such a high prescription rate of 
cardiovascular drugs in diabetes has been found in other studies. Wandell et al. 
(1996) studied the overall drug use among diabetes and non-diabetes by analysing 
the computerised Surveys of Living Conditions In Sweden. The authors found a 
higher number of patients using cardiovascular drugs (52% of patients) among 
10.' ; 
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diabetic subjects compared with the general population (36%). Evans et al. (2000) 
reported the increased use and cost of prescription drugs in a population of 974 
patients with Type 1 diabetes and 6,869 patients with Type 2 diabetes in Tayside, 
Scotland. They found cardiovascular drugs were the most commonly used drugs in 
Type 2 diabetes accounting for 30% of volume of the total prescriptions. It was also 
commented that the increased use of drugs for the cardiovascular system is possibly 
because of the increased risk of cardiovascular diseases in diabetic patients. 
Within the active and control group all patients were accounted for throughout the 
study (Figure 5.1). Overall 80% of patients attended two or more clinics with 53% 
attending all three clinics. Drop out rates were comparable between the active and 
control groups. It can be concluded that the two groups were comparable at each 
stage of the study. 
6.3.2 Outcome measures 
6.3.2.1 Glycaemlc control 
The UKPDS (1998e) had mean levels for HbA1c of 7.2% (normal range 4.5 - 6.2%) 
in diabetic subjects at baseline. The median HbA 1 c during the 10 years of follow up 
was 7.4% in the metformin group and 8.0% in the conventional treatment group. In 
this study. the mean HbA 1 c at baseline was 8.3% In the active group, which was 
1.0% higher than the upper limit of the reference range (3.8 - 7.3%) and 0.1% lower 
than in the control group. At the clinic visit 2, the mean HbA 1 c was increased by 0.1 % 
in the active group and 0.2% in the control group. Analysis of the data revealed that 
neither active nor control group had a Significant change in HbA 1 c from clinic visit 1 
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to 2, or clinic visit 1 to 3. Nor were there significant differences in HbA 1 c between 
active and control groups at any of the clinic visits. 
Several barriers to the control of blood glucose in diabetes have been acknowledged 
(Dalewitz et aI., 2000), particularly attitudinal, medical, and communication problems, 
as well as the nature of Type 2 diabetes which is a multisystemic, chronic, and 
complex disease making it more difficult to achieve desired normal or near-normal 
targets. 
A large clinical trial, UKPDS (1998e), found improved glucose and HbA1c levels, but 
the HbA 1 c levels at the end of the study were not close to normal. In the last 5 years 
of follow up, the median HbA 1 c values in the metformin group and the conventional 
control group were 8.3% and 8.8%. A randomised controlled study by Kinmonth et al. 
(1998) assessed the effect of additional training of practice nurses and GPs on the 
lifestyle, psychological and physiological status of patients with newly diagnosed 
Type 2 diabetes. This study resulted in greater treatment satisfaction and patient 
well-being but no change in glycaemic control after one year of follow up. 
A limited number of studies have been performed in diabetes aiming to improve or 
achieve a normal range of HbA 1 c values after pharmacist intervention (Jaber et al. 
1996; Coast-Senior et aI., 1998). The authors claimed significant improvement in 
glycaemic control was achieved in the intervention group as evidenced by 
glycosylated haemoglobin. However the limitations of the studies indicate that the 
results should be interpreted with caution. In the study of Jaber et aI., the numbers of 
subjects was too small (n = 39) and the study period of insufficient duration. A study 
with larger numbers of subjects and of longer duration needs to be carried out for 
further evaluation. In the study of Coast-Senior et aI., the study design did not include 
a control group therefore it is likely that the improvement in HbA 1 c noted was due to 
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the introduction of insulin. The study has the limitations in that the total number of 
patients was not reported, only those completing the study. The study is not 
generalisable due to its very narrow inclusion criteria with only Type 2 patients 
requiring insulin being included. 
Recently Kelly and Rodgers (2000) described a pharmacist-managed diabetes 
service and reported a reduction in HbA 1 c values. The authors claimed a significant 
difference between groups at the end of the study as evidenced by HbA 1 c values at 
baseline and seven months follow up which were 9.0 and 8.5 for the control group 
and 9.0 and 7.5 for the intervention (P = 0.02). However, one limitation of the study 
was that prospective active patients were compared with a historical control, which 
may lead to an experimental bias, as the previously recorded data available for the 
controls are likely to be inferior and subject to missing information. In addition, the 
study covered a small number of patients (16 control, 32 intdrvention) which could 
affect the power of the study. However, the study reported no significant difference of 
HbA 1 c observed between groups (P =0.12) if using an intention to treat analysis. 
Also selection bias, due to the study subjects being referred by the physician to the 
study was noted. 
The present study found no difference in change of HbA 1 c values within and between 
the active and control groups. Perhaps further studies with larger number of patients 
over longer periods of time are required to evaluate whether more intensive 
pharmaceutical care clinics would improve HbA 1 c outcome. 
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6.3.2.2 Blood pressure control 
The benefit of blood pressure control with regard to cardiovascular end-points has 
been confirmed by several large trials. The hypertension optimal treatment (HOT) trial 
(Hansson et aI., 1998) studied 18,790 hypertensive patients randomised to three 
different levels of target blood pressure. This trial contained a large subgroup 
analysis of patients with diabetes (n = 1,501). with approximately 500 patients in each 
of the three target blood pressure groups. After 3.8 years of mean follow up the three 
different mean blood pressures achieved were 150/81, 141/83 and 144/85 mmHg. In 
patients with diabetes, significant reductions in cardiovascular mortality (60%) and 
major cardiovascular events (51 %) were shown in the group that achieved a diastolic 
blood pressure of 81 mmHg. The lowest incidence of major cardiovascular events 
occurred at a mean achieved diastolic blood pressure of 83 mmHg, with the lowest 
risk of cardiovascular mortality at 87 mmHg. 
In the subset of patients with hypertension in the UKPDS, blood pressure control was 
effective In reducing the risk of macrovascular complications. A mean decrease of 10 
mmHg for systolic blood pressure and 5 mmHg for diastolic blood pressure was 
associated with significant reductions in deaths related to diabetes and stroke 
(UKPDS Group 1998a). 
Analysis of the data in this study indicates that a significant systolic blood pressure 
change was found within the active group from clinic visit 1 and 2 (9 mmHg), but not 
between the active and control group at visit 2. The within group in the active group 
between clinic visit 1 and 3 (15 mmHg) was also significant. A significant difference 
was found between the active and control groups at clinic visit 3 (P = 0.030). This 
greater Improvement in the active group and the significant difference between 
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groups at clinic visit 3 could have resulted from a bias if patients who attended all 
three clinic visits were more compliant with their therapeutic regimen than non-
attenders. No significant change in diastolic blood pressure was found within and 
between group. 
The reduction of systolic blood pressure found in this study is in agreement with other 
studies that aimed to demonstrate that pharmacist intervention could significantly 
improve blood pressure control (Morse et aI., 1986; Carter et aI., 1997). Carter et al. 
(1997) conducted a 6- month RCT, single blind parallel group study in 51 
hypertensive patients. In the active group, systolic blood pressure was reduced from 
151 mmHg at baseline to 140 mmHg at 6 months. This is similar to the difference 
between before and after intervention in the study by Morse et al. (1986). After five to 
eight months of follow up, mean blood pressures for patients with severe 
hypertension reduced from 193/124 to 140/92 mmHg, moderate hypertension from 
161/109 to 131/92 mmHg, and mild hypertension 171/100 to 137/88 mmHg. Hawkins 
et al. (1979) compared care by pharmaCists and phYSicians in hypertensive and 
diabetic patients. SystOliC blood pressure was one of the outcome measures in the 
study and they found significantly lower mean systoliC blood pressure in the control 
group. 
Kelly and Rodgers (2000) evaluated the impact of a pharmacist-managed diabetes 
service in 48 diabetic patients. They reported no statistical difference in systolic blood 
pressure and diastolic blood pressure between the intervention and control groups, 
although there was a trend toward a lower systolic blood pressure in the intervention 
group. 
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6.3.2.3 Health related quality of life 
Quality of life is a humanistic patient outcome measure, and its improvement is 
supported as one of the goals of pharmaceutical care as defined by Hepler and 
Strand (1990). However diabetes by its nature is a chronic progressive disease 
therefore it would be unrealistic to expect to improve QOL. International 
Pharmaceutical Federation (FIP, 1998) adapted the goal of pharmaceutical care to 
take account of improvement or maintenance of quality of life therefore perhaps 
maintenance of QOL is a more realistic goal in this patient group. 
While some researchers included both generic and disease specific QOL measures 
in their studies, others e.g., Eiser and Tooke (1993) commented that there was little 
advantage to this. It was pOinted out that there is a considerable overlap between 
generic and disease specific scales in the items measuring QOL. With regard to 
sensitivity of the measurement to change in diabetes management, a diabetes 
specific QOL questionnaire was used in this study to measure humanistic outcomes. 
Using both measures may have resulted in a reduced response rate in view of the 
increase in burden to the patients. 
As expected, the patient's response rate was high at clinic visit 1 (98%) compared to 
clinic visit 2 (72%). Some questions might not be relevant to the patients and this was 
considered by the authors (Bradley et aI., 1999) providing N/A options for some 
items. There appeared to be a higher number of patients choosing not to respond to 
the questions concerning employment/career and sex life. This consideration has 
been noted previously (Bradley et aI., 1999; Hammond and Aokl, 1992). Overall 14 
patients were excluded from the analysis because of incomplete questionnaires, 
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especially the omission of importance rating. In these cases, impairment to COL 
would probably have been overestimated without incorporating this rating. 
The result of the general COL question and overall scores showed no change in 
median scores within group and between groups. The general QOL scores could be 
thought to be a summary measure of QOL. However, it was found that general 
measures are not as strongly related to objective life circumstances, as might be 
anticipated (Wilson and Cleary, 1995). This was considered to be due partially to the 
change in patient's expectations and aspirations as circumstances change. Therefore 
specific questions regarding diabetes may be more sensitive to such changes. 
A number of studies have examined the effects of pharmacist intervention for the 
patients and some of these studies have incorporated measures of HRCOL. Our 
analysis on HRCOL outcome showed a similar result to the 5tudies by Hanlon et al 
(1996) and Jaber et al. (1996). Hanlon et al. evaluated the effect of clinical 
pharmacist interventions on elderly outpatients with polypharmacy. They found no 
differences in SF-36 among the patients that received the intervention after 12 
months of the RCT at the sample size of 169 completed HRCOL. Jaber et al. 
assessed the impact of pharmaceutical care on diabetes treatment using SF-36 in a 
study incorporating a RCT design over a 4-month period. They also found no 
significant differences in any COL domains. This study had a smaller sample size at 
39 patients. 
Carter et al. (1997) evaluated a community pharmacist training programme in 
management of hypertension. The authors reported significant changes in three 
domains namely physical functioning, physical role limitations, and bodily pain using 
the SF-36 after 6 months of the ReT. Quoted P values were not adjusted for multiple 
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comparisons. Since there were eight domains in the study the Bonferroni method was 
used and accepted P < 0.006 as significant. When multiple outcomes were taken into 
account with Sonferroni's adjustment, no difference was detected in the three 
domains. Shibley and Pugh (1997) reported the results of a before and after 
pharmaceutical care intervention for patients with dyslipidaemias who completed the 
SF-36 questionnaire. The authors claimed significant improvement on three domains, 
which were the role-physical, general health, and vitality domains. However, this 
conclusion may have been drawn from inappropriate statistical analysis, as only the 
general health domain was shown to be significantly different when multiple 
comparison was taken into account (P < 0.006). 
The varied effect of pharmacist intervention on patient HROOL may be better 
understood by examining the strengths and weaknesses of the studies. Studies with 
ReT design should minimise the potential for confoundinga.nd bias. There was no 
details of method of questionnaire administration in these studies. Self-completion 
before the session of the intervention could prevent possible bias from the pharmacist 
input. The three studies described above were longer than six months whilst the 
study by Jaber et al. took four months to complete. In this study the comparison 
between clinic visit 1 and 2 was 19 weeks. It is possible that the time period was not 
long enough to detect an improvement In HROOL among the diabetic patients. 
However, a longer study period may cause some problems with the analysis as the 
participation rate and patient's response rate seemed to be lower over time. Erickson 
et al. (1997) described that a longer study period may negate the effect on OOL of 
outcomes of hypertension therapy. Almost all changes relating to SF-36 dimensions 
In the intervention group tended to be negative. On the other hand, a potential 
improvement in HRQOL may be achieved if sufficient follow up is possible, and 
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patients adjust from initial denial to acceptance of their conditions and become more 
comfortable with the management of their diseases (Pickard et aI., 1999). 
This study found that the pharmacist interventions had no significant effect on 
HROOL of Type 2 diabetic patients. Nonetheless it was noted that most ADDOoL 
domain scores (12113) in the control group declined from clinic 1 to 2 whilst most of 
the domain scores (9/13) in the active group improved, suggesting that a significant 
improvement might be attainable, perhaps over a longer period of time or in 
subgroups with a lower baseline HROOL. 
However, the inability to detect statistically significant differences in HROOL in this 
study may partly result from the responsiveness of the questionnaire to the impact of 
pharmacist intervention, as the model did not focus only diabetes, but also other 
therapeutic areas as a whole and reflected all DRPs a pi1armacist can identify. 
Different aspects of an individual's OOL should be observed using an additional 
generic HROOL instrument (Jacobson et aI., 1994). Using both generic and specific 
instruments is recommended for future study. 
6.3.2.4 Drug related problems 
The number and types of DRPs identified by the pharmacists, the percentage of 
recommendations accepted by the GP and the status of the DRPs at follow up are 
the process measures that are potentially linked to beneficial patient outcomes. The 
rationale for their inclusion is straightforward, without DRP identification and GP 
acceptance achieving the outcome measures discussed above would not be 
possible. There have been previous studies involving the pharmacist in the 
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management of diabetes patients, as described before, but unfortunately they did not 
report the details of process outcomes in their studies. 
The pharmacists in this study identified 2.1 and 2.5 DRPs per patients in the active 
group and control groups at the first clinic visit. Currie et al. (1997) and Kassam et aI., 
(2001) reported 2.0 and 3.9 DRPs per patient respectively. Comparison is not 
possible between all three studies, as the definition of DRP is not consistent. 
There were 83 (12% of all DRPs) administrative DRPs identified by the pharmacists 
as 'repeat file inaccurate'. This finding raises important quality issues related to lack 
of regular review of the repeat prescriptions. However, whether or not this led to a 
clinically significant DRP could not be revealed through the study. 
Improvement of the quality of patient care by the pharmacists .::an only be achieved if 
the recommendations are accepted. A high degree (80%) of complete acceptance of 
pharmacists' recommendations regarding drug therapy was found in this study. 
Overall 18% of recommendations were partially agreed and only 2% were rejected. 
This high agreement rate indicated that the pharmacists' recommendations were 
being agreed in the majority of cases, which lends support to the delivery of the 
pharmaceutical care model as a successful and beneficial service. In fact, the 
immediate outcome from the study shows that the majority of the agreed actions 
(71 %) were accepted by patients and implemented by the pharmacist with only 11 % 
left to the GP to action. 
Twenty-three studies of clinical pharmacy service provision were reviewed by Klopfer 
and Einarson (1990). They found an average acceptance rate of 84% with a range 
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from 58% - 98%. The 80 percent acceptance rate in this study compares well with 
that reported in the review literature. 
The importance of acceptance is clearly expressed when one considers its influence 
on the patients. In this study NNTs were used to convey the numerical power of 
clinically relevant end-point. It was found that the intervention by the pharmacists 
produced an NNT of 4 for number of DRPs. That is, for every 4 DRPs identified by 
the pharmacists, one DRP would be resolved after 19 weeks. The pharmacist 
reduced the relative risk by 59%. 
When number of patients with one or more DRPs was examined" the benefits 
conferred by the pharmacist intervention were seen between clinic visit 1 and 2 as 
evidenced by an NNT of 6 for patients with one or more DRPs. That is, for every 6 
patients identified with one or more DRPs, one patient woulj be completely free of 
DRPs at 19 weeks follow up. The pharmacist reduced the relative risk of experiencing 
DRP by 80%. 
The number of patients with one or more DRPs (51% to 94%) and the number of 
DRPs per patient (0.7 to 2.7 DRPs per patient) varied among the pharmacists. 
However, each pharmacist was assigned to a different practice therefore no 
conclusion can be drawn on this variation which could relate to the practice GPs, the 
patient population or the individual pharmacist or likely all three. Further study is 
needed. 
Overall ineffective therapy was Identified as the most common clinical DRP amongst 
the pharmacists (32% of all DRPs), often resulting in suggesting the initiation of 
therapy or an Increase in dose. The second most common DRP was monitoring 
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required (19%). This is significant because many of the complications of diabetes are 
preventable with early recognition and treatment (Diabetes UK, 1999). However, 
opportunities for early treatment may be lost if patients do not receive routine 
screening. 
The Saint Vincent Declaration aims to achieve a reduction in long term, disabling 
complications of diabetes including a reduction in the rate of limb amputation, new 
blindness, end-stage renal failure, and morbidity and mortality from coronary heart 
disease (Anonymous, 1990). Elements of care which evidence confirms are important 
in the management of diabetic patients include the monitoring of blood pressure, 
urine protein, eyes, and feet. It is recommended that all diabetic patients should 
undergo a regular review at least once a year and this review should include, as a 
-
minimum, cardiovascular risks, fundoscopy and foot inspection (BDA, 1997; ADA, 
1998c). 
Khunti et al. (1999) conducted a large scale survey involved 17 primary care audit 
groups from different part of the UK, with a total of 38,288 diabetics from 495 
practices. The study highlighted a number of deficiencies in care indicating that the 
quality of care needs improving. For example, they reported that in the last 12 months 
38% (16 - 47%) had lipids checked, 49% (40 - 67%) had creatinine checked, 63% 
(52 - 74%) had visual acuity checked, 66% (28 - 80%) had urine checked, and 68% 
(40 - 91 %) had feet checked. 
Fletcher and Dolben (1996) surveyed 100 elderly diabetic patients at St James's 
University Hospital to examine the care of these patients in term of general 
supervision, prevalence of risk factors for complications, and uptake of chiropody and 
fundoscopic services. They found 71% had two or more risk factors for the 
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development of foot complications, only 50% had seen a chiropodist within the . 
preceding 12 months, and 48% did not undergo annual fundoscopic examination. 
These figures suggest that more effort should be made to arrange an annual 
fundoscopic examination and to encourage patients with diabetes to be seen by a 
chiropodist regularly. 
In the UK 37% of patients with Type 2 diabetes had retinopathy at the time of diagnosis, 
according to the UKPDS (Aldington et aI., 1994). In Type 2 diabetes (diagnosed after 30 
years of age) of 15 or more years' duration, the risk of any retinopathy is approximately 
78% (Neely et aI., 1998). One British study of patients attending a hospital diabetes 
clinic (Young et aI., 1993) found that diabetic peripheral neuropathy was present in 
more than 50 percent of Type 2 diabetic patients aged over 60 years. Other studies in 
the UK reported that prevalence of neuropathy in Type 2 diabetes varied widely from 
17.2% (Walters et aI., 1992),32.1% (Young et aI., 1993) to 41.6% (Kumar et aI., 1994) 
mainly due to differences in diagnostic criteria and selection criteria used in the studies. 
In the present study, there was a record of 64% of patients having hypertension, 25% 
hyperlipidaemia, 9% peripheral neuropathy, 5% nephropathy, and 1 % had a limb 
amputation, In the individual patient notes at baseline. The frequency of documented 
retinopathy and foot problems in our study was 16% and 24% respectively. These 
figures were lower than expected according to other studies. These differences may 
be explained by the poor recording for data on biochemical evaluation, clinical 
history, eye and foot examinations in patient notes, which also has been reported by 
Yudkin et al. (1980) and Liesenfeld et al. (1996). 
A low dose of aspirin was recommended by the pharmacists in 18 active patients, 
which was accepted fully by the GPs. It was found that the benefit of aspirin therapy 
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was similar in diabetic and non-diabetic patients (Passa 1998). The HOT trial 
(Hansson et aI., 1998) also showed that aspirin reduced cardiovascular event by 15% 
and myocardial infarction by 36% in 18,790 hypertensive patients. Fatal bleeding 
episodes, including intracerebral bleeding, were equal in the aspirin and placebo 
groups, while nonfatal bleeding episodes were more common in the aspirin group. 
6.4 Implications of the results for future service provision 
This study has major implications for future service provision. Firstly a significant 
reduction in systolic blood pressure was achieved in patients receiving 
,.. 
pharmaceutical care. Secondly, the referral rate of 85% is comparable to the referral 
rate found by Mackie et al. (1999) who noted an 83% referral for patients receiving ~ 
4 drugs. Patients in the current study were targeted by disease rather than 
polypharmacy. Of the DRPs identified, 90% were clinical and 10% administrative. 
The NNT was calculated at 4, that is for every 4 DRPs identified, 1 remains resolved 
at 19 weeks (clinic 2) and 32 weeks (clinic 3). The equivalent NNT for patients was 6, 
that is for every 6 patients receiving the intervention, 1 patient is completely free of 
DRPs at 19 weeks (clinic 2) and 32 weeks (clinic 3). This is significant because if six 
patients attend each clinic then one would be free of DRPs. Thirdly, there was a high 
GP acceptance rate with only 2% of recommendations rejected. Fourthly, the 
pharmacists' confidence increased significantly at the end of the study. Although 
these pharmacists had experience of medication review they were not familiar with 
taking blood pressures and capillary blood samples. There are 214 registered 
pharmacies in Glasgow, with greater than 25% having pharmacists who have been 
trained and are experienced in general medication review clinics, with a further cohort 
of 20 currently undergoing training. Therefore the nine pharmacists cannot be 
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classed as atypical and it is likely that future service provision can be met by this 
extended group. 
In terms of patients, whilst 71 % of the DRP actions were implemented by the 
pharmacist, it is notable that none of the pharmacist suggestions were rejected by the 
patient. Patient satisfaction was not assessed in this study, however, the 80% return 
rate for clinic 2 suggests good acceptability to patients. The lower rate at clinic 3 
requires further study. HRQOL was maintained throughout the study. 
This study was not designed to measure the economic impact of the model on health 
care costs. Therefore future studies should compare this model with a more intensive 
model to achieve target HbA 1 c < 8.0% and patient satisfaction and economic 
outcomes should be included in addition to the outcomes measured in this study. 
Implementing pharmaceutical care is not easy for pharmacists whu have not had 
experience in monitoring patients' drug therapy in the past. Extending this 
pharmaceutical care model to Type 1 diabetes or other diseases requires clinical 
skills and training in specific areas. Pharmaceutical care can be provided when the 
relationships are in place between the patient, pharmacist, and physicians and also 
accessibility to information to adequately monitor patients (Hepler and Strand, 1990). 
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6.5 Conclusion 
The hypothesis that 'pharmaceutical care delivered by community pharmacists does 
improve patient outcomes of Type 2 diabetics in a primary care setting' has been 
confirmed in part. Improvement in systolic blood pressure and resolution of DRPs 
without evidence of a diminished HRQOL was achieved. It was not possible, 
however, to demonstrate a significant reduction in HbA 1 c under the study conditions. 
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GREATER GLASGOW COMMUNITY/PRIMARY CARE 
LOCAL RESEARCH ETHICS COMMITIEE 
CluJimUln: Dr Main G B Scott 
Rev LFisher Deputy: 
Administrative Secretary: Mrs EDykes 
EDILC 
261h May 1999 
MrRLowrie 
RGU Primary Care R&D Unit 
1795 Paisley Road West 
Cardonald 
Glasgow 
Dear Mr Lowrie 
Developing a pharmaceutical care model to support the management of type 2 diabetes in 
a primary care setting • 
Thank you for your lctter answering the points made by the Committee. I am now happy to give 
Chairman's approval for this study to proceed in this area with the participation of: 
Suchada Soorapan, School of Pharmacy, Robert GordonUniversity. Aberdcen. 
Yours sincerely 
M G B Scott 
Chairperson 
WEST OF SCOTLAND MEDICAL EDUCATION BOARD 
1 Horst'icthill Road 
Clasgow C 12 !JLX 
Tr!epnone:0141·330 69.S,,) Fax: 0141·330 4737 
.' 
Appendix II: Ethics committee approval for the 
main study 
Chairman; 
Deputy; 
Administrator: 
GREATER GLASGOW COMMUNITY/PRIMARY CARE 
LOCAL RESEARCH ETIDCS COMMITTEE 
Dr. Mairi G.B. Scott 
Rev. L. Fisher 
Mrs L. Falconer 
Our Ref:89199 
(pie ... quote In all corr .. pondenc.) 
17 January 2000 
Richard Lowrie 
Primary Care Research & Development Unit 
Education and Training 
Chronic Disease Management 
1795 Paisley Road West 
Glasgow G52 3SS 
Dear Richard 
Appemdix II 
Study. Randomlsed controlled trial to assess the Impact of Clinical Pharmacist 
Intervention on Pharmaceutical Outcomes and Quality of Life In Type 2 
diabetics .. 
Thank you for your letter of 22 December 1999 in answer to queries raised by the 
Committee. At its meeting on Thursday 13 January 2000 the Committee discussed 
your responses and approval was given to this study at local level. 
Yours sincerely 
{Q?~-~~ 
MG B~ott 
Chairman 
The Royal College of General Prdctitioners 
West of Scotland Faculty . 
4 Lancaster Crescent 
GLASGOW G 12 ORR 
Telephone; 0141 211 3374 Fax: 0141211 3375 
Appendix III: Letter of invitation and consent 
. fonn for the pilot study 
Ap;:endix III 
Surgery name and address 
Date as postmark 
Dear <title> .......... <last name> ............................ . 
The doctors in the practice are currently working in close collaboration with a phamacist 
on a project designed to gather information about the treatment of patients with diabetes. 
It is hoped that this information might be used in the future to improve the quality eX care 
of patients with diabetes. All the information gathered will be coded to ensure 
confidentiality at all times. 
I would like to arrange an appointment for you with the pharmacist (lasting appl'OlDmately 
30 minutes) to discuss your medication and how you think you are responding to it. This 
will also give you an opportunity to ask questions about your treatment and alro. us to 
identify any additional requirements you may have. We will contact you within the next 
two weeks, by telephone, and if you are willing to partiCipate, we will arrange an 
appointment at the surgery at a time convenient to you. 
If you wish to take part, please sign where indicated below and bring this letter 1Dgether 
with all your medicines (both prescribed and purchased) to the surgery at the agreed 
appointment time. If you use reading glasses or use. a booklet to record your t*xxf or 
urine sugar results, please bring them along with you. 
Yours sincerely 
Project Pharmacist 
Patient consent 
I <title> .......... <last name> ............................. of <address> .......................... . 
................................................................ consent I do not consent to take ::>art in 
this study. I understand that strict confidentiality will be kept at all times. 
Signed ................................................. . Date ............................. . 
Appendix IV: Medication review form for the 
pilot study 
Date of summary: Name: 
Address: 
Tel: DOB: Age: 
Appendix IV 
Pharmacist 
medication 
• review 
Patient details 
Audit code: 
-------
Height: Weight: 
.. ------- ---._---_._-----~-- -------_.-._-_ ... _--_._-------.-------
GP: 
Interview: 
Referral to GP: 
Referral from GP: 
Copy to notes: 
Record update to staff: 
Records updated: 
Prescription issued: 
Patient contacted: 
r"\ ... ~ ... _, I ... tt ...... ..... . 
Smoker ~-'.~ Non-smoker C] r -Ex-smoker l_ 
Case progress summary 
Date Initials 
Appendix IV 
No Drug and dosage Indication Formulation Expected 
apparent? appropriate? efficacy evident? 
no no nla 
yej yej no yes I I 
_J L.l C 
2 0 [] ~ 0 C 
3 0 [J C 0 0 
4 0 0 C 0 0 
5 0 0 0 CJ 
6 0 0 l_ 0 0 
7 0 0 r- [] [] L_ 
a 0 [J r:::: [] Ll 
9 [] [] [] [J 
10 0 0 L .. _ [J 0 
Date Care issue/Desired output Proposed action 
----- ------_._---------- ---- ------_._---
Appendix IV 
Pharmacist medication review 
Patient interview 
Current drug treatment, compliance, knowledge and suitability 
Side-effects Drug contra- Compliance Knowledge Generic 
present? indicated? substitution 
yes yes never no no, bio-inequivalent 
no no seldom unsure no, compliance 
I I 
frequent I 
yes . 
I yes substitute I I I already generic. I 
--; r: [] [J ,- 0 0 -l L , 
--' '-- ~-
:::J C 0 0 [J 0 [J -~ 0 ~ c:: 
-, c 0 0 [] [J D 0 CJ [J 
-
;:] C 0 [J 0 D 0 -, 0 :J [J 
U C ::J 0 0 
---
[] [] [J :::J 0 0 [J 
:J [: 0 0 ~.....; 0 [J II :...J [] rJ 0 
=:J C 0 [J [] [J [] -, C}· [J [] ....J ,-.J 
;:] C 0 0 [] [J [] r, D 0 LJ --! • ...J 
[] [J :::J [J 0 r-- [] [J [] ::J [] 0 [] l_. 
0 [J =:J [] f.J [J [] 0 [J .:::J [] 0 0 
PharmaceLltical care plan 
Team Immediate Patient 
response outcome outcome 
----- ------
I 
L_ .. _._. _____ ._ - .. --.-------.--.-... -_ ... _- .--- -----.. -- ---.. _---_. --_ .... _-.- .. --_ ... -.-.---- -_.-._--_ ... - .. ----.-.- -'---'._-'_."-'---_ .. -.... -
Appendix IV 
Pharmacist medication review 
Summary from computer records & case notes 
Date Relevant medical history 
------- ----------------------------------------------------
Current drug therapy Previous drug therapy 
1 1 
2 2 
3 3 
4 4 
5 5 
6 6 
7 7 
8 8 
.---
9 9 
,._--
10 10 
Relevant investigations 
Details of current secondary care monitoring 
Monitoring by practice 
General comments by pharmacist 
... -~-.--"~.- .~"'----. .. --~,-.-.-"-.--.-,----~~.--,.---.,-.----~ .. ---.-----~.-~--.-....----.--.~--.. --~~.-~--.-.-. 
- __ ,~. ~ _fr' .. ~ ___ •• ___ •• _ •••••• 
ApperdixlV 
Record update 
Name: OOB: Audit code: 
Address: 
Data Action lAPdated by 
Initials: Date: 
- .. ------ -------
.. 
Appendix V: Diabetes data collection form for the 
pilot study 
Appendix V 
Diabetes Data Collection Form 
Code number: RD ____ _ Date: ...... .1 •.•..• .1 ....... . 
Height: ____ _ Weight: _____ BMI (Kg/ml) _____ Year/month of diagnosis: ___ _ 
Smoking habit: 0 smoker C non-smoker 0 ex-smoker: when stopped smoking __________ _ 
Relevant medical history: 0 Hypertension 0 HyperJipidaemia 0 Obesity 0 Stroke/transient ischaemic attack 
o Heart disease (e.g. myocardial infarction, congestive cardiac failure) 0 Renal failure 
Current relevant problems: Macrovasular: 0 angina 0 myocardial infarction 0 uncontrolled hypertension 
o uncontrolled dyslipidaemia 0 others ......................................... . 
Microvascular: 0 retinopathy 0 microalbuminuria 0 painful somatic neuropathy 0 oth~rs .................................. . 
Attendance at diabetic clinics 0 Surgery 
o Hospital 
Use of glucose monitoring: 
Blood 0 
o current 0 past (last appoinment ...... J ..... ..I. ....... ) 
o current 0 past (last appoinment ...... .1 .••..• .1 •••.•... ) 
frequency 
Urine 0 ...................................................... . 
What is the patient's reading(s)/ when? ........................................................................................ , ...................... . 
HbAlc ('Yo) (Normal range: .......... - ......... %) 
fasting plasma glucose (mmolll) 
Random plasma glucose (mmolll) 
Total cholesterol (mmol/l) 
Tnglyccndes (mmol/l) 
Iligh density lipoprotem cholesterol (mmol/l) 
Serum creatmme (I-Imol/l) 
Albumin (gil) 
LFT:speclfy"" .... ,,, ....... ,, ..... ,, ........... ,,, ... ,.,, ... ,, .. , ...... .. 
l3Iood pressure (mmHg) 
History orront exam (with dates): 11 normal n foot ulcer 
n other ............................................................................................. ' 
Date oflast exam: ...................... .. 
History of eye exam (with dates); '1 normal flretinopathy n decrease in visual acuity 
:~ other: ........................... : .............................................................. ,,,. 
Date oflas! eye exam: ............... .. 
Comment: previous therapy for diabetes or hypertension with dates • 
....... _ .............................................................. , .................................................................................................... . 
•••••••••••• u ............................................................................................................................................................. . 
Diabetic education provided at interview; 
............................................................ , ............................................................................................................. , . 
......................................................................................................................... " .................................... , 
Appendix V 
Questions to ask patient 
1. How often have you had any of the following symptoms during the past 6 weeks: 
1.1 Hypoglycaemic symptoms: for example, feeling unusually hungry before meal, sweating, having cold 
hands and feet, headache, weakness, palpitations, anxiety. 
D Never D one time 02-4 times D > 5 times 
1.2 Hyperglycaemic symptoms: for example, frequent urination (especially during night), always hungry, 
weight loss despite appetite, abnormal thirst. 
D Never D one time 0 2-4 times 0 > 5 times 
1.3 Feeling of pins and needles, pain, numbness or burning in your feet 
D Never D one time 0 2-4 times D > 5 times 
1.4 Blurred vision 
D Never 0 one time 02-4 times D > 5 times 
1.5 Symptoms ofGI disturbances, specify ............................................................................................................. . 
D Never D one time 0 2-4 times D > 5 times 
1.6 Ask the patient how do you feel in general? if not normal, specify 
2. Have you run out of your diabetic medication during the last 6 months? 
DNo D Yes, drug name: .......................................................... . 
3. Have you taken any new medicine (prescription or nonprescription) during the last 6 weeks? 
DNo D Yes, drug name: .......................................................... .. 
TI 1 H h 1 I 1 I' mr nflll rt or PI armueul t'a urr act v hr5 
Pharm. Care ActIVIties Range of lime spent on each Comments 
activity (mins) 
Check ./ in appropriate box 
< 10 11-20 21- 30 > 30 
I. Pre-interview: revIew of medIcal notes, 
prepare database 
2. Pallent interVIew 
3. Post-Interview: complete the forms, proVide 
education 
Comments/criticisms on method, forms, etc. : 
............................... , .................................................................................................................................................... . 
.......... , ........................................................................................................................ " ............................................. . 
t., •••••••• · •••••••••••••••••••••••••.••••••••••.••.•.•...••.•••••..•.••••.••••••.••••.•••••••••...••.••• , ......................................................................... . 
......................................................................................................................................................................... , ........ . 
Appendix VI: Patient diabetes information leaflet for 
the pilot study 
leaflet for Diabe!iC~  
• Hning bypoglycaemia (some people call it a 'HYPO') means that the 
blood sugar has dropped below its nonnallevel. 
Causes: - Eating too little or too late. 
- Too large a dose of insulin or tablets. 
- Not enough food before exercise. 
The warning signs include sweating, shakiness, tingling around the 
mouth, dizziness, pallor, irritability and feeling of hunger. These vary 
greatly between different people. Try to identify your own particular 
'early warning signs'. 
• How to treat a hypo? 
Take a short-acting carbohydrate, such as glucose tablets, chocolate, 
sweets, glass of fruit juice, or glass of soft drink (not "diet" drinks) 
immediately. This will raise the blood sugar level quickly. Then follow 
with a longer-acting carbohydrate such as sandwiches, fruit, bowl of 
cereal, or biscuits and milk to prevent the hypo again. Take more glucose 
if your symptoms persist. If your symptoms still don't go away, seek 
medical advice. If you are taking acarbose (Glucobay), it is important to 
take only glucose in the form of glucose tablets. Acarhose blocks the 
absorption of starchy food, therefore eating these carbohydrates does 
not correct hypo. 
• Always carry some form of diabetes identification. 
• If you have forgotten to take your tablets and it is only an hour or two 
from the time that you should have taken them. just take them as soon as 
possible. If longer than 2 hours, miss the dose out and take the next one at 
the usual time. Do not take a double dose of tablets to make up for the 
missed dose. 
• When you are ill your blood sugar tends to rise. If you are on tablets, 
continue to take them and try to eat your normal meals and drink plenty 
of sugar-free liquids as well. If you are being sick and cannot eat your 
meals or take your tablets, then contact your doctor or diabetes clinic. 
• Don't take any medications, even with over the counter drugs, witbout 
checking with your doctor or pharmacist that they are suitable for 
diabetics. 
• Rcmcl11hcr that YIIU can always discuss any questions you may 
have about your treatment with your doctor, nurse, or pharmacist. 
The RobeI1 Gordon University ~ 
"leanet~.for. Di abeti (~ 
What is Diabetes? 
Diabetes mellitus is a condition in which the body either does not have 
enough insulin or cannot use insulin as well as it should. This causes a 
high level of glucose in the blood. Insulin, a hormone produced by the 
pancreas, is needed to help glucose get into the cells of the body to give 
you energy. 
Some of the symptoms of untreated diabetes are increased thirst, increased 
output of urine, tiredness, loss of weight, blurred vision and infections. 
In women, vaginal itching is a common early symptom. 
Type 1, or insulin dependent diabetes 
Insulin-dependent diabetes is also known as type 1 diabetes. This type of 
diabetes starts commonly in patients before the age of 40 and has to treated 
by insulin injections and diet. Type 1 diabetics must use insulin to remain 
weII because their body cannot produce insulin at all. 
Type 2, or non-insulin dependent diabetes 
Non-insulin dependent diabetes is also known as type 2 diabetes. This type 
of diabetes usually begins in adults over age 40 and can be controlled by 
diet alone or by diet and tablets or, sometimes, by diet and insulin 
injections. People who are overweight are more likely to develop it. 
The major difference between type 1 and type 2 is that people with type 2 
diabetes may still produce insulin, but it does not work properly or they do 
not produce enou/lh im.ulin, 
The Robert Gordon University ~ 
;5-
I )(' 
~ 
leaflet for Diabe!i~ ~ 
Diabetes Treatment 
Treatment aims to achieve nonnal blood glucose levels which, together 
with healthy eating and exercise, will help to improve wellbeing. This will 
also protect against long-term damage to the eyes, kidneys, nerves, heart 
and major arteries. 
Treatment of type I diabetes: Treatment requires injections of insulin 
for the rest ofthe patients' lives and a healthy diet which contains the right 
balance of foods. 
Treatment of type 2 diabetes: Treatment typil:.ally includes a healthy diet 
and exercise. If this is not enough to control your diabetes, your doctor 
may prescribe tablets along with your diet and exercise to help keep your 
blood glucose levels normal. 
t.WuI~_'T}P2LlaWP! 
• Eat a healthy,low fa~ low sugar, high fibre diet. Avoid 
being overweight. It is more difficult to control diabetes in 
overweight people. 
• Take regular exercise such as brisk walking. 
• It is important to remember that the tablets are not instead of 
the diet. When taking tablets, you will still follow your diet 
and exercise plans. 
• Make sure you have your eyes examined yearly. 
• Gh'e up smoking. 
~ 
The Robert Gordon University ~ 
l~aflet for Diabetic~ 
• Foot Care: 
* Wash your feet with soap and warm water every day. Dry 
your feet thoroughly with a soft towel, particularly 
between the toes. 
• Keep your skin healthy by using moisturising cream after 
bathing. Remember never to apply any cream between 
your toes. 
* Cut your nails straight across. Do not cut into the corners 
and never cut them too short. 
* Make sure that your feet are not exposed to extremes of 
heat or cold. 
* Make sure that your socks and shoes are not too tight. 
* Always seek help with your feet if you notice any signs 
such as swollen areas or changes in the colour of your 
skin, pain, and sores or cuts that do not heal. Do not try 
to treat injuries, corns or other foot problems by yourself. 
* Keep regular appointments with the chiropodist. 
• Alcohol: Do not drink too much alcohol. 
* For men: up to 3 units of alcohol in anyone day. 
• For women: up to 2 units of alcohol per day. 
* One unit of alcohol = Yz pint of beer or lager, or one 
standard glass of wine or one pub measure of spirits. 
* Warning: Low-alcohol beers and wines may have a high 
sugar content. 
* Alcohol on an empty stomach can provoke a hypo. 
* Some tablets should not be taken with a1cohol- this 
should be checked with the doctor or pharmacist. 
The Robert Gordon University ~ 
~ 
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Appendix VII: The Audit of Diabetes Dependent 
Quality of Life (ADDQol) 
Appendix VII 
iADDQoLI Code Number: ___ _ 
Date: __ , __ , __ 
This questionnaire asks about your quality of life and the effects of 
your diabetes on your quality of life. Your quality of life Is how good 
or bad you feel your life to be. 
There are no right or wrong answers; we just want to know how you 
feel about your life now. All of your answers will be treated In the 
strictest of confidence. We would be very grateful if you would take 
the time to answer these questions. 
If you have any questions about how to complete the questionnaire, 
please ask your pharmacist. 
ADDQoL © Prof. Clare Bradley: 24.2.94 (latest revision 11.2.98) 
Reformatted in larger print by Prof. Clare A. Mackie and Colleagues: 16.2.00 
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Please put an X in the box which best indicates your 
response on each scale. 
A) In general, my present quality of life is: 
as good very good good 
as 
it could 
possibly 
be 
neither 
good nor 
bad 
bad very bad 
For the next statement please consider the effects of your 
diabetes, its management and any complications you may have. 
8) If I did not have diabetes, my quality of life would be : 
very much much a little 'the same a little much ,::ttl} very J1 
better better better worse worse wo 
Please read the additional instructions on the next 
page carefully. 
ADDQoL © Prof, Clare Bradley: 24,2.94 (latest revision 11 .2.98) 
Reformatted in larger print by Prof. Clare A. Mackie and Colleagues: 16.2.00 
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Please respond to the 13 more specific statements on the 
pages that follow. 
For each statement, please consider the effects of your 
diabetes, its management and any complications you may 
have on the aspect of life described by the statement. 
In each of the following boxes: 
Some statements have a 'not applicable' option. 
Please put an 'X' in the N/A box if that aspect of life does 
not apply to you. 
ADDQoL © Prof. Clare Bradley: 24.2.94 (latest revision 11 .2.98) 
Reformatted in larger print by Prof. Clare A. Mackie and Colleagues: 16.2.00 
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.'\ ppendix VII 
1. If I did not have diabetes, my working life and work-re I ated 
oppo rt T Id b una les wou e: 
very much a little the same a little much very 
much better better worse worse. mucJm 
better worse N/A 
This aspect of my life is ... (please circle the answer that applies for yOU) 
very important important somewhat not. f;lt all important important 
2 If I d'd t h . I no ave d' b t . I I"f la e es, my socia I ewou Id b e: 
vert , ~uqh a little the same a little mucl) very.' 
mUGh ,~ better better worse . worse much 
beRer . 
" 
. worse 
This aspect of my life Is ... (please circle the answer that applies for yOU) 
very important impo~ant somewhat nbt at all 
.. .... 
. important . important 
3. If I d'd I not h ave d' b t f '1 I"f la e es, my amlly Ie wou Id b e: 
very much a little the same a little much very 
much better better worse worse mucrn 
better worse N/A 
This aspect of my life is ... (please circle the answer that applies for you : 
very important important somewhat not at all important i ,. important 
ADDQoL © Prof. Clare Bradley: 24.2.94 (latest revision 11 .2.98) 
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4 If I d'd t h . I no ave d' b t f' d h' la e es, my nen SipS WOU Id b e: 
very much a little the same a little much very 
much better better worse worse mudT 
better worse: 
This aspect of my life is ... (please circle the answer that applies for yow 
very important important somewhat not at~alE 
'important important 
5 If I d'd t h . I no ave d' b t I"f la e es, my sex I e wou Id b e: 
very much a little the same a little much very 
much better better worse' worse mudT 
bettec . (. worse 
N/A 
This aspect of my life is ... (please circle the answer that applies for YOUII 
very imp'~:>rtant important somewhat not at all f· f, important I ~·; important 
6. If I did not have diabetes, my holidays or leisure activities 
would be: 
very much a little the same a little much very 
much better better worse worse much' 
better i ~ worse-
This aspect of my life is ... (please circle the answer that applies for YOU I 
very important important somewhat not at all important important 
ADDQoL © Prof. Clare Bradley: 24,2,94 (latest revision 11 ,2,98) 
Reformatted in larger print by Prof, Clare A, Mackie and Colleagues: 16,2,00 
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7. If I did not have diabetes, problems with travelling (either 
local or long distance) would be: 
very much a little the same a little much very 
much better better worse worse much 
better worse 
This aspect of my life is ... (please circle the answer that applies for you) 
very important impor:tant somewhat n t at. all 
, important .'~ :10:! important 
8. If I did not have diabetes, my worries about my future (e.g. 
health, independence, income) would be: 
. verf much a little the same a little much very 
~ , . 
I: better better Worse muchl much , worse 
beiter I '~ worse 
This aspect of my life is ... (please circle the answer that applies for you) 
very important important somewhat not at all 
• l~ l important I :~ important 
9. If I did not have diabetes, my worries about the future of 
my family and close friends (e.g. their health, 
independence, income' would be: 
very much a little the same a little much very 
much better better worse worse much-
.' better worse 
This aspect of my life is ... (please circle the answer that applies for yOU) 
very important important somewhat not at all important important 
N/A 
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10. If I did not have diabetes, my motivation to achieve th "'9s 
would be: 
very much a little the same a little much v~' 
much better better worse worse mudrl 
, , 
better " worse 
This aspect of my life is ... (please circle the answer that applies for yOUJ 
very important important somewhat 'not at ~II im~ortant " I?i .important 
11. If I did not have diabetes, the things I could do physically 
would be: 
I '~ I.r;.. '~ " , 
1/ " 'fiery:" . . much' a little the same a little much very 
mucH ~ better better l i~,~._ worse worse mudn better ' , , . WOI'Siile 
This aspect of my life is ... (please circle the answer that applies for YOUi 
very important important . somewhat :nQt at all important r I·~ ifl1Qort~ 
12. If I did not have diabetes, the extent to which people W'ould 
f b t m t h Id b uss or worry a ou e 00 muc wou e: 
much a little the same a little much ;' . : very very 
much better better worse worse muCT 
better _ worse 
This aspect of my life is ... (please circle the answer that applies for you. ' 
very important important somewhat not at all important im~ortant 
ADDQoL © Prof, Clare Bradley: 24.2.94 (latest revision 11.2.98) 
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13. If I did not have diabetes, my enjoyment of food woulc 
be: 
very much a little the same a little much very 
much better better worse worse much 
better I ·· worse 
This aspect of my life is ... (please circle the answer that applies for you) 
very important important somewhat . not at all important ': 11 . important. 
c.ppendix VII 
If there are any other ways in which diabetes and its managenent 
and complications affect your quality of life, please say what they 
are below. 
Thank you for taking the time to answer these ques~tions. 
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Appendix VIn: Diabetes - 39 
Appendix VIII 
Code Number: RD _____ Date:_'_'_ 
Diabetes-39 Quality of Life Questionnaire 
A person's quality of life is affected by many things. These things migbt include bealtb, tbe 
opportunity for relaxation and holidays, friends and family, and occupation. This question-
naire is designed to belp us learn about what affects tbe quality of life of people with diabetes. 
All of your answers will be treated in tbe strictest of confidence. We would be very grateful 
if you would take tbe time to answer tbese questions. 
How to complete the questionnaire. 
• For each ofthe following questions we want to know how much your quality oflife has been atTec~. Please 
answer the questions by putting a cross (X) somewhere on the line following each question. The line starts at 
number I and a cross here means that your quality of life has not been affected at all. The line ends at 7 and a 
cross here means that your quality of life has been extremely affected. Place your cross (X) on the line at the 
point which you think best describes how your quality of life has been affected in the past month. If you do 
not do one of the activities. for example home glucose monitoring, then your answer should be that you are not 
. affected at all. 
• It is very important that you answer every question. However, you may prefer not to answer some questions 
which ask about your personal life. If you choose not to answer thcse, please leave them blank and go on to the 
next question. 
• Example 
If you thought "air pollution" affected your quality oflife to some extent, but not extremely, you might mark 
the line as shown. 
DURING THE I'AST MONTH, HOW MUCH WAS THE QUALITY OF YOlJR 
LIFE AFFECTED BY: 
1. air pollution 
Not affected 
at all 
2 4 5 6 7 Extremely 
affected 
• I f you were to answer the same question, where would you put your cross? I f you think you ha\ ;: he~'11 1l111h: 
affected by air pollution in the past month than the person in the aho\1,! CXJlllph:. you should plJ.:'c :- ollr 
cross somewhere to the right of the existing cross, Howe\w. I f you think you ha\ e heen less af(;:,(cd, Ihl.'l1 
your cross should be pl:!el.'d 50Ille\\ hcre to the lell of the c\istll1g cross. TL) pra,tis\.'. pkasl.' I'll;: .. 'lIr ,'ross 
all the line, 
Please complete the t'olltm ing questions. if ~ou han' an,' questions ahout h(m to lOmpll'll' 
the questionnaire. ph.'asl' ask ~'our pharmacht. 
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During the past month, how much was the quality of your life affected by: 
1. your daily medication for your diabetes 
Not affected 1 2 3 4 5 6 7 Extremely 
at all '--_--1. __ ~ __ ...L-_ ___I __ __'_ _ ....Io.__~, affected 
2. worries about money matters 
Not affected 1 2 3 4 5 6 7 Extremely 
at all '--_---"' __ ~ __ ...L-_ ___I __ _'_ __ _J._ _ ____'J affected 
3. limited energy levels 
Not affected 1 2 3 4 5 6 7 Extremely 
at all '--_--1. __ ~ __ ...L-_ ___I'__ _ __L. __ _J._ _ ____'1 affected 
4. following your doctor's prescribed treatment plan for diabetes 
Not affected 1 2 3 4 5 6 7 Extremely 
at all '--_-1. __ ~ __ ...L-_ ___I'__ _ _'_ __ _J._ _ ____', affected 
5. food restrictions required to control your diabetes 
Not affected 2 3 4 5 6 7 Extremely 
a t all '--_---"' __ --L.. __ -L-_'__'--_--L.. __ --J-._--l' affected 
6. concerns about your future 
Not affected 2 3 4 5 6 7 Extremely 
at all '--_-1. __ ~ __ ..l...__---J'--_--L.. __ ....J------I1 a frected 
7. other health problems besides diabetes 
3 5 6 7 E\tnmd~ 'ot affl'tted 
at all ------'---~ __ ..l...__---J"--_--1-__ ....J-_--'1 a ffl'l'tcd 
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During the past month, how much was the quality of your life affected by: 
8. stress or pressure in your life 
1 2 3 4 5 6 7 Extremely Not affected 
at all L-__ ~~ __ ~ ____ ~ ____ -L ____ ~ ____ ~ __ --JI aff~ed 
9. feelings of weakness 
1 2 3 4 5 6 7 Extremely Not affected 
at all L-__ ~ ____ ~ ____ ~ ____ -L ____ ~ ____ ~ __ --JI aff~ed 
10. restrictions on how far you can walk 
1 2 3 4 5 6 7 Extremely Not affected 
at all L-__ ~~ __ ---L __ --L. ____ --'-____ -L-____ -'--__ --II affeeted 
11. any daily exercise for your diabetes 
1 2 3 4 5 6 7 EJ.tremely Not affected 
at all L-__ ~~ __ ~--__ ~------'-____ -L ___ -L-_..-JI affected 
12. loss or blurring of your vision 
1 2 3 4 5 6 7 Extremely Not affected 
at all L..-__ ~~ __ .--L ____ --'-____ --'-____ -L ___ -'--__ --II affected 
13. not being able to do what you want 
2 3 4 5 6 7 Extremely 1'0t affected 
at all L..-_----l""-__ .--L __ --'-__ --'-___ -I-__ -'--__ ----J1 a ff Ci't ed 
1.t. ha\'ing diabetes 
"of affected 2 -' .t 5 6 7 E\tn:nH,'" 
at all L..-_----l""-_--I. __ -L __ -L __ -L __ ..L-------li aft't','tl'd ' 
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During the past month, how much was the quality of your life affected by: 
15. losing control of your blood sugar levels 
Not affected 1 2 3 4 5 6 7 Extremely . 
at all I affected 
16. other illnesses besides diabetes 
Not affected 1 2 3 4 5 6 7 Extremely 
at all I affected 
17. testing your blood sugar levels 
Not affected 1 2 3 4 5 6 7 .. , Extremely 
at all I affected 
18. the time required to control your diabetes (for example time required 
for taking tablets, following a special diet, monitoring sugar levels) 
Not affected 1 2 3 4 5 6 7 Extremely 
at all L--_--'-__ -L.-_----J'--_~ __ ...L_ _ ___''__ ___ ' affected 
19. the restrictions your diabetes places on your family and friends 
Not affected 1 2 3 4 5 6 7 Extremely 
at all L--._--'-__ ....l..-_---IL--_--L __ -'--_-.J __ ...-J' affected 
20. being embarrassed because you have diabetes 
Not affected 1 2 3 4 5 6 7 Extremely 
at all afft~cted 
21. diabetes interfering \lith ~'our sex life 
:\ot affected 2 3 -I 5 6 7 E\tremrl~ 
atalt affected 
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During the past month, how much was the quality of your life affected by: 
22. feeling depressed or low 
1 2 3 4 5 6 7 Extremely Not affected 
at all L--_--1. __ --L-__ -'--__ .l..-_.........I'--_-1.. __ ...J1 affected 
23. problems with sexual functioning 
1 2 3 4 5 6 7 Extremely Not affected 
at all L..-_--1. __ --L-__ -'--__ .l..-_---l __ --'-__ ..J1 affected 
24. getting your diabetes well controlled 
1 2 3 4 5 6 7 Extremely Not affected 
all L..-_--1. __ --L-__ -'-__ .L.-_---l __ --'-__ ...J1 affected 
25. complications from your diabetes 
1 2 3 4 5 6 7 Extremely Not affected 
at all l..-_--L. __ --L-__ -'-__ .L.-_--' __ -l.._---ll affected 
26. doing things that your family and friends don't do 
1 2 3 4 5 6 7 Extremely Not affected 
at all '--_--1. __ --L-__ -'--__ .l..-_.........I __ -.1.._----J1 affected 
27. keeping a record of your blood sugar levels 
Not affected 2 3 4 5 6 7 Extremely 
at all I affected 
28. the need to eat at regular intervals 
~ot affl'cted ., 3 4 5 6 7 E\trt.'meh .. 
at all I affl'l'ted 
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During the past month, how much was the quality of your life affected by: 
29. not being able to do housework or other jobs around the lIouse 
Not affected 1 2 3 4 5 6 7 Extremely 
at all affected 
30. a decreased interest in sex. 
Not affected 1 2 3 4 5 6 7 Extremely 
at all Ii affected 
31. having to organize your daily life around diabetes 
Not affected t 2 3 4 5 6 7 Extremely 
at all I affected 
32. needing to rest often 
Not affected 1 2 3 4 5 6 7 Extremely 
at all affected 
33. problems in climbing stairs or walking up steps 
Not affected 
ataH 
Extremely 
L....-_-..J. __ -L-__ -'--_---I __ --1-__ -1-. __ affected 
2 3 4 5 6 7 
34. having trouble caring for yourself (dressing, bathing, or using the 
toilet) 
~ot affected 
at all 
35. restless sleep 
:\ot affl'cted 
at all 
2 3 
, 
-
3 
~. 5 6 
6 
7 
7 
E\tremcl~' 
.affected 
£\trcnH'I~ 
J fft.'('ti.'d 
During the past month, how much was the quality of your life affected by 
36. walking more slowly than others 
Not affected I 2 3 4 5 6 7 Extremel~ 
at all I affected 
37. being identified as a diabetic 
Not affected I 2 3 4 5 6 7 Extremel}" 
at all I affected 
38. baving diabetes interfere with your family life 
Not affected I 2 3 4 5 6 7 Extremely 
at all I affected 
39. diabetes in gene~al 
Not affected I 2 3 4 5 6 7 Extremely 
at all I affected 
OVERALL RATINGS 
1. Please place an "X" on the line below to indicate your rating of overall quality of life. 
1 2 3 4 5 6 7 Highest Lowest 
quality "--_--L __ ~ __ _'__ _ .1._ _ ___Ji..._.__~ __ _'1 quality 
2. I'lease place an ··X" on the line below to show how severe you think your diabetes is 
2 3 4 5 6 7 E\tremcl~ \ot senre 
at all "--_--L __ ~ __ _L_ _ ...I...._ _ _l __ __L.. ___ SE.'\'cre 
Thank you for taking the time to answer these questions. 
Appendix IX: GP referral form for the pilot study 
~ GP referral 
)( 
I 
~ 
Name: DOB: Date of interview: Alldit r.ollo: 
Address: GP: 
Rationalisation/simplification plan 
Care issue/Desired output Proposed action Team response 
-------------~- .- ---- -- -- - - -- _._--
- ---~-- - ~-- ---... -" - ---- ---". ---.-- - --- - ----
.. -_.-_. ----.-------.--------
Agreed action 
Detail only if different from above 
------------------------------- . 
GP Pharmacist 
Date: Signature:---- ---------- ----- ---Da~-- Signature: 
Appendix X: Pharmacist feedback survey fonn 
Appendix X 
A Survey of Diabetes Pharm. Care Pilot Study 
Dear Pharmacist 
The following questionnaire has been devised to allow feedback from the pharmacists in order for the 
research team to identify of any problems in the pilot study. 
It would be appreciated if you would take the time to complete the form, and return it to us in the mclosed 
pre-paid envelope, if possible within 1 week. 
Pharmacist's name ...................................................................................... .. 
1. Please use the space below to make any comments about the data collection form (for e"Kllmple 
ease of use). 
2. Are there any other relevant data should be added or deleted from the data collection form? Please 
give details. 
3. Are the documents and training programmes, you received adequate I Inadequate (circle)? 
If inadequate, please suggest ways in which this could be improved. 
4. lIow many patients per day you have seen in the clinic? ................ patient(s) per day. 
Do you feel this figure is too little or too many to handle? 
" .. 
Appendix XI: Patient diabetes information leaflet for 
the main study 
School of Pharmacy 
The Robert Gordon University 
leaflet for Diabetic~ 
• Some tablets should not be taken with alcohol- this 
should be checked with the doctor or pharmacist. 
• Always carry some form of diabetes identification. 
• When you are ill your blood sugar tends to rise. If you are 
on tablets, continue to take them and try to eat your normal 
meals and drink plenty of sugar-free liquids as well. If you 
are being sick and cannot eat your meals or take your tablets, 
then contact your doctor or diabetes clinic. 
• Don't take any medications, even over the counter 
• medicines, without checking with your doctor or 
pharmacist that they are suitable for diabetics. 
• Remember that you can always discuss any 
questions you may have about your treatment with your 
doctor, nurse, or pharmacist. 
SchoolofPharma~ 
The Robert Gordon University 
PATIENT INFOR!\IATION LEAFLET 
,leaflet-for -Diabeti(~ 
TYPE 2, OR NON-INSULIN DEPENDENT 
DIABETES 
Non-insulin dependent diabetes is also known as type 2 diabetes. 
This type of diabetes usually begins in adults aged over 40 and 
can be controlled by diet alone or by diet and tablets or, 
sometimes, by diet and insulin injections. People who are 
overweight are more likely to develop it. 
The major difference between type 1 and type 2 diabetes is that 
people with type 2 diabetes may still produce insulin, but it does 
not work p~operly or they do not produce enough insulin. 
~ 
"0 
CD 
::l Q. 
x' 
~ 
. Schuul uf Pharmu(y iJ, \ ,~) The Robert Gordon University 
TREATMENT 0 F TYPE 2 DIABETES 
Treatment aims to achieve normal blood glucose levels which. 
together with healthy eating and exercise, will help to improve 
well-being. This will also protect against long-tenn damage to 
the eyes, kidneys, nerves, heart and major arteries. 
Treatment typically includes a healthy diet and exercise. If this is 
not enough to control your diabetes, your doctor may prescribe 
tablets along with your diet and exercise to help keep your blood 
glucose levels normal. 
UJefut Ad\b~T~2Jlabetics 
• Eat a healthy, low fat, low sugar, high fibre diet. 
Avoid being overweight. It is more difficult to 
control diabetes in overweight people. 
• Take regular exercise such as brisk walking. 
• 
• 
• 
It is important to remember that the tablets are not instead of 
the diet. When taking tablets, you will still follow your diet 
and exercise plans. 
l\take sure you have your eyes examined every year. 
Give up smoking. ~ 
P':' 
School of Pharmacy 
The Robert Gordon University 
• FOOT CARE: 
• 
• Wash your feet with soap and wann water every 
day. Dry your feet thoroughly with a soft towel, 
particularly between the toes. 
• Keep your skin healthy by using moisturising 
cream after bathing. Remember never to apply 
any cream between your toes. 
• Cut your nails straight across. Do not cut into 
the comers and never cut them too short. 
• Make sure that your feet are not exposed to 
extremes of heat or cold. 
• Make sure that your socks and shoes are not too 
tight. 
• Always seek help with your feet if you notice 
any signs such as swollen areas or changes in 
the colour of your skin, pain, and sores or cuts 
that do not heal. Do not try to treat injuries, 
corns or other foot problems by yourself. 
• Keep regular appointments with the chiropodist. 
ALCOHOL: Do not drink too much alcohol. 
• For men: up to 3 units of alcohol in anyone day. 
• For women: up to 2 units of alcohol per day. 
• One unit of alcohol = Y2 pint of beer or lager, or 
one standard glass of wine or one pub measure 
of spirits. ~ 
15 j 
Co 
x' 
~ 
· Appendix XII: GP referral form for the main study 
x 
)( 
'6 
c 
~ 
~ 
The following issues have been identified After re,·ie"·:"'lg case notes and 1. discussion with the pat;"nt at surgery 0 
by phone 0 
1. in the patient's absence 0 
If YOli agree with the proposed action(s), please sign as indicated and the pharmacist will update the computer record and contact the patient. 
Name: DoB: Date of Review: Audit Code: 
Address: GP: 
Care issue Proposed action GP response 
Pharmacist Signature: Date: GP Signature: Date: 
DOl1id irtltk~1.u1.: 
Appendix XIII: Patient information about the main 
. study 
Appendix XIII 
PATIENT INFORMATION SHEET 
The following answers some questions we think you might have 
about the study. If you have any more questions, please feel free 
to ask the Pharmacist at your doctor's surgery. 
What is the study about? 
It is designed to look at the effect on diabetes control and quality of 
life after a pharmacist reviews your medication with your doctor. 
Have pharmacists run clinics to review medicines before? 
Yes. About 10,000 patients have had their medicines reviewed by 
pharmacists in Glasgow surgeries over the past 4 years. 
Why should I take part? 
The information gathered from the study could help to improve the 
future care of patients with diabetes. You mayor may not benefit 
personally from participation in the study. You will, however have the 
opportunity to find out more about your medicines. 
Will this study replace the usual care provided by my doctor? 
No. Your usual care will be maintained throughout the study. Any 
benefits you may experience as a result of participation are in 
addition to your usual care. 
.' 
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Where will the study take place? 
In your doctor's surgery. 
When will the study take place? 
It will start in March 2000 and continue for about 8 months. You will 
be invited to attend your surgery to discuss your medicines with the 
pharmacist on 3 separate occasions. If you do not wish to attend after 
the first appointment, you are free to withdraw from the study at any 
time. Your appointments will be made after discussion with you, at a~' 
time suitable to you. 
What will happen if I agree to partiCipate? 
Your name will be placed in one of two groups. Patients in both 
groups will be asked to see the pharmacist in the surgery. If you are 
in group 1, you may have changes to your care suggested by the 
pharmacist and these may be agreed by your doctor. If you are in 
group 2, you will not have any changes made by the pharmacist 
during the study. 
Why are two groups needed? 
Two groups are needed so that a comparison can be made between 
them at the end of the study. This will allow us to see if there are any 
differences in your diabetes control or quality of life as a result of the 
appointments with the pharmacist. 
. 
:.-
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How will I be allocated to a particular group? 
This will be done by placing you at random into the first or second 
group. This means that there is an equal chance of you being part of 
the first group or the second group. 
Will I be told which group I am in? 
No. However, if you are informed of any changes to your medication 
as a result of any of the appointments, this will indicate that you have 
been placed in the first group. 
What will happen at each appointment? -
You will be asked to bring along your current medications and the 
pharmacist wi" discuss them with you. This will allow us to identify 
any additional requirements you might have. You wi" be asked to 
complete a questionnaire, you may be asked to provide a 'pin prick' 
(a few drops) of blood from your finger for blood sugar measurement 
and you blood pressure will also be checked at the appointment. 
How long will each appointment take? 
Each appointment will take about twenty minutes. 
What will happen if I decide not to take part? 
You wi" continue to receive your usual care from your doctor. 
Appendix XIII 
Who is paying for the study? 
The pharmacists are paid a normal salary by the NHS for discussing 
how best to use medication, and if appropriate, suggesting ways that 
your care might be improved. The study is part of their job, and they 
do not receive any extra payment for it. Your doctor will not be paid 
extra for their involvement, and therF3 is no commercial sponsorship of 
any description in the study. 
How will the study affect my private health insurance? 
If you have private medical insurance, please check that entry into ., 
the study will not invalidate your cover. 
What will happen at the end of the study? 
You will continue to receive usual care from your own doctor. If you 
were in group 1 and your treatment has changed during the study, 
this will remain changed as long as you and your doctor regard the 
changes as helpful. If you were in group 2, and changes to your 
medication were agreed by you and your doctor during the study, 
these may be made at the end of the study. 
... . 
Appendix XIV: Letter of invitation and patient consent 
form for the main study 
Appendix XIV 
Surgery name and address 
Date as postmark 
Dear <title> .......... <last name> ............................ . 
The doctors in the practice are currently working with a pharmacist on a study designed 
to gather information about your medicines and in particular, your treatment for diabetes. 
We would like to invite you to participate in this study. 
Please find enclosed an information sheet which explains more about the study. Please 
take time to read it, and feel free to phone your surgery to speak to the pharmacist if you 
require more information. All information gathered will be coded to ensure confidentiality 
at all times. 
·We will contact you by telephone within the next two weeks. If you are willing to 
participate, we will arrange an appOintment for you to attend the surgery at a time 
convenient for you. 
If you decide to take part, please sign below and bring the tear off slip with you to the 
surgery at the agreed appointment time. We also ask that you bring all your medicines 
(both prescribed and purchased), together with reading glasses and/or a list of your 
recent results from blood or urine sugar tests, if this applies to you. 
If you decide not to take part, this will not affect the care your normally receive from your 
doctor. 
Yours sincerely 
Project Pharmacist Dr .................................... .. 
,--------_.--------------------------------------------------------------------------------------------------------
Patient consent 
I <title> .......... <last name> ............................. of <address> .......................... . 
................................................................ consent I do not consent to take part in 
this study. I understand that strict confidentiality will be kept at all times. 
Signed .................................. , .............. . Date ................................ . 
.. ' 
Appendix XV: Medication review form for the 
main study 
Patient details 
Date of summary: Name: 
Address: 
Basic health data 
Height: Weight: BMI: 
Date Relevant medical history 
ADR's/sensitivities: 
Appendix XV 
Primary care medication review 
DOB: GP: 
Tel: Audit code: 
Smoker 0 Non-smoker 0 Ex-smoker 0 
Date Relevant medical history 
Current drug therapy date started Previous drug therapy date/reason stopped 
-------------- ------ --------------- ------------
2 
3 
4 
5 
6 
7 
8 
9 
10 
Relevant investigations 
2 
3 
4 
5 
------ ------------
6 
7 
8 
9 
10 
------- --------------------------------------
Details of current secondary care monitoring 
Monitoring by practice 
General comments by pharmacist 
Pharmacist: 
Patient interview 
Medical problems Drug and dosage 
Formulation 
appropriate? 
no 
_________________ __________________________________ vej 
-- -, 
Pharmaceutical care plan 
Date Care issue/Desired output 
---------
Appendix XV 
Expected 
efficacy evident? 
nla 
no 
yes 
I I 
I 
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Proposed action 
Appendix XV 
Current drug treatment. compliance. knowledge and suitability 
Sida-effects Drug contra- Generic 
present? indicated? Compliance Knowledge substitution 
yes yes never no no, biD-inequivalent 
no no seldom unsure no, compliance 
I I 
frequent 
I 
yes 
I 
yes substitute I 
I I already generic, I 
--------------------- -------------------------------------------------
---------------------------------------------------------- ------- ----- ---
Team 
response 
Immediate 
outcome 
Patient 
outcome 
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Notes 
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Appendix XVI: Update medication review fonn 
Appendix XVI 
UPDATE PHARMACEUTICAL CARE MEDICATION REVIEW Date •••• .J--'_ .... 
o second appointment OR o third appointment (tick ./ as appropriate) 
Patient name: __________ _ DOB: GP: _____ _ 
Please note below if there is any change from the last form 
UPDATE RELEVANT MEDICAL HISTORY 
Date Relevant medical history 
UPDATE DRUG THERAPY 
Current drug therapy date started 
2, ______ _ 
3 ______ _ 
4 ______ _ 
5 ______ _ 
6 ______ _ 
,-------
Previous drug therapy date stopped 
2, ______ _ 
3 ______ _ 
4 ______ _ 
5 ______ _ 
6 ______ _ 
,-------
reason stopped 
Appendix XVII: Diabetes data collection fonn 
for the main study 
Appendix XVII 
Diabetes Data Collection Form (first visit) Date of interview: ......... 
Patient code number: ________ _ DOB: ...... .1 ...... .1 ....... . Year of diagnosis: _____ _ 
Height: ____ Current weight: ____ (Date of weighing: .... ..1 ...... / ...... ) BMI (Kg/ml) ____ _ 
Relevant medical history: (please write down year of diagnosis, if indicated) 
o Hypertension (year ........... ) 0 Hyperlipidaemia (year ......... ) 
o Stroke/transient ischaemic attack (year ......... ) 0 Obesity (year ......... ) 
o Heart disease (e.g. myocardial infarction, congestive cardiac failure, ..................... ) (year ......... ) 
o Renal failure (year ......... ) 0 Visual Impairment (year ............ ) 
o Microalbuminuria (year ......... ) 0 Peripheral neuropathy (year ......... ) 
o Limb Amputation (year .......... ) 0 others ........................................... (year .......... ) 
Objective data: (last two readings) 
Parameter 
Blood pressure l-'J!ULl1Ili.~~~WoIJoI,}J..J.lL--f 
(mmHg) 
slltln 
Blood pressure f-JLn.I.t.llJiiQlol~l4-'JoI>4al~~---I 
Immlig) 
.tlndln 
UbAlc(%) 
Plrase specify 'normal range' for each record 
Today's HbAic ("!o): ................................. . 
Plasma glucose (mmoI/L) 
If indicated, pleased add 'F' =Fasting 
'R' - Random or '?' - not sure in each bo~ 
Total cholesterol (mmoI/L) 
Trlglycerldes (mmoI/L) 
Low density lipoprotein cholesterol (mmoI/L) 
High denSity llpoproleln cholesterol (mmoI/L) 
Scrum Clcattntnc (Iimoi/LI 
ProtctnUrialM Icroalbunllnuna 
-- muimum 2 
If none in last J years, put 
any single reading here '" 
.. I 
'" If there IS no record of any objective data, please wnte down 'NR' In the space provided. 
Please- staple four 
blood pressure 
(2 sitnmg BP and 
2 stamdmg BP) 
print Qlut papers 
HEJt.f.. 
Re:ading I 
Re2ding 2 
Re:ading 3 
Rc:.ading 4 
Attendance at diabetic clinics 0 Never 0 Yes (If patient had appointment but DNA in the last year. 11!(:'ase tlck0) 
If yes, attend at 0 Surgery Ifregularly, how frequent? ........... . 
When was the last time? (date) .. .............. and next time'! (date) ........ . 
o Hospital If regularly, how frcqucnt'! ............ . 
When was the last ttme'.> (date) .. .............. and next tllnt'" (date) ..... . 
"'0111 exam: Date oflast foot exam: ...................... .. Result: 0 normal 0 foot uker 0 other .. 
If regularly. how frequent? ................... ,. 
Eye exam: Date of last eye exam:.... .................... Result: 0 nomlal 0 retinopathy 0 other: 
If regularly. how frequent? ..................... . 
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Questions to ask patient 
I. Use of glucose monitoring at home, currently: 0 No DYes 
If yes, using 0 blood glucose monitoring How frequently? .............. What is the usual result? .............. . 
o urine glucose monitoring How frequently? ............... . 
What is the usual result? 0 lots 0 trace 0 none 
Does patient know target? 0 yes 0 no 
2. Smoking habit: 0 smoker 0 non-smoker 0 ex-smoker: when stopped smoking ........................... . 
3. Have you had any of the following symptoms during the past 6 weeks: 
3.1 Hypoglycaemic symptoms: for example, feeling unusually hungry before meal, sweating, having cold 
hands and feet, headache, weakness, palpitations, anxiety. 
DYes 0 No 
3.2 Hyperglycaemic symptoms: for example, frequent urination (especially during night), always hungry. 
weight loss despite appetite. abnormal thirst. 
DYes 0 No 
3.3 Feeling of pins and needles, pain, numbness or burning in your feet, or having foot ulceration 
DYes 0 No 
3.4 Change in vision 
DYes 0 No 
3.5 Symptoms ofGI disturbances, specify ................................................................................................. . 
DYes 0 No 
3.6 Ask the patient how do you feel in general? If not normal, specify 
4. Have you run out of your diabetic medication during the last 6 months? 
o No 0 Yes, drug name: .......................................................... . 
S. Have you taken any OTC mcdication(s) during the last 6 weeks (e.g., medication(s) for callous, ,'orn, etc.)? 
o No 0 Yes, drug name: ........................................................... . 
General Comments from patient: 
Appendix XVIII: Update diabetes data collection 
form 
Appendilf XVIII 
Diabetes Data Continuation Form Date of Interview: ........ ...... .i ....... . 
Patient follow-up: visit 0 2 0 3 
Patient code number: ________ _ DOB: ...... .1 ...... .1 ........ 
Current weight: ____ (Date of weighing: ..... J ..... .! ...... ) BMI (Kglml) ____ _ 
Objective data: (since last appointment) 
HbAlc (%) 
Please SCII' 'normal ran e' for each record. 
Today's HbAlc(%): ........................................ . 
Plasma glucose (mmol/L) 
I f indicated, please add 
F - Fastin R - Random in each box 
Total cholesterol (mmoI/L) 
Tnglycendes (mmoI/L) 
Lo" denSII) lipoprotein cholesterol (mmoliL) 
High density lipoprotein cholesterol (mmoIiL) 
Serum creallnlne (fimol/L I 
ProtelnuflaiM,croalbumlnuna 
* If there IS no record of any obJecllve data, please wnte down 'NR' in the space provided. 
Please stawle four 
blood pJ'C!ti!iure 
(2 sttting IBP and 
2 standin!!! BP) 
print out pmpers 
HERE.. 
Readiiug 1 
.., 
Readillg 2 
ReadiiDg 3 
ReadiiDg 4 
Attendance at diabetic clinics 0 Never 0 Yes (If patient had appointment but DNA in the last :l.:ar. please tick 0) 
If yes, attend at 0 Surgery If regularly, how frequent'! ................ . 
When was the last time? (d,lte) ................ and next time? (datci 
o Hospital If regularly, how frequent? ................ .. 
When was thc last time? (date) ................ and next time? (dmc l 
Please detail any changes to diabetic mediCine since last appointment: ........................ .. 
ruot exam: Date of last foot exam: . 
Result: 0 normal 0 foot ulcer 0 othcr " ....................... "" .......... . 
E~·~ exam: Date oflast eye exam: ............... " ..... .. 
Result: 0 normal 0 rctlnopathy 0 otht'r: ........... " .. " .. " .. " ........ . 
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Questions to ask patient 
1. Vse of glucose monitoring at home, currently: 0 No DYes 
If yes, using 0 blood glucose monitoring How frequently? .............. What is the usual result·! 
o urine glucose mOnitoring How frequently? ............... . 
What is the usual result'! 0 lots 0 trace 0 none 
Does patient know target? 0 yes 0 no 
2. Smoking habit: 0 smoker 0 non-smoker 0 ex-smoker: when stopped smoking ........................... . 
3. Have you had any of the following symptoms during the past 6 weeks: 
3.1 Hypoglycaemic symptoms: for example, feeling unusually hungry before meal. sweating. having cold 
hands and feet, headache, weakness, palpitations, anxiety. 
DYes 0 No 
3.2 Hyperglycaemic symptoms: for example, frequent urination (especially during night), always hungry. 
weight loss despite appetite, abnormal thirst. 
DYes 0 No 
3.3 Feeling of pins and needles, pain, numbness or buming In your feet, or having foot ulceratIOn 
DYes 0 No 
3.4 Change in viSIon 
DYes 0 No 
3.5 Symptoms ofGI disturbances, specify ....................................................................... ; ......................... .. 
DYes 0 No 
3.6 Ask the patient how do you feel in general'! lfnot normal, specify 
4. Have you run out of your diabetic medication since last appointment? 
o No 0 Yes, drug name: ......................................................... .. 
S. Have you taken any OTe medication(s) since last appointment (e.g., medicalion(s) for callous, CIIIT'D, etc.)? 
o No 0 Yes, drug name: ........................................................... . 
-----------------------------------------------------------------------------
GClll'raJ COOllTIl'nts from paticnt: 
Appendix XIX: Letter of thanks to patients after 
attending first appointment 
Appendix XIX 
Dr ............................................. & partners 
Surgery Address 
Date as postmarked 
Dear ................................ . 
May I take this opportunity to thank you for attending the diabetes clinic. Subsequent to 
our recent discussions I have spoken to your doctor who has agreed the action(s) 
indicated in the box below 
------,--------------------------------------------------------------------
,--,--------------- .-.".---------------------------
If you wish to discuss any of these points further please contact me at the surgery or 
alternatively feel free to discuss them with your doctor at any time. If you regularly 
attend one community pharmacy, it would be useful to show them this letter to allow 
them to update your pharmacy held medication records. 
I look forward to meeting you again and thank you for your continued support. 
I 
Yours sincerely 
Clinical Pharmacist 
[Note: this form is for active patient with referral.] 
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Dr .............................................. & Partners 
Surgery Address 
Date as postmark 
Dear ...................... . 
May I take this opportunity to thank you for attending the diabetes clinic. 
We will telephone you in approximately 3 months to arrange another appointment at a 
time convenient to you. 
I have enclosed a copy of an information leaflet, which I hope you will find interesting. 
The information provided at your interview has been very useful and could help us 
improve the future care of people with diabetes. 
I look forward to meeting you again and thank you for your continued support. 
Yours sincerely 
Clinical Pharmacist 
[Note: this form is for control or active with no referral.] 
Appendix XX: Letter of thanks to patients after 
attending second appointment 
Appendix XX 
Dr ............................................. & partners 
Surgery Address 
Date as postmarked 
Dear ................................ . 
May I take this opportunity to thank you for attending the diabetes clinic. Subsequent to 
our recent discussions I have spoken to your doctor who has agreed the adion(s) 
indicated in the box below 
--------------------
------------------
---------------,------ . ---- --
_ .. __ .. -.. ----------------------------- -------,----
If you wish to discuss any of these paints further please contact me at the surgery or 
alternatively feel free to discuss them with your doctor at any time. If you regularly 
attend one community pharmacy, it would be useful to show them this letter to allow 
them to update your pharmacy held medication records. 
I look forward to meeting you again and thank you for your continued support. 
Yours sincerely 
Clinical Pharmacist 
[Note: this form Is for active patient with referral.] 
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Dr .............................................. & Partners 
Surgery Address 
Date as postmark 
Dear ..................... .. 
May I take this opportunity to thank you for attending the diabetes clinic. 
We will telephone you in approximately 3 months to arrange another appointme~rit at a 
time convenient to you. 
I have enclosed a copy of an information leaflet, which I hope you will find interesting. 
The information provided at your interview has been very useful and could help us 
improve the future care of people with diabetes. 
I look forward to meeting you again and thank you for your continued support. 
Yours sincerely 
Clinical Pharmacist 
[Note: this form is for control or active with no referral.] 
Appendix XXI: Letter of thanks to patients after 
attending third appointment 
Appendix XXI 
Dr ............................................. & partners 
Surgery Address 
Date as postmarked 
Dear ................................ . 
May I take this opportunity to thank you for attending the diabetes clinic and participating 
in the study, which has now finished. Subsequent to our recent discussions I have 
spoken to your doctor who has agreed the action(s) indicated in the box below 
----------_._._ .---_ .._ .. '--....... . ....... 
---------------------_.,---_... _ ......... . 
---------.----------------------
, _________ u ______ , ____________ __ 
------,---_._.----------------
If you wish to discuss any of these pOints further please contact me at the surgery or 
alternatively feel free to discuss them with your doctor at any time. If you regularly 
attend one community pharmacy, it would be useful to show them this letter to allow 
them to update your pharmacy held medication records. 
Kind regards, 
Yours sincerely 
Clinical Pharmacist 
[Note: this form is for active or control patient with referral.] 
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Dr .............................................. & Partners 
Surgery Address 
Date as postmark 
Dear 
May I take this opportunity to thank you for attending the diabetes clinic and participating 
in this study, which has now finished. 
The information provided at your interview has been very useful and could toelp us 
improve the future care of people with diabetes. 
I look forward to meeting you again and thank you for your continued support. 
Yours sincerely 
Clinical Pharmacist 
[Note: this form is for control or active patient with no referral.] 
· --
Appendix XXII: Questionnaire - Pharmacist feedback on 
experience since completing the clinics 
Appendix XXII 
QUESTIONNAIRE 
1. GENERAL INFORMATION 
Your age: ................ . 
2. EDUCATIONAL BACKGROUND 
Where did you graduate? When? (year) Quallflcation(s) gained 
(name of university) 
Continuing education? (Please specify course of study and date of enrollment) 
..................................................................................................................................... 
..................................................................................................................................... 
..................................................................................................................................... 
..................................................................................................................................... 
..................................................................................................................................... 
3. WORKING EXPERIENCE 
3.1 How long have you been practicing as a pharmacist? .......................... .. 
3.2 At the time of the study, were you a full-time or a part-time pharmacist? 
................................................................................................................................. 
3.3 Which sector were you working in when the study took place? (community, hospital, 
primary care, other please state) 
3.4 Are you still working in the same sector after finishing the research? ...... Yesl ..... No 
If no, please specify .............................................................................................. . 
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4. ABOUT THE MAIN STUDY (date March 2000· Feb 2001) 
4.1 Before doing the main study, had you ever run the medication review clinic before? 
..... Yes/ ..... No 
If yes, how long have you been doing the medication review clinic before the study? 
................................................................................................................................. 
4.2 How many days per week did you run the clinic at that time (during the study)? 
................................................................................................................................. 
4.3 Have you continued working in medication review clinic after finishing the research? . 
•... Yes/ ..... No 
If yes, what type of clinics are you currently delivering? and where? 
................................................................................................................................. 
4.4 After finishing diabetes clinic, please rate your confidence in running the clinic (scale 0 
(low) -10 (high» both before the study and after finishing the study. 
Before study: confidence (scale 0-10) ................. .. 
After study: confidence (scale 0-10) ................. .. 
Finally, if you would like to make any comments regarding this research or would like 
to add more information to the answer above, there is space below for you to do so . 
.................. , ................................................. , ... , ............... , ......................................... . 
..... ..................... ............................................. , ....... , ............... , ....................................... . 
....... , ............................................. ,., ... , ............................... , ............................ , .............. . 
May I thank you once again for your participation and co-operatlon. You will be 
sent a summary of the final project report for your Information. 
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" 
obtaining a capillary 
blood sample for 
HbAIC test 
Appendix XXII' 
PROCEDURE STEPS FOR FINGER PRICKING 
I. PREPARING FINGERTIP 
1. Clean the surface of the patient's finger. 
• Wash hands with soap and warm water and 
dry thoroughly before sampling. 
• Instructs the patient to let arm hang down at 
side of body for a while (30 sec) to allow 
blood flow to finger and grasp the finger near 
the area to be pricked and gently squeeze for 
few seconds. 
2. Select a site on the outer edge of the finger. 
:11f~ 
\
.' .... ./01 .. I 
.,;.,- . t 
.. 
• The sides of the finger has the best blood supply 
and are less sensitive than the tip . 
, 
. .)/1'" 
II. USING SOFTCL/~ PRO LANCING DEVICE 
protective cap 
cap with penetration 
depth adjustment 
cap openmg 
SOHnIX'" Pro Lancet 
platfOim 
release button 
indentation 
SELECTING PENETRATION DEPTH: 
housmg 
lancet ejector 
button 
Softclix® Pro offers three depths of penetration, which are indicated on 
the cap by numbers 1, 2 and 3. Select 1 for the smallest and 3 for the 
greatest depth of penetration. 
Appendix XXIII 
When selecting the correcting depth of penetration for a particular 
patient, his or her skin type should be taken into consideration, e.g. 
select 1 for softer-than-average skin, 2 for average skin or 3 for thicker-
than-average skin. The amount of blood required for the test should 
also be taken into account. 
Select the desired depth of penetration 
by turning the front part of the cap. 
Grip the cap at the indentations and 
turn the housing in a clockwise 
direction as far as it will go. Softclix® 
Pro is now primed and the housing will 
return to its initial position when you let 
go. 
INSERTING A LANCET: Place a new 
Softclix® Pro lancet in the instrument 
by holding the protective cap of the 
lancet and pushing it into the instru-
ment as far as it will go. The platform 
will snap into position in the cap 
opening thus closing it. The blue lancet 
ejector button is released when the 
lancet is inserted and is now visible. 
REMOVING THE PROTECTIVE CAP: 
Unscrew the protective cap from the 
lancet. Hold it at the indentations to co 
so and turn. 
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TAKING A BLOOD SAMPLE: Hold 
Softclix® Pro against the side of the 
patient's finger tip and press gently. 
Press the release button. 
Wait a few seconds to allow the 
puncture site to open so that a blood 
drop can form. 
, 
If the blood drop is too small, gently 
compress the tip of the finger from 
the base upward to obtain more blood. 
IV. REMOVING THE LANCET: 
Hold Softclix® Pro pointing downwards 
over a waste bin and press the ejector 
button. The lancet and the platform will 
fall out. 
3/3 
CAPILLARY BLOOD SAMPLE FOR HBA1C TEST 
1. Take one capillary out of the capillary 
dispenser and attach it in the capillary 
holder. Fill the capillary with blood 
(from fingertip). 
IMPORTANT: The capillary must be 
filled end-to-end. 
2. Transfer the filled capillary into the 
Sample Preparation vial. 
3. Cap the vial and shake it to rinse the 
blood completely from the capillary. 
IMPORTANT: Make sure that no 
blood remains in the capillary. 
4. Label the vial with the label provided 
in the kit. On the vial, place the label 
on the free space below the notches. 
Appendix XXIII 
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5. The specimen can now be passed on for analysis. 
Samples prepared using this procedure are suitable 
for 2 weeks at room temperature or four weeks at 2-8C. 
... 
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Append:x XXIV 
HOW TO USE THE OMRON 705CP 
Components 
Air tuhe 
Air jack 
for stllred 
readin~s 
for current 
measure· 
ments 
Pressure pre 
set switch 
Display of 
systolic blood 
pressure/time 
Ihour) 
Display of 
diastolIc blood 
pressure/pulse! 
time Iminutes) 
\ 
\ 
START 
hutton 
I ~ I 
On/Off 
blltton I 011 ) 
BJ tt ery com· 
[,Jrtmcnt 
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Preparation for use 
1. Inserting the batteries 
2. Setting the date and time 
• The buttons for setting date and time are located under the printer 
cover. Remove the cover by pulling it off in the direction indicated by 
the arrow. 
• After inserting the batteries, PM 12:00 appears on the display. Press 
the TM button. The month display then flashes. 
• Now press T5 button to set the current month. 
Page 2 or' ~ 
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• After setting the month, press the TM button again. The 'DAY' 
symbol then flashes. Set the current day using the TS button. 
• The hour and minutes flash after you press the TM button. Set the 
hour and minutes using the TS button and then press TM button 
again so that the hour and minutes are displayed. 
3. Inserting the printer paper 
• Remove the printer cover. Before 
inserting the paper, remove the 
adhesive strip and cut the end of the 
paper off straight and slant. 
• Insert the end of the paper into the 
slot whilst at the same time holding 
down the paper feed button PF 
• Place the paper roll into the 
compartment and pull the strip 
through the opening in the printer 
cover. Then close the cover. 
Preparing for measurement 
1. Switching on the blood pressure measurement function. 
• When the preparations are complete, the ready to measure symbol (¥) 
appears on the display. 
2. Pressure pre set switch 
• Select a setting that is one value higher than the expected systolic 
blood pressure. 
• The 170 mm Hg or 200 mm Hg setting is recommended. 
AUTO 170 200 240 
"-----,., r'...-----' ((OJ) 
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• If the value you have set proves to be inadequate, the monitor 
automatically inflating until the pressure is sufficient for measurement. 
• If you hold down the START button, inflation will still continue even 
after the pressure you have set has been reached. 
• You can also put the pressure pre set switch to the AUTO position. In 
this case the inflation pressure is automatically adapted to the last 
systolic pressure measurement taken. 
The measuring procedure 
1. Fitting the cuff and starting measurement with automatic inflation 
• Fit the cuff around the patient's arm so that 
the green mark is located 2-3 cm over the 
brachial artery. ", 
• Position the patient's arm on the level with 
the heart and press the 5T ART button. 
• Please ensure that clothing does not 
constrict the blood flow. 
2. Automatic deflation and display of measurements 
• As soon as the patient's pulse has been 
detected, the (.) symbol starts to flash and, 
at the same time, the monitor beeps. 
• When measurement has finished, the 
systolic and diastolic BP are displayed. 
• The pressure drop symbol ( .. ) indicates 
that the cuff is deflating. 
• When all the air has escaped, the (.) 
symbol appears on the display and the 
blood pressure and pulse are displayed 
alternately for approy.. 5 minutes. 
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Print out of readings 
• Check the readings as soon as measurement has 
finished and then press the P button. It does not 
matter whether the blood pressure or pulse is 
showing on the display when you press the 
button. 
• Caution: The measurements can only be printed 
out when the blood pressure or pulse values are 
shown on the display. No printout is possible 
when the time is displayed. 
Appendix XXIV 
PM p 
o~o 
Month Date Time 
7 -3 12:09 PM 
SYS 116mmHg 
DIA 77mmHg 
PULS 821min 
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Table 5.32: Comparison of the number of DRPs identified by each of the pharmacists (includes active and control patients) 
Pharmacist No. of patients No. of patients with one or Mean no. of DRPs per patient 
interviewed more DRPs (%) (range) 
A 51 44 (86) 2.3 (0-7) 
B 51 48 (94) 2.3 (0-4) 
C 36 29 (81) 1.7 (0-6) 
0 61 57 (93) 2.2 (0-5) 
E 43 27 (63) 1.1 (0-4) 
F 36 34 (94) 2.7 (0-7) 
G 38 23 (60) 0.9 (0-4) 
H 52 42 (81) 2.0 (0-7) 
35 18 (51) 0.7 (0-3) 
Total 403 322 (80) 1.8 (0-7) 
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